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1. PARATHYROID GLANDS
Anatomy
The parathyroid glands were the last classical endocrine glands to be identified, 
with the first description made in a rhinoceros by Richard Owen in 1850 (1). The 
large size of this species probably enabled to macroscopically distinguish the 
parathyroids from the adjacent thyroid gland (1). Three decades later the
parathyroid glands were finally described in humans by Sandström (Figure 1) (1,2).
Parathyroid glands vary from 2-7 mm in length, 2-4 mm in width and 0.5-2 mm in 
thickness (3). Although the majority of normal adults (84%) have 4 glands, 1-7% 
have 3 glands and 3-13% have 5 glands (4-7). The superior glands arise from the 
fourth branchial (pharyngeal) pouch and descend into the neck together with the 
thyroid gland. The superior glands are thus most commonly found near or within 
the thyroid capsule. The inferior glands, together with the thymus, arise from the 
third branchial pouch and can be found anywhere from the lower thyroid pole to
deep in the mediastinum.
Figure 1: Anatomy of the parathyroid glands
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Physiology
The parathyroid glands are essential for normal calcium homeostasis via the 
production of parathyroid hormone (PTH), which is exclusively produced by the 
chief cells of the parathyroid glands. PTH production depends on the number of 
parathyroid chief cells and the secretion of PTH per cell. PTH secretion depends on 
the setpoint of calcium-dependent secretion, on the secretory capacity of the chief 
cells and on the number of chief cells that are in the secreting phase. PTH secretion 
is episodic and rhythmic and once in the circulation, PTH has a very short half life 
of only a few minutes, enabling very flexible and rapid changes in circulating serum 
calcium levels. PTH is broken down by Kupfer cells in the liver and PTH fragments 
are secreted via the kidney together with still intact PTH. 
PTH secretion is regulated by extracellular calcium ions, which bind to the 
calcium sensing receptors (CASR), which are located on the chief cells of the 
parathyroid gland. Binding of calcium to the CASR activates the receptor, which 
leads to inhibition of PTH secretion, of PTH gene expression and thus PTH 
synthesis, and of parathyroid cell proliferation (8). PTH secretion is also inhibited 
by binding of active vitamin D (1,25(OH)2D) to the vitamin D receptor, which is 
also located in the chief cells of the parathyroids.
In contrast, hypocalcaemia results in a release of available PTH from its 
intracellular reservoir, in a decrease in intracellular break down of PTH, in a
increase of PTH biosynthesis and in a decrease of the secretory rest phase of the 
parathyroid cell (9). Long-term hypocalcaemia eventually results in four-gland 
parathyroid hyperplasia.  
Pathophysiology of hyperparathyroidism
Hyperparathyroidism is the disease state resulting from one or more parathyroid 
glands producing too much PTH. This disease state is associated with an increase in 
the calcium-dependent setpoint of PTH secretion, an increase in the number of PTH 
secreting cells and an increase in parathyroid parenchymal cells. 
Hyperparathyroidism can be secondary to a decrease in serum calcium 
concentration caused by a negative calcium balance, due to vitamin D deficiency, 
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renal insufficiency, gastro-intestinal disorders, or hypercalciuria of renal origin. 
Long-term stimulation of the parathyroids by persistent hypocalcaemia is eventually 
associated with monoclonal changes, resulting in autonomous "tertiary" 
hyperparathyroidism. In this case the production of PTH is no longer regulated by 
circulating serum calcium concentrations, which is analogous to the case in primary 
hyperparathyroidism. 
In primary hyperparathyroidism (PHPT) one or more parathyroid glands are by 
definition autonomous. The increase in the calcium-dependent setpoint of the chief 
cells, leads to increased PTH secretion despite increased levels of serum calcium 
(Figure 2). The most important determinant of the calcium-dependent setpoint for 
PTH secretion is the number and function of CASR. Although, mutations in the 
CASR gene and downregulation of CASR expression, have been described in 31% 
of parathyroid carcinomas, the majority of patients with PHPT have normal 
expression and function of the CASR (10,11).                                   
Figure 2: Changes in the calcium-dependent setpoint leading to PHPT
II. PRIMARY HYPERPARATHYROIDISM
Incidence
The estimated incidence of PHPT is 0.4% in adult men, 1.7% in adult women and 
2-3% in women above the age of 60 years (12-14).
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Clinical features
Over the past few decades, the clinical profile of PHPT, originally described as
“bones, stones, groans and psychic moans”, has drastically changed to an almost 
asymptomatic disease, due to the introduction of automated calcium screening.
Chronic exposure of the skeleton to high circulating PTH concentrations increases
bone turnover in favour of bone resorption, ultimately leading to decreased bone 
mineral density, predominantly at cortical sites, and increased risk of fractures. PTH
has been shown to influence bone metabolism by stimulating RANKL secretion, an 
osteoclast activator, and by suppressing OPG secretion, the natural decoy receptor 
for RANKL (15-25).
Figure 3: The effect of increased PTH concentrations on bone, kidney and intestine
In the kidney, high circulating PTH levels increase tubular reabsorption of 
calcium and decrease tubular reabsorption of phosphate. However, approximately 
30% of patients with PHPT demonstrate hypercalciuria, with increased risk for 
nephrocalcinosis and nephrolithiasis. Renal function may deteriorate due to 
hypercalcaemia and associated dehydration and to recurrent renal stones. PTH also 
stimulates 1α-hydroxylase enzyme synthesis in the kidney, which is essential for the 
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conversion of 25-hydroxyvitamin D, into its active metabolite, 1,25-
dihydroxyvitamin D. Active vitamin D stimulates the intestinal absorption of 
calcium. 
The net result of increased circulating PTH concentrations on bone, kidney and 
intestine is an increase in extracellular serum calcium concentration. Clinical 
manifestations of hypercalcaemia include polyuria, polydipsia and constipation. 
Hyperparathyroidism may also be associated with non specific symptoms, such as 
tiredness, mood swings, depression, irritability, forgetfulness, bony pain and muscle 
weakness. 
Pathological changes
Primary hyperparathyroidism can most commonly occur sporadically or more rarely 
in the context of a genetic syndrome, such as MEN-I (OMIM 131100), MEN-IIa 
(OMIM 171400) or hyperparathyroidism-jaw tumor (HPT-JT; OMIM 607393)
(26). The disease is caused by a solitary parathyroid adenoma in more than 80% of 
cases, hyperplasia in 15-20% of cases and parathyroid carcinoma in 0.1 to 5% of 
cases (27-31).
A parathyroid adenoma is characterized by the presence of an encapsulated 
benign neoplasm usually involving a single gland with an adjacent rim of normal 
glandular tissue (32).
Parathyroid hyperplasia is characterized by an absolute increase in parathyroid 
parenchymal cell mass resulting from proliferation of chief cells, oncocytic cells 
and transitional oncocytic cells in multiple parathyroid glands in the absence of a 
known stimulus for PTH hypersecretion such as renal failure or vitamin D
deficiency (32). A diagnosis of hyperplasia is also favoured when synchronous 
multiglandular disease is found at surgery. 
Parathyroid carcinoma is a malignant neoplasm derived from parathyroid 
parenchymal cells, which, according to the criteria of the World Health 
Organization, is characterized by vascular invasion, perineural space invasion, 
capsular penetration with growth into adjacent tissues and/or metastases (32). The 
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presence of a trabecular pattern, fibrous bands and/or multiple mitoses are 
considered to be only minor diagnostic criteria. 
Localization studies
Localization studies are not required in case of traditional bilateral neck exploration,
because experienced surgeons have an 86–100% chance of excision of all 
pathological tissue as the procedure entails visualization of all four parathyroid 
glands (33,34). However, localization studies become mandatory when a more 
focused unilateral or minimally invasive approach is opted for.
Technetium 99m sestamibi (Tc99m-MIBI), particularly when complemented 
with single emission computed tomography (Tc99m-MIBI-SPECT), is currently the 
imaging technique of choice for the preoperative localisation of parathyroid 
adenomas (33,35). Tc99m-MIBI is a monovalent lipophilic cation that diffuses 
passively through cell membranes and accumulates almost exclusively in 
mitochondria following negative membrane potentials (36). In primary 
hyperparathyroidism, the increased uptake of Tc99m-MIBI is based on an 
abundance of mitochondria in parathyroid oxyphil cells, which sequester sestamibi 
intracellularly, and on increased perfusion of hyperactive parathyroid glands. The 
sensitivity of Tc99m-MIBI-SPECT for localising hyperactive parathyroid glands 
ranges from 66% to 90% and the positive predictive value ranges from 83 to 100% 
(33,37-44).
In experienced hands, an ultrasound (US) of the neck is a highly sensitive
technique, which is more convenient and less expensive than Tc99m-MIBI-SPECT
and particularly more sensitive for intrathyroidally located parathyroids, which is a 
difficult location for other non-invasive localization techniques. US, however, is of 
limited value in the case of retrosternal or posteriorly located parathyroid glands.
The reported sensitivity is highly variable, ranging from 47% to 89%, depending on 
parathyroid pathology and the presence of thyroid nodules (33,45-48).
The use of Computed Tomography (CT)-scans and of Magnetic Resonance 
Imaging (MRI)-scans is recommended in the case of a suspected ectopic 
mediastinal parathyroid gland, to better define size and location of the lesion 
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relative to adjacent structures (49). The sensitivity of CT-scans for localising
hyperactive parathyroid glands remains, however, lower than that of Tc99m-MIBI-
SPECT and US, despite recent developments in equipment and in diagnostic 
protocols and algorithms (45). A very promising localization method is the novel
four-dimensional CT scan (4D-CT), which provides both functional and highly 
detailed anatomic information about parathyroid tumors. This method is reported to 
have a sensitivity of 70% for localising hyperactive parathyroid glands (50). MRI is 
time-consuming, expensive, difficult to interpret and a number of patients cannot 
undertake the procedure because of indwelling pacemakers and other metallic 
implants (51).
Selective venous sampling (SVS) of parathyroid hormone (PTH) is an invasive 
technique that can be used when the above mentioned noninvasive localization 
studies are negative or disconcordant. During SVS a catheter is introduced under 
local anaesthesia via a sheath in the right femoral vein by an intervention radiologist 
and is guided by fluoroscopy to each of the jugular, subclavian and brachiocephalic 
veins, the azygos vein and to the vena cava superior and inferior, from which serial
blood samples are obtained for PTH measurement. SVS is based on the anatomical 
assumption that regional drainage of each parathyroid gland occurs via the veins of 
the thyroid plexus into the adjacent superior, middle and inferior thyroid veins (52).
However, there are many variations in the venous anatomy of the parathyroid 
glands due to embryological differences, but most often also due to previous 
surgical interventions disturbing local anatomy and venous drainage. Despite these
anatomical variations, SVS has been reported to be successful in predicting the side 
of a pathological parathyroid gland in 39-93% of patients with primary 
hyperparathyroidism (49,52-60) and in 66-75% of patients with negative 
noninvasive studies (57,58,61). SVS is also successful in identifying the anatomical 
location of an ectopic parathyroid gland, with a sensitivity 66-100% (62,63).
Management of primary hyperparathyroidism
In primary hyperparathyroidism (PHPT), surgical removal of all pathological 
parathyroid glands is the only approach that provides definitive and durable cure. 
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Cure rate is 94-100% for bilateral neck as well as less invasive surgery, more than 6 
months after parathyroidectomy (PTx) (33,38,40-44,64-66) with a complication rate 
of 0.4%-7.7% in the hands of experienced surgeons (41,43,44,65,66). The risks of 
surgery for PHPT consist in 13-20% of patients in hypoparathyroidism, in 1-6% of 
patients in transient or permanent vocal cord damage due to unilateral or bilateral 
damage to the nervus laryngeus recurrens and in <1% to mortality.
                                  
Figure 4: Resection of an enlarged parathyroid gland during minimally invasive neck 
surgery
Surgery can be performed by standard bilateral neck exploration, which consists 
of visualization of all four parathyroid glands followed by either excision of a single 
enlarged parathyroid gland, or subtotal or total parathyroidectomy with auto 
transplantation if more than one parathyroid gland is found to be enlarged. 
Unilateral neck exploration and minimally invasive neck exploration both 
require  pre-operative localization of the enlarged parathyroid gland and the use of 
intra-operative PTH (IOPTH) measurement to predict that the pathological 
parathyroid tissue has been fully excised. The “Miami criteria” are used to interpret 
IOPTH measurement: a PTH decrease of more than 50% after excision of all 
pathological parathyroid tissue (67,68). If the IOPTH does not drop below 50% or if 
a pathological gland is not found during minimally invasive surgery, the procedure 
is conversed to bilateral neck exploration. IOPTH monitoring has a sensitivity of up 
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to 99% (69,70) and has been shown to significantly increase cure rate by about  
10% (69,71).                                                                  
Cinacalcet is the only registered medical treatment for PHPT and is available for 
clinical use in the Netherlands since the summer of 2009. Cinacalcet is a
calcimimetic approved by the European Medicines Agency Committee for 
Medicinal Products for Human Use for “the reduction of hypercalcaemia in patients 
with primary hyperparathyroidism for whom parathyroidectomy would be indicated 
on the basis of serum calcium levels (as defined by the relevant treatment 
guidelines), but in whom parathyroidectomy is not clinically appropriate or is 
contraindicated” (72). Calcimimetics increase the sensitivity of the calcium sensing 
receptor (CASR) on parathyroid cells to extracellular calcium concentration (73-
79), thereby significantly decreasing serum PTH and calcium concentration. This 
agent has been reported to normalize serum calcium concentration in ~88% of 
patients with PHPT (76-79).
Fate of complications after successful surgery
In PHPT, the importance of achieving cure has been highlighted in a number of 
studies focusing on the effect of parathyroidectomy on bone mineral density, 
nephrolithiasis and neurocognitive function (80-82). Patients who are cured after 
PTx demonstrate a significant postoperative increase in bone mass, with BMD 
remaining significantly higher than baseline values for up to 15 years after 
parathyroidectomy (81-83). This is in contrast to patients treated conservatively, in 
whom significant cortical bone loss and increased fracture risk is observed in the 
long-term. As reported in a number of published studies, patients with 
nephrolithiasis at presentation demonstrate no recurrence of renal stones after 
successful PTx, in contrast to a 75-100% chance of recurrent nephrolithiasis in 
conservatively treated patients (80,83). Symptomatic and also “asymptomatic” 
patients undergoing parathyroidectomy have also been reported to experience a 
significant improvement in various parameters of quality of life compared to 
patients who did not have surgery (84-88).
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III. PERSISTENCE OR RECURRENCE OF PHPT
Definitions
Persistence of hyperparathyroidism is defined as high serum calcium and PTH 
concentrations or inappropriate concentrations of one parameter with respect to the 
other, documented directly post-operatively or within the first 6 months after 
parathyroidectomy, and persisting thereafter. Recurrence of hyperparathyroidism is
defined as the recurrence of elevated serum calcium and PTH concentrations after 
successful PTx and a period of normalization of both parameters of at least 6 
months after surgery.  
Etiology
Persistent hyperparathyroidism is reported to occur in 2-7% of patients after
parathyroidectomy (33,89,90). Excluding insufficient experience of the operating 
surgeon, persistent PHPT may be caused by a pathological gland which is missed 
during initial surgery (6.3-69%), a second adenoma (6.3%), non-recognition or 
incomplete excision of multiple gland hyperplasia (9-29%), an ectopically located 
hyperactive gland undetected at initial surgery (11-77%), supernumerary glands 
(4.2-8%) or rarely parathyromatosis from parathyroid cell spillage during initial 
surgery (0.7-6.3%) (90-98). The diagnosis of persistent hyperparathyroidism may 
be delayed because of initial suppression of multiple pathological glands by a 
dominant enlarged gland, falsely suggesting cure immediately post-operatively. 
These pathological glands eventually overcome their suppressed state leading to 
overt hyperparathyroidism.  
In a 5 year follow-up of 91 patients successfully operated for PHPT, Westerdahl 
et al reported a recurrence rate of hyperparathyroidism of 4%, largely due, however, 
to previously undiagnosed germline mutations in the MEN-1 gene and,
consequently, multiple gland pathology (99). Other causes of recurrence of PHPT 
are metastases from a parathyroid carcinoma or newly developed adenomas, most 
of the times arising in hyperplastic parathyroid glands (91-93).
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Location of ectopic parathyroid glands 
In 24-77% of patients who undergo revision surgery for PHPT missed glands are 
found in ectopic locations, such as the tracheoesophageal groove (2.8-33%), thymus 
(8.3-27%), retroesophageally (1.8-10.4%), intrathyroidally (4-10%), the carotid 
bifurcation (8.3%), the mediastinum (2.6-7.3%), the aortic-pulmonary window (1.3-
6.3%), the carotid sheath (2.1-5.5%) and parapharyngeally (2.1%) 
(56,93,94,100,101).   
Most ectopias of the superior gland are acquired ectopias due to the effect of 
gravity on an enlarged gland, causing the gland to travel down the prevertebral 
plane towards the posterosuperior mediastinum (102). Congenital ectopias of the 
superior glands, are due to undescended glands, found behind the pharynx, above 
the superior thyroid pole or at the posteromedial aspect of the thyroid lobe, while an 
excessively migrated gland can be found intrathyroidal (102). Most inferior gland 
ectopias are congenital ectopias caused by abnormal embryological migration of the 
parathymic complex, extending from the angle of the mandible to the pericardium 
(102). An undescended inferior parathyroid gland can be found along the carotid 
sheath, from the angle of the mandible to the lower thyroid pole (103), while an 
excessively migrated gland can be found in the anterior mediastinum, within the 
thymus or at the posterior aspect of the thymic capsule. 
Supernumerary glands develop from accessory parathyroid fragments caused by 
the rapid caudal and medial migration of the thymus, which may drag a fragment of 
the third branchial pouch, the origin of the inferior parathyroid glands (102). 
Supernumerary glands may also be found in close contact with the vagus nerve or 
sometimes within it (104). There is a close spatial relationship between the vagus 
nerve and the third and fourth pharyngeal pouches, the origin of the inferior and 




A second (or subsequent) neck exploration is technically more challenging than 
initial surgery and  may  be  associated  with  an  up  to  3-fold increase in morbidity 
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(33,93,105,106). Localization studies are, therefore, highly recommended prior to 
revision surgery in order to decrease operation time, improve surgical outcome and 
reduce the risk of complications due to lengthy surgical explorations 
(33,91,93,105,106).
The sensitivity of Tc99m-MIBI-SPECT prior to revision surgery varies from as 
low as 27% to as high as 94%, depending on the selection of patients, the pathology 
of the parathyroid gland(s) and the methods used to determine the accuracy of the 
technique (49,94,96,97,100,101,107-111). Tc99m-MIBI-SPECT has a lower 
sensitivity in patients with multiple hyperplastic parathyroid glands compared to 
patients in whom a single adenoma is found at surgery (94% vs. 43%) (112). The 
sensitivity of Tc99m-MIBI-SPECT is also decreased in patients who have had 
previous resection of pathological parathyroid gland(s) compared to patients who 
have had previous negative neck exploration (89% vs. 27%) (108).
Ultrasound of the neck (US) is reported to have a sensitivity of 17%-90% prior 
to revision surgery (49,94,96,97,101,107,108,110-113). In contrast to Tc99m-MIBI-
SPECT, US is not influenced by the pathology of the parathyroid gland (112).
When both Tc99m-MIBI-SPECT and US are negative or when results of these 
localisation techniques are disconcordant, an MRI-scan, CT-scan or selective 
venous sampling for PTH (SVS) can be helpful to identify residual pathological
parathyroid gland(s). The sensitivity of MRI-scan prior to revision surgery is 33-
89% (49,97,110-112), that of CT-scan is 33-50% (49,97,110) and that of SVS is 50-
91% (49,94,97,111,114). 4D-CT has shown a promising sensitivity of 80% prior to 
revision surgery in patients with PHPT who have had previous unsuccessful 
parathyroidectomy (108).
Outcome of revision surgery
Despite the challenges of revision surgery, the reported cure rate remains high after 
re-exploration ranging from 82% to 100% (49,56,94,96,100,101,107-
109,111,115,116). However, the highest cure rates (98-100%) are found in patients 
who had previous thyroid surgery or negative neck explorations and in patients who
have solitary adenomas (101,109,115) and the lowest cure rates (82-83%) are found 
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in patients with persistent hyperparathyroidism after removal of one or more 
pathological parathyroid glands (94,108). Patients with multiple gland hyperplasia 
and patients who have had 3 previous neck explorations are less likely to achieve 
cure after further surgery (96,107).
Complications of revision surgery
Re-operations are associated with an increased risk of complications due to 
distortion and scarring of surgical planes caused by previous interventions. The 
overall complication rate after revision surgery is reported to be none to 29% 
(49,56,94,96,101,107,108,117,118). The most common complications are 
hypoparathyroidism (2.6-12.9%) and permanent or transient recurrent laryngeal 
nerve injury (0.08-25% and 2.3-13.5%, respectively) 
(49,56,94,97,100,101,107,111,117-119). Other possible complications are post-
operative bleeding requiring blood transfusion (1.1-2.1%), mandibular nerve injury 
(0.4-1.6%), wound hematoma (0.08-2.2%), pneumothorax (1.6-4.4%), pneumonia 
(0.4%-2.2%) and deep venous thrombosis or pulmonary embolism (1-2.2%) 
(56,94,100,101,108,117). Rare complications are Horner syndrome after 
sternotomy, chylous fistulas, arrhythmia, myocardial infarction, wound erythema
and renal failure (56,108,117).
IV. OUTLINE OF THIS THESIS
Part I. Cure after parathyroidectomy for primary hyperparathyroidism
Primary hyperparathyroidism is the most common cause of hypercalcaemia in the 
outpatient setting. Surgical removal of all pathological parathyroid glands is the 
only approach that provides definitive and durable cure in these patients. Patients 
who are cured after surgery show a significant postoperative increase in bone mass 
(81-83), no recurrence of renal stones (80,83) and improvement in various 
parameters of quality of life compared to patients who had no or unsuccessful 
surgery (84-88). In Chapter 2 we assessed the prevalence of persistent and recurrent 
hyperparathyroidism after surgery for primary hyperparathyroidism in our hospital 
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over a 24 year period. We also evaluated the fate of clinical symptoms and 
complications of PHPT after successful surgery.   
 
Part II. Localization studies in persistent primary hyperparathyroidism  
The need for preoperative localization of pathological parathyroid gland(s) before 
initial surgery depends on the chosen surgical approach. In case of traditional 
bilateral neck exploration localization studies are not deemed necessary, but they 
become mandatory prior to more focused unilateral or minimally invasive surgery 
(33,34). Accurate localization studies are even more important before revision 
surgery for persistent hyperparathyroidism, as a second (or subsequent) neck 
exploration is technically more challenging than initial surgery (33,93,105,106). In 
Chapter 3 we evaluated the predictive value of Tc99m-MIBI-SPECT in patients 
with persistent PHPT prior to revision surgery compared to the predictive value of 
this technique in patients with sporadic PHPT prior to initial surgery. 
We also evaluated the predictive value of selective venous sampling for PTH in 
patients with persistent PHPT prior to revision surgery compared to the predictive 
value of Tc99m-MIBI-SPECT in the same patient group. Results of this study are 
described in Chapter 4.    
 
Part III. Complications of the surgical management of primary 
hyperparathyroidism  
PHPT is associated with decreased bone mineral density, due to the stimulating 
effects of increased circulating levels of PTH on osteoclastogenesis by the 
stimulation of RANKL secretion, an osteoclast activator, and the suppression of 
OPG secretion, the natural decoy receptor for RANKL (15-25). The increased bone 
turnover in favour of bone resorption induced by the pre-operative hyperparathyroid 
state, leads to demineralization of bone particularly at cortical sites. Following 
successful surgery, the rapid decrease in serum PTH levels and the pre-operative 
high bone turnover state, lead to a transient hypocalcaemia, due to increased influx 
of calcium, phosphate and magnesium into bone. Restoration of mineralization of  
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bone and eventual decrease in bone turnover lead to a significant increase in bone 
mass (81-83).
Post-operative severe persistent hypocalcaemia is usually due to a hungry bone 
syndrome, a syndrome seldom seen in patients with sporadic PHPT. The syndrome 
is predominantly observed in patients with severe hyperparathyroidism-associated 
increased bone turnover, specially those with parathyroid carcinoma. Data on this 
rare complication of the treatment of primary hyperparathyroidism are scarce and 
its management remains a challenge. In Chapter 5 we performed a systemic review 
of the literature on hungry bone syndrome, summarizing its main features and 
suggestions for its prevention and management. 
Part IV. Aspects of osteocyte function in primary hyperparathyroidism 
Some of the effects of PTH on bone are exerted by the specific binding of PTH to
its receptor PTHR1 in osteocytes, resulting in inhibition of the expression of the 
Sost gene (120-123). This gene encodes for the protein sclerostin, which decreases 
bone formation by inhibition of the Wnt signaling pathway in osteoblasts (124,125).
Intermittent PTH administered to post-menopausal women has been shown to 
decrease circulating sclerostin levels (126). To assess whether chronic 
hypersecretion of PTH also inhibits sclerostin secretion, we measured serum 
sclerostin concentrations in patients with untreated PHPT and in patients cured after 
successful parathyroidectomy for PHPT. Results are reported in Chapter 6.
Binding of PTH to the PTHR1 on osteocytes has been reported to upregulate 
Fibroblast Growth Factor 23 (FGF23) mRNA production (127,128), a stimulator of 
tubular phosphate transport and a suppressor of 1α-hydroxylase production by the 
kidney (129,130). Reports on the effect of chronic high circulating levels of PTH, as 
characteristic of PHPT, on FGF-23 levels are scarce and not always concordant 
(130-132). In Chapter 7 we evaluated the effect of chronic excess of PTH on
FGF23 concentrations by measuring FGF23 concentrations in patients with PHPT 
before surgery and in those with euparathyroidism cured after successful 
parathyroidectomy for PHPT.
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Part V. Clinical and molecular aspects of parathyroid carcinoma
In Chapter 8 we report the many challenges and pitfalls encountered in the 
management of a patient with multiple metastases from parathyroid carcinoma over 
a 17 year period. 
Several genes have been discovered to play a role in the etiology of PHPT,
among which the MEN-1, HRPT2 and CASR genes. Mutations in the 
HRPT2/CDC73 gene, which encodes for the protein parafibromin (133), are 
associated with the hyperparathyroidism-jaw tumor syndrome (HPT-JT; OMIM 
607393). Patients with a HPT-JT syndrome have a 15-24% chance of developing 
parathyroid carcinoma (29,134-136) and loss of heterozygosity of chromosome 1q, 
the location of the HRPT2/CDC73 gene, is reported to be found in 55% of
parathyroid carcinomas (1,17,19-21). Downregulation of the CASR has been 
reported in patients with the HPT-JT syndrome, as well as in patients with sporadic 
carcinoma (137).
The aim of the study described in Chapter 9 was to evaluate the role of 
mutations in the HRPT2/CDC73 gene, loss of parafibromin staining or 
downregulation of CASR expression as determinants of prognosis in patients with 
an established diagnosis of parathyroid carcinoma.
Part VI. Management of patients with persistent primary hyperparathyroidism
In patients with persistent primary hyperparathyroidism who had undergone 
multiple surgeries, re-explorations are associated with a more than 3-fold increased 
risk of morbidity (33,93,105,106), due to scarring of the operation field and 
disruption of the normal patterns of drainage by previous surgeries. In Chapter 10 
we assessed the demographic, clinical, biochemical, surgical and pathological 
characteristics of patients with persistent PHPT to identify predictive factors for
cure after revision surgery.
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ABSTRACT 
 
Objective: Cure rate for primary hyperparathyroidism (PHPT) is reported to be 94-
100% 1 year after surgery, but recent data suggest recurrence in 4% of patients 1-5 
years postoperatively. The aim of our study was to establish the cure rate and its 
maintenance in the long-term after parathyroidectomy (PTx) in patients with 
sporadic primary hyperparathyroidism.  
 
Design: Evaluation of recurrence in patients with sporadic hyperparathyroidism 
who underwent PTx 1-24 years prior to the study. 
 
Patients & Methods: We identified 111 patients who underwent initial PTx 
between 1984 and 2008 and had no MEN-1, MEN-2 or CASR mutation; parathyroid 
carcinoma; a history of lithium use; or renal failure. Thirty-eight patients were lost 
to follow-up or were unwilling or unable to participate in the study. Cure was 
defined as maintenance of normal serum calcium and parathyroid hormone 
concentrations 6 months after PTx. 
 
Results: Cure was achieved in 68 of 73 patients studied (93%) and was sustained in 
all for 6±5 years.  
 
Conclusion: The cure rate of sporadic PHPT after initial surgery is 93%. When 
cure is achieved, this is sustained in 100% of the patients for up to 24 years post-
operatively. Our data suggest that closer early follow-up is advocated in all patients 
undergoing PTx to definitively establish cure and to provide a safety net for those 
with residual gland pathology. The data do not support the need for long term 
follow-up when cure is established 6 months after PTx. 
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INTRODUCTION
In primary hyperparathyroidism (PHPT), surgical removal of all pathological 
parathyroid glands is the only approach that provides a definitive and durable cure. 
Cure rate has been reported to be in the range of 94-100% for bilateral neck, as well 
as less invasive surgery, more than 6 months after parathyroidectomy (PTx) (1-10).
Residual postoperative biochemical features of PHPT may be due to either recurrent 
or persistent PHPT. In a 5 year follow-up of 91 patients successfully operated for 
PHPT, Westerdahl et al. reported a recurrence rate of 4%, largely due to previously 
undiagnosed germline mutations in the MEN-1 gene and consequent multiple gland 
pathology (11). Persistent hyperparathyroidism is usually due to a pathological 
parathyroid gland missed at initial surgery. Such a gland is often small, usually 
forming a part of unrecognized multiple gland hyperplasia (12,13). The diagnosis of 
persistent hyperparathyroidism may be delayed because of the initial suppression of 
multiple pathological glands by a dominant enlarged gland, falsely suggesting cure 
immediately post-operatively. These pathological glands eventually overcome their 
suppressed state leading to overt hyperparathyroidism. 
In PHPT, the importance of achieving cure has been highlighted in a number of 
studies focusing on the effect of PTx on bone mineral density (BMD),
nephrolithiasis and neurocognitive function (14-16). Patients who are cured show a 
significant post-operative increase in bone mass, with BMD remaining significantly 
above baseline for up to 15 years of follow-up (17). This is in contrast to BMD 
changes in patients treated conservatively, in whom significant cortical bone loss 
and increased fracture risk are observed. As reported in a number of studies, 
patients with nephrolithiasis at presentation demonstrate no recurrence of renal 
stones after successful PTx, in contrast to a 75-100% chance of recurrent 
nephrolithiasis if not operated (14,17). Symptomatic and also ‘asymptomatic’
patients undergoing PTx have been reported to experience a significant 
improvement in various parameters of quality of life compared to patients who had 
no surgery (18-22). The aim of our study was to establish the cure rate and its 
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maintenance in the long-term after initial PTx in patients with sporadic PHPT who 
underwent surgery in our hospital between 1984 and 2008.
PATIENTS AND METHODS
Study population
All patients with a diagnosis of PHPT who had a PTx in the Leiden University 
Medical Center (LUMC) from March 1984 to May 2008 were identified from our 
hospital records and were considered for study. Patients who were not initially 
operated in our institution and patients with parathyroid carcinoma, renal failure, or 
a history of lithium use were excluded from the study. Patients with a MEN-1, 
MEN-2 or CASR mutation were also excluded from the final analysis, although 
genetic testing may have been undertaken some years after initial PTx. Details on 
the outcome of these 32 patients with a documented mutation are shown in Figure 
1. One hundred and eleven patients with sporadic PHPT were thus eligible for the 
study and were recalled for a follow-up visit at the outpatient clinic of the 
Department of Endocrinology and Metabolic Diseases. 
Figure 1.  Study flow diagram
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Methods
A detailed medical history was obtained from all patients with special emphasis on 
symptoms related to hypercalcaemia and non specific symptoms of 
hyperparathyroidism, such as tiredness, mood swings, depression, feeling irritable, 
being forgetful, feeling weak, bone pain, muscle weakness, constipation and 
polyuria/polydipsia. These symptoms represent 10 of the 13 items of the validated 
Pasieka’s ‘Parathyroid Assessment of Symptoms Score (PAS)’ (21,23). Blood was 
collected from all patients. Operative and pathology data were obtained from 
patients’ hospital records. Fracture history was obtained by direct questioning and 
was confirmed by reviewing available radiological data spanning the period before 
and after PTx.
Serum Biochemistry 
Serum concentrations of calcium (reference range 2.15-2.55 mmol/l), albumin 
(reference range 34-48 g/l), phosphate (reference range 0.90-1.50 mmol/l), and 
creatinine (reference range 44-80 μmol/l) were measured using semi-automated 
techniques. Creatinine clearance was calculated using the Cockcroft formula. Serum 
concentrations of intact parathyroid hormone (PTH: reference range 1.5-8 pmol/l)
and 25-hydroxycholecalciferol (25 (OH) D3) (reference range 30-120 nmol/l) were 
measured using standard RIAs. Vitamin D status was judged to be inadequate when 
25(OH)D3 concentrations were <50 nmol/l (24,25).
Radiological investigations
BMD was measured at the lumbar spine (L1-L4) and femoral neck, using dual 
energy X-ray absorptiometry (DXA, Hologic QDR 4500; Waltham, MA, USA), in 
46 patients who had a baseline BMD measurement before PTx. World Health 
Organization criteria were used to define osteopenia (T-score between -1 and -2.5) 
and osteoporosis (T-score <-2.5) (26). Lateral X-rays of the thoracic and lumbar 
spine were performed in 35 patients, when medically indicated, in case of height 
loss or back pain, and in those who had baseline X-rays before PTx. 
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Fifty one patients, including those with persistent PHPT and those with a history 
of nephrolithiasis or nephrocalcinosis, and representing 70% of the study 
population, had an ultrasound of the kidneys to document the presence or absence 
of nephrocalcinosis and/or nephrolithiasis.  
Surgical procedure
The indication criteria for surgery were based on the 1990 (27) and subsequent 
2002 (28) NIH Consensus guidelines. The 1990 guidelines were broadly followed 
in our institution in the period preceding their publication. Before the introduction 
of intra-operative PTH (IOPTH) measurement in our hospital in 1997, almost all the
patients underwent bilateral neck exploration with visualization of all the four 
parathyroid glands. This led either to the excision of a single enlarged parathyroid 
gland, or to subtotal or total PTx with auto transplantation if more than one 
parathyroid gland was found to be enlarged. If all parathyroids could not be 
visualized and no enlarged parathyroid was found, dissection of the ipsilateral 
anterior compartment extending from the level of the hyoid bone superiorly to the 
suprasternal notch inferiorly and hemithyroidectomy were undertaken on the side of 
the missing parathyroid. After standardizing the use of IOPTH, a more selective 
surgical approach was opted for, and less invasive neck exploration was undertaken 
in patients with positive preoperative localization studies. IOPTH monitoring 
consisted of two initial baseline measurements with an interval of 15-20 minutes, 
followed by five measurements at 3-minute intervals after excision of the 
pathological parathyroid(s). Surgery was considered successful if IOPTH decreased 
by more than 50% within 7 minutes of excision of a pathological parathyroid 
gland(s).
Definition of cure, persistence and recurrence of hyperparathyroidism
Successful surgery or cure was defined as normal serum calcium and PTH 
concentrations as measured more than 6 months after PTx. Persistence of 
hyperparathyroidism was defined as high serum calcium and PTH concentrations or 
inappropriate concentrations of one parameter with respect to the other, documented 
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directly post-operatively or within the first 6 months after PTx, and persisting 
thereafter. Recurrence of hyperparathyroidism was defined as the recurrence of 
elevated serum calcium and PTH concentrations after successful PTx and a period 
of normalization of both parameters of at least 6 months after surgery.  
Statistical analysis
Statistical analysis was performed using the SPSS 16.0 for Windows (Chicago, IL, 
USA). Results are expressed as mean ± S.D. unless otherwise stated. χ2 test and 
Student’s t-test were used as appropriate for categorical variables and continuous 
variables. A probability level of random difference of P<0.05 was considered 
significant. 
The study was approved by the local ethics committee, and informed consent was 
obtained from all patients prior to inclusion in the study.
RESULTS
Demographic data
Seventy-three of the 111 patients who were invited to participate in the study agreed 
to take part. Of the remaining 38 patients, 13 had died, 10 were lost to follow-up 
and 15 were physically unable or unwilling to take part in the study (Figure 1). 
Fifty-six women and 17 men, with a mean age of 56 ± 10 years at the time of 
the diagnosis were included in the study (Table 1). At the time of the first 
presentation, only 18 of the 73 patients (25%) were asymptomatic. Although only 7 
patients had symptoms related to hypercalcemia such as polyuria, polydipsia, and 
constipation, nonspecific symptoms were common. Tiredness was reported in 44%, 
muscle or bone pain in 22%, and depressive symptoms in 16% of the patients. 
Twenty- seven patients (37%) had symptoms related to renal stones and six patients 
(8%) had sustained a documented fracture, two vertebral and four non-vertebral 
after some degree of trauma. Mean pre-operative serum calcium concentration was 
2.76 ± 0.20 mmol/l and mean PTH level was 19.5 ± 15.7 pmol/l. Renal impairment, 
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as defined by a creatinine clearance of <60 ml/min, was documented in 21% of 
patients. Renal stones were documented on ultrasound of the kidneys in 41% of 
patients and 38% had BMD evidence for osteoporosis on DXA.
Sixty-three of the 73 patients (86%) had undergone parathyroid localization 
studies before PTx, using Tc99m-MIBI-SPECT scan and/or ultrasound scan of the 
neck. Forty-seven of the 73 patients (64%) had undergone bilateral neck 
exploration, 12% had unilateral neck exploration and 23% had a minimally invasive 
procedure. Surgery was guided by IOPTH monitoring in 53 patients (73%).  In 14 
of the 73 patients (19%), PTx was combined with a hemithyroidectomy. The 
decision for this procedure was based on pre-operatively identified thyroid 
pathology in seven patients and negative bilateral neck exploration in the other 
seven patients. However, an intra-thyroidal parathyroid gland was found in only 3 
of the 14 patients.
Since 2001, due to the availability of IOPTH monitoring and the increased 
popularity of less invasive surgical procedures, the percent of bilateral neck 
explorations decreased from 76 to 56% and that of the more focused surgical 
approaches increased from 24 to 44%. Parallel to the use of less invasive surgical 
approaches, the use of pre-operative localization studies increased from 77 to 95% 
and the use of IOPTH monitoring increased from 43 to 93% (Figure 2). A single 
adenoma was removed at surgery in 56 of the 73 patients (77%), and one or more 
hyperplastic glands were removed in 16% of the cases.
Short-term follow-up, within one year of parathyroidectomy
At the time of first follow-up, within 3 months of surgery, 70 of the 73 patients
(96%) had evidence for biochemical cure of hyperparathyroidism. At the time of the 
second post-operative follow-up, 6 months after PTx, 68 of the 73 patients (93%) 
had evidence for cure. Five patients (7%) demonstrated persistence of 
hyperparathyroidism; in two of whom this was originally overlooked because of a 
transient normalization of serum calcium and PTH concentrations post-operatively. 
In these two patients, a second laboratory measurement demonstrated elevated 
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Table 1. Demographic, laboratory, clinical and surgical data of patients who 
underwent initial surgery for sporadic primary hyperparathyroidism 
s: serum, u: urinary, renal impairment=creatinine clearance <60 ml/min
Achieved cure Persistence after 
Total patients after initial PTx initial PTx P value
N=73 N=68 N=5
Gender (men:women) 17:56 16:52 1:4 0.857
Age at diagnosis (years) 56 ± 10 56 ± 11 56 ± 6 0.910
Age at follow-up (years) 63 ± 11 63 ± 11 69 ± 5 0.199
Years after PTx 6 ± 5 6 ± 5 12 ± 5 0.013
Follow-up time after PTx (months) 39 ± 56 33 ± 50 129 ± 66 0.000
Biochemistry prior to intial surgery
      s-calcium (mmol/l) 2.76 ± 0.20 2.77 ± 0.20 2.68 ± 0.08 0.313
      PTH (pmol/l) 19.5 ± 15.7 20.2 ± 16.0 9.9 ± 2.0 0.161
      phosphate (mmol/l) 0.88 ± 0.18 0.89 ± 0.19 0.85 ± 0.15 0.676
      Creatinine clearance  (ml/min) 72 ± 14 72 ± 14 66 ± 5 0.068
      u-calcium (mmol/24 h) 11.05 ± 4.80 10.96 ± 4.89 12.13 ± 3.67 0.604
Clinical presentation
      Polyuria & polydipsia 6/73 (8%) 6/68 (9%) 0/5 0.488
      Constipation 1/73 (1%) 1/68 (1,5%) 0/5 0.785
      Tiredness 32/73 (44%) 31/68 (46%) 1/5 (20%) 0.266
      Muscle or bone pain 16/73 (22%) 15/68 (22%) 1/5 (20%) 0.914
      Depressive symptoms 12/73 (16%) 12/68 (18%) 0/5 0.304
Complications
      Renal impairment 15/73 (21%) 14/68 (21%) 1/5 (20%) 0.925
      Nephrolithiasis 30/73 (41%) 28/68 (41%) 2/5 (40%) 0.959
      Osteoporosis 28/73 (38%) 27/68 (40%) 1/5 (20%) 0.382
      Fractures 7/73 (10%) 6/68 (9%) 1/5 (20%) 0.413
Pre-operative localization studies
      US and/or MiBi-SPECT 62/73 (86%) 58/68 (85%) 4/5 (80%) 0.671
Type of surgery
      Bilateral neck exploration 47/73 (64%) 44/68 (65%) 3/5 (60%) 0.832
      Unilateral neck exploration 9/73 (12%) 8/68 (12%) 1/5 (20%) 0.589
      Minimally invasive 17/73 (23%) 16/68 (24%) 1/5 (20%) 0.857
   Combined with thyroidectomy 14/73 (19%) 13/68 (19%) 1/5 (20%) 0.961
      Combined with thymectomy 5/73 (7%) 4/68 (6%) 1/5 (20%) 0.228
      Use of IOPTH monitoring 53/73 (73%) 50/68 (74%) 3/5 (60%) 0.513
Pathology
      Adenoma 56/73 (77%) 53/68 (78%) 3/5 (60%) 0.360
      Hyperplasia 12/73 (16%) 11/68 (16%) 1/5 (20%) 0.824
      No pathological glands found 5/73 (7%) 4/68 (6%) 1/5 (20%) 0.228
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serum calcium and PTH concentrations at respectively 3 and 5 months post-
operatively. There were no significant differences in demographic or biochemical 
data before or after PTx between patients who were cured after initial surgery and 
those (n=5) who demonstrated persistence of PHPT (Table 1). 
Figure 2. Pattern of change in surgical procedures, use of pre-operative localization studies 
and IOPTH monitoring, and cure rate over 24 years of follow-up. In the first decade of the 
study (1982-1991) all patients underwent bilateral neck exploration and IOPTH monitoring 
was not yet available. * P<0.05, ** P <0.001.
Long-term follow-up
Patients were evaluated after a mean of 6 ± 5 years and up to 24 years after PTx, 
with the majority of the patients (68%) being assessed more than 5 years after PTx. 
Median age at follow-up was 63 years compared to 55 years before PTx.  Cure was 
sustained for the length of follow-up in all 68 patients in whom cure was 
established at 6 months after initial surgery. Regardless of age, 29% of the patients 
complained of tiredness, only two of whom were older than 70 years, 22% of 
muscle or bone pain, and 15% of depressive symptoms, which persisted despite 
complete cure. The mean corrected serum calcium concentration was 2.27 ± 0.13 
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mmol/l, with a mean serum PTH concentration of 4.4 ± 2.4 pmol/l. Two of the five
patients with persistent HPTH had undergone successful revision surgery, resulting 
in cure after excision of one or more additional hyperactive parathyroid glands, one 
of which was situated retrosternally. The third patient is being treated 
conservatively because of the mild asymptomatic nature of her PHPT and the 
failure of localization studies to identify the site of the hyperactive gland(s). A 
conservative approach was also originally opted for in the fourth patient because of 
the mild asymptomatic nature of his persistent PHPT, but he is now scheduled for 
revision surgery as he demonstrated significant symptomatic and biochemical 
progression of his HPTH 9 years after his initial surgery (Figure 3). The fifth patient 
still has persistent PHPT after unsuccessful full neck and mediastinal explorations,
and is being treated successfully with the calcimimetic cinacalcet. 
Predictive factors for cure after parathyroidectomy
There were no significant differences in gender and age at presentation between 
patients who achieved and maintained cure and patients with persistence of HPTH 
after initial PTx (Table 1). Clinical presentation (symptomatology and skeletal 
and/or renal complications) was also not significantly different in patients in whom 
HPTH persisted post-operatively. None of the laboratory investigations, including 
serum calcium, PTH, phosphate, urinary calcium, and creatinine clearance, showed 
a significant difference between cured and noncured patients. There was also no 
significant difference in the availability of pre-operative localization studies, type of 
surgical approach, or use of IOPTH monitoring between groups. No pathological 
tissue was found at initial surgery in one of the five patients with persistent HPTH, 
but this was also the case in 4 patients who were subsequently cured. It is of note 
that all five patients with persistent HPTH had undergone surgery before 2001 and 
all had undergone localization studies in the form of ultrasound of the neck and/or 
Tc99m-MIBI-SPECT scan. Three of the five patients also had IOPTH monitoring 
(Table 2), in 2 of whom IOPTH monitoring indicated cure, with a decrease in PTH 
levels of 96 and 71,6% respectively after excision of a pathological parathyroid 
gland. In both patients, this was associated with a transient normalization of serum 
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calcium and PTH concentrations lasting 3 and 5 months respectively after PTx. In 
the third patient with persistent HPTH, only one hyperplastic gland could be 
identified and removed during surgery, but there was no significant decrease in 
IOPTH levels and hyperparathyroidism persisted post-operatively.
Figure 3. Serum calcium and PTH concentrations in a patient conservatively treated for mild 
asymptomatic persistent hyperparathyroidism after incomplete parathyroidectomy (PTx). 
Clear demonstration of progression of biochemical features associated with clinical 
manifestations of overt hyperparathyroidism 9 years after surgery, outlining the importance 
of long-term follow-up in these patients.
Fate of symptoms/complications of primary hyperparathyroidism after cure
After successful parathyroidectomy, none of the 68 cured patients had specific 
symptoms related to hypercalcaemia, particularly no polyuria and polydipsia 
(Figure 4). Although there was a trend towards a decrease in reported tiredness 
(P=0.05), there was no significant change in a number of other non-specific 
symptoms, such as depressive symptoms, muscle pain or muscle weakness after 
cure. The frequency of nephrolithiasis decreased significantly from 41% to 10%, 
(P=0.000). There was also a significant improvement in BMD, with only 16% of 
patients having evidence for osteoporosis a mean of 6 years after PTx compared to 
PTx
PTx






































































































































































































































































































































































40% before surgery P=0.002). After parathyroidectomy, 4 patients, all of whom 
were post-menopausal women aged 59 to 78 years, sustained 4 documented 
fractures, one vertebral and 3 non-vertebral (2 hip fractures and 1 Colle’s fracture). 
64% of patients who had renal impairment prior to PTx demonstrated a 35% 
improvement in their renal function after successful surgery. In the remaining 
patients with renal impairment at initial surgery, this remained stable in 21% and 
further decreased by 22% in 14% of patients who achieved and maintained cure. 
Renal function decreased over time of follow-up in 4 patients who had normal renal 
function pre-operatively. 
Figure 4. Change in symptomatology and in renal and skeletal complications after successful 
surgery for sporadic primary hyperparathyroidism, after a mean 6 years follow-up. * P<0.05, 
** P <0.001.
DISCUSSION
In our population of patients with sporadic PHPT, we observed an overall cure rate 
of 93%, which has risen to 100% over the last 7 years with the increasing use of 
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pre-operative localization studies and IOPTH monitoring. We demonstrated that 
when cure is achieved in these patients, this is sustained in all for up to 24 years of 
follow-up. 
Cases of ‘recurrent HPTH’ reported by Westerdahl et al. (11) and Hedback et al.
(29) were shown to be due to initially unsuspected MEN-1 or MEN-2 mutations or 
due to secondary or tertiary hyperparathyroidism, all potentially associated with 
multiple gland disease. Data from our study, in which we excluded patients with 
known germ cell mutations in the MEN-1 or MEN-2 gene or other genes controlling 
parathyroid growth and PTH secretion, support the notion that ‘recurrent’ HPTH 
does not occur in sporadic PHPT when cure is established 6 months after PTx. This 
is in clear contrast to the outcome in patients with a known germ cell mutation, who 
were excluded from the study, in whom hyperparathyroidism recurred post-
operatively in 44% of the cases (Figure 1). In this context, DNA analysis is strongly 
advocated in all the cases of ‘recurrent’ HPTH to assess the possible presence of a 
specific germ cell mutation as this holds significant clinical implications for the 
management of these patients.
Following adequate surgery, persistent HPTH is most commonly due to multiple 
gland disease with additional pathological glands often missed during initial 
surgery. Transient normalization of serum calcium and PTH concentrations occurs 
post-operatively in multiple gland disease due to the suppression of the activity of 
smaller glands by a dominant large gland. Pathological small parathyroid glands 
may take sometimes up to 6 months to recover and become hyperactive in their own 
right. Failing to consider this possibility may result in premature discharge of 
patients from follow-up because of the erroneous impression of permanent cure. 
This is illustrated in one of our patients with persistent HPTH, who demonstrated 
progression of HPTH 9 years after initial PTx. Solorzano et al. also showed that 
patients with normal calcium and inappropriately high PTH values after surgery 
have, in fact, persistence of HPTH which can take up to 2 years to become 
symptomatic (30). Follow-up is therefore strongly advocated for more than 6 
months after PTx to definitively establish cure and provide a safety net for those 
patients with pseudo-cure, who have residual gland pathology. 
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In addition to the essential requirement of an experienced surgeon, pre-operative 
localisation studies and IOPTH monitoring appear to significantly contribute to a 
successful outcome of surgery. In our hands, implementation of these measures has 
resulted in a 100% cure rate over the last 7 years. 
In contrast to the widely observed shift in clinical presentation of PHPT from a 
symptomatic to a largely asymptomatic one, more than 70% of our patients were 
symptomatic and had renal impairment, renal stones or osteoporosis with or without 
fractures. Our institution is a tertiary referral center treating the more severe forms 
of PHPT, and patients with more severe forms of the disease are thus 
overrepresented in our study. However, this bias also represents the strength of our 
study, as we do show that despite the severity of hyperparathyroidism, cure can be 
achieved and sustained and is associated with significant beneficial effects on 
kidneys and bones. 
We observed a significant decrease in the frequency of nephrolithiasis, an 
improvement in renal function in those with pre-operative renal impairment, and a 
general improvement in BMD after successful surgery. Other studies have also 
shown this positive effect of PTx on BMD, supporting the notion that osteopenia 
and osteoporosis are at least partially reversible after PTx (15-17). In our study, the 
limited number of X-rays performed in the study population combined with the 
small number of fractures sustained before or after PTx precludes a meaningful 
analysis of an effect of PTx on fracture risk.
The retrospective nature of the analysis of changes in neurocognitive function 
represents a limitation of our study, particularly with a time span of up to 24 years 
from presentation. It was notable, however, that a high proportion of patients, who 
were permanently cured, still had residual nonspecific symptoms, such as tiredness 
and depressive symptoms. This suggests that to some extent these symptoms may 
have been falsely attributed to PHPT, although irreversible changes in 
neurocognitive function may have also occurred as a result of long-term exposure to 
high circulating levels of PTH.  
Our findings from this study hold significant clinical implications. The absence 
of recurrence of sporadic PHPT, when cure is established 6 months post-
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operatively, strongly suggests that long-term follow-up of these patients is not 
necessary. In contrast, close follow-up is advocated within the first 6 months after 
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ABSTRACT
Background:
In primary hyperparathyroidism (PHPT) the predictive value of technetium 99m 
sestamibi single emission computed tomography (Tc99m-MIBI-SPECT) for 
localizing pathological parathyroid glands before a first parathyroidectomy (PTx) is 
83-100%. Data are scarce in patients undergoing reoperative PTx for persistent 
hyperparathyroidism. The aim of our study was to determine the value of Tc99m-
MIBI-SPECT in localizing residual hyperactive parathyroid tissue in patients with 
persistent PHPT after initial excision of one or more pathological glands. 
Method:
We retrospectively evaluated the localizing accuracy of Tc99m-MIBI-SPECT scans 
in 19 consecutive patients with persistent PHPT who had a scan before reoperative 
parathyroidectomy. We used as controls 23 patients with sporadic PHPT who had a 
scan before initial surgery. 
Results:
In patients with persistent PHPT, Tc99m-MIBI-SPECT accurately localized a 
pathological parathyroid gland in 33% of cases before reoperative 
parathyroidectomy, compared to 61% before first PTx for sporadic PHPT. Tc99m-
MIBI-SPECT accurately localized intra-thyroidal glands in 2 of 7 cases and a 
mediastinal gland in 1 of 3 cases either before initial or reoperative 
parathyroidectomy. 
Conclusion:
Our data suggest that the accuracy of Tc99m-MIBI-SPECT in localizing residual 
hyperactive glands is significantly lower before reoperative parathyroidectomy for 
persistent PHPT than before initial surgery for sporadic PHPT. These findings 
should be taken in consideration in the preoperative workup of patients with 
persistent primary hyperparathyroidism. 
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INTRODUCTION
Primary hyperparathyroidism is one of the most common endocrine disorders. 
Surgical removal of all pathologic parathyroid tissue is the only therapy that leads to
definitive and durable cure. The need for preoperative localization of pathological 
parathyroid gland(s) before initial surgery depends on the chosen surgical approach. 
In case of traditional bilateral neck exploration, localization studies are not deemed
necessary because experienced surgeons have, on average, a 98% chance of excising
all pathological tissue, as the procedure entails visualization of all four parathyroid 
glands (1,2). However, localization studies become mandatory when the surgeon 
opts for a more focused unilateral or minimally invasive approach. Accurate 
localization studies are even more important before reoperative parathyroidectomy 
for persistent hyperparathyroidism, as a second (or more) neck exploration is 
technically more challenging than initial surgery and may be associated with as 
much as a threefold increase in morbidity (1,3-5). Persistent hyperparathyroidism is 
reported to occur in 2-7% of patients who have had a parathyroidectomy (1,6,7).
Excluding insufficient experience of the operating surgeon, persistent PHPT may be 
caused by a second adenoma, multiple gland hyperplasia, an ectopically located 
hyperactive gland undetected at initial surgery, or, rarely, parathyromatosis from 
gland spillage during initial surgery (8).
Technetium 99m sestamibi (Tc99m-MIBI), particularly when complemented by 
single emission computed tomography (Tc99m-MIBI-SPECT), is a widely used 
imaging technique for the preoperative localization of parathyroid adenomas (1,9).
Tc99m-MIBI-SPECT has a sensitivity ranging from 66 to 90% and a positive 
predictive value ranging from 83 to 100% for pathological parathyroid glands (1,10-
17). However, the test is also known to have lower sensitivity for small adenomas 
weighing <500 mg (15,18) and in the presence of multiple gland pathology 
(1,9,15,17-20).
Tc99m-MIBI was originally developed for myocardial perfusion imaging. It is a 
monovalent lipophilic cation that diffuses passively through cell membranes and 
accumulates almost exclusively in mitochondria following negative membrane 
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potentials (21). The imaging technique has been used to detect benign tumours as 
well as several primary malignancies and metastatic tumours (22). In primary 
hyperparathyroidism, the mechanism by which Tc99m-MIBI can localize a 
pathological parathyroid gland is based on the increased uptake of the 
radiopharmaceutical by functionally hyperactive glands; on the abundance of 
mitochondria in parathyroid oxyphil cells, which sequester sestamibi intracellularly; 
and on the increased perfusion of hyperactive parathyroid glands. However, imaging 
studies are often negative in persistent hyperparathyroidism. Potential contributory 
factors to false negative scans are a postoperative disturbance in the perfusion of 
remaining pathological glands and a predominance of parathyroid chief cells, which 
are poorer in mitochondrial content compared to oxyphil cells (18).
In patients undergoing reoperative parathyroidectomy for persistent
hyperparathyroidism, the accuracy of Tc99m-MIBI-SPECT in localizing hyperactive 
parathyroid tissue has been largely assessed in mixed patient groups, including 
patients in whom no parathyroid tissue was found at initial surgery (23,24), patients 
with a known MEN-1 (multiple endocrine neoplasia type 1) mutation (25), and 
patients with secondary or tertiary hyperparathyroidism (26,27). Data on the ability 
of Tc99m-MIBI-SPECT to detect and localize residual hyperactive parathyroid 
tissue in patients with persistent primary hyperparathyroidism are particularly 
scarce. The available data do suggest, however, that the predictive value of this 
technique falls dramatically from 80% or higher before initial surgery for single 
gland disease (SGD) to as low as 50% before reoperative parathyroidectomy for 
persistent PHPT (28-30). Because reoperative parathyroidectomy may be associated 
with increased morbidity, accurate localization of residual hyperactive tissue 
becomes of paramount importance in patients with persistent PHPT (28-30). Correct 
preoperative localization of a hyperactive parathyroid gland by Tc99m-MIBI-
SPECT would allow for more focused and efficient exploration, thus reducing the 
risk of damage to the recurrent laryngeal nerve(s) and significantly increasing the 
likelihood of cure.
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The aim of the present study was to determine the ability of Tc99m-MIBI-
SPECT to detect and localize residual hyperactive parathyroid glands prior to 
reoperative parathyroidectomy in patients with persistent PHPT. 
PATIENTS AND METHODS
Patients 
Using hospital records, we identified 19 consecutive patients who required 
reoperative parathyroidectomy for persistent hyperparathyroidism and who had 
parathyroid localization studies with Tc99m-MIBI-SPECT before surgery. These 
were 14 women and 5 men with a mean age of 55 ± 12 years at diagnosis, who had 
undergone between one and three unsuccessful earlier neck explorations. Sixteen of 
the 19 patients had their initial surgery and earlier reoperations, if applicable, at 
other institutions and were referred to our unit for further workup before reoperative 
parathyroidectomy. We compared these patients with 23 patients with sporadic 
primary hyperparathyroidism due to single gland disease who also had a Tc99m-
MIBI-SPECT scan prior to initial surgery. These were, respectively, 21 women and 
2 men with a mean age of 59 ± 12 years at diagnosis. All surgical procedures were 
undertaken by two surgeons with considerable experience in endocrine surgery. 
Methods
Demographic data, operative data, preoperative and postoperative laboratory data 
and histological findings were obtained from patients’ hospital records. In the 
present study, cure is defined as sustained normal serum calcium and PTH 
concentrations more than 6 months after parathyroidectomy (6). Persistent 
hyperparathyroidism is defined as persistently elevated serum calcium and PTH 
concentrations in consecutive samples within and beyond 6 months after surgery (6).
Histological preparations were independently reviewed by an experienced 
pathologist. A diagnosis of parathyroid adenoma was based on the presence of a 
benign encapsulated neoplasm usually involving a single gland with an adjacent rim 
of normal glandular tissue (31). Parathyroid hyperplasia was defined as an absolute 
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increase in parathyroid parenchymal cell mass resulting from proliferation of chief 
cells, oncocytic cells, and transitional oncocytic cells in multiple parathyroid glands 
in the absence of a known stimulus for PTH hypersecretion such as renal failure or 
vitamin D deficiency (31). A diagnosis of hyperplasia was also being favoured when 
synchronous multiglandular disease was found at surgery. 
TC99M-MIBI-SPECT imaging technique
The Tc99m-MIBI-SPECT scan was performed as follows: after intravenous 
injection of 500 MBq of Tc99m methoxy-isobutyle-isonitrile (MIBI), planar images 
of the head and neck region and chest were performed at a matrix size of 256 x 256 
(10 minutes per frame). Scintigraphy was performed as a dual-phase single tracer 
examination. Images were acquired with the patient in the supine position, 15 min 
and 2 h after injection of the radiopharmaceutical. A gamma camera (Toshiba GCA-
7200, Tokyo, Japan) equipped with low-energy high-resolution (LEHR) collimators 
was used for image acquisition. Single photon emission computed tomography 
(SPECT) was performed in a 128 x 128 matrix size, using a step angle of 4o and a
step time of 35 s per step, 90 minutes after the injection. The filtered back projection 
was used for image reconstruction, using a Butterworth filter (8 order, subset 12). 
All Tc99m-MIBI-SPECT scans were reviewed by an experienced nuclear medicine 
physician who was blinded to the outcome of the surgical procedure.
Surgical procedures
Bilateral neck exploration consisted of visualization of all four parathyroid glands,
followed by either excision of a single enlarged parathyroid gland or subtotal or 
total parathyroidectomy with auto transplantation if more than one parathyroid 
gland was found to be enlarged. If not all four parathyroid glands could be 
visualized and no enlarged parathyroid gland was found, dissection of the ipsilateral 
anterior compartment extending from the level of the hyoid bone superiorly to the 
suprasternal notch inferiorly and hemithyroidectomy were undertaken on the side of 
the missing parathyroid. Unilateral neck exploration and minimally invasive neck 
exploration were guided by intraoperative PTH measurement.
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Figure 1. Positive Tc99m-MIBI-SPECT imaging scan demonstrating increased radioactive 
pharmaceutical uptake in the right lower neck suggesting a pathological parathyroid gland in 
this location (A), concurring with subsequent operative findings of a 2,5 cm pathological 
parathyroid adenoma (B). 
Analysis of data
The ability of Tc99m-MIBI-SPECT to detect and localize hyperactive parathyroid 
tissue was evaluated in three different ways, thereby providing the answers to three 
different questions that are clinically relevant to the operating surgeon. 
The first question we addressed is “Is the Tc99m-MIBI-SPECT scan able to 
detect any parathyroid hyperactivity?” This question relates to the overall sensitivity 
of the scan for detecting the presence of hyperactive parathyroid tissue in the 
scanned neck and mediastinal regions (Figure 1). A scan was considered true 
positive when it correctly identified the presence of an abnormal gland at any site. A 
scan was considered true negative when no pathological parathyroid gland(s) was 
found at surgery, and no presence of hyperactive parathyroid tissue was suggested 
by the scan. A scan was considered false positive when no pathological glands were 
found at operation, although the scan had suggested the presence of hyperactive 
parathyroid tissue. A scan was considered false negative when a pathological 
parathyroid gland was removed at surgery, although the scan had not demonstrated 
the presence hyperactive parathyroid tissue.
The second question addressed is “Is the scan able to lateralize the area of 
hyperactive parathyroid tissue?”, thus indicating which side of the neck should to be 
Tc99m-MIBI-SPECT in persistent PHPT  /  67
explored. This question relates to the sensitivity and specificity of the scan in 
identifying the side of the neck in which hyperactive parathyroid tissue is localized 
(Figure 2A). A true positive side was defined as a neck side from which a 
pathological parathyroid gland was removed at surgery, and in which the presence 
of hyperactive parathyroid tissue was suggested by the preoperative localization 
test. A true negative side was defined as a neck side in which no pathological 
parathyroid gland was found at surgery, and in which no presence of hyperactive 
parathyroid tissue was suggested by the preoperative localization test. A false 
positive side was defined as a neck side in which no pathological parathyroid gland 
was found at surgery, although the presence of hyperactive parathyroid tissue was 
suggested by the preoperative localization test. A false negative side was defined as 
a neck side from which a pathological parathyroid gland was removed at surgery,
although no presence of hyperactive parathyroid tissue was suggested by the 
preoperative localization test.
Figure 2. Analysis of the ability of Tc99m-MIBI-SPECT scan to correctly localize a 
pathological parathyroid gland as confirmed by localization at surgery by dividing the neck 
into 2 anatomical areas (the right and left side of the neck) (A) or into 5 anatomical areas (the 
four thyroid quadrants and a 5th area of all possible ectopic localizations in the mediastinum) 
(B).
68  /  Chapter 3
The third question is “Is the scan able to accurately localize the region of the 
neck where the hyperactive parathyroid tissue is present?”, thus providing an even 
smaller operative field for the surgeon to focus upon. This third question takes 
accuracy of localization of the imaging modality a step further by identifying the 
localization of the hyperactive parathyroid tissue in any of 5 designated anatomical 
areas of the neck (four thyroid quadrants, and a fifth “elsewhere” area combining all 
possible ectopic localizations in the mediastinum) (Figure 2B). With respect to the 
risk of damaging the recurrent laryngeal nerve, a correct answer to question 2 would 
limit the risk to one nerve only, whereas a correct answer to question 3 would 
provide additional information on the magnitude of this risk by identifying the 
specific region to be explored. A true positive region was defined as a region from 
which a pathological parathyroid gland was removed at surgery, and in which the 
presence of hyperactive parathyroid tissue was suggested by the preoperative 
localization test. A true negative region was defined as a region in which no 
pathological parathyroid gland was found at surgery, and in which no presence of 
hyperactive parathyroid tissue was suggested by the preoperative localization test. A 
false positive region was defined as a region in which no pathological parathyroid 
gland was found at surgery, although the presence of hyperactive parathyroid tissue 
was suggested in this region by the preoperative localization test. A false negative 
region was defined as a region from which a pathological parathyroid gland was 
removed at surgery, although no presence of hyperactive parathyroid tissue was 
suggested in this region by the preoperative localization test.
True negative and false positive scans, sides or regions could only be determined 
in patients who were cured after the surgery by the finding and removal of a 
pathological parathyroid gland elsewhere in the neck or mediastinum (this latter 
condition precluding comprising the sensitivity and specificity by false negative 
surgery).
In all three analyses widely accepted definitions for sensitivity and specificity 
were used to address each of the three different questions posed. Sensitivity was thus 
judged to be the power of the test to identify the presence of pathological 
parathyroid glands at any site regardless of accuracy of localization (question 1), on
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the correct side of the neck (question 2), or in the exact region of neck (question 3). 
Specificity was judged to be the power of Tc99m-MIBI-SPECT to recognize the 
absence of a pathological parathyroid gland in the truly negative side of the neck 
(question 2) or in the exact region of the neck (question 3).
Statistical analysis
Statistical analysis was performed using the SPSS 16 software (SPSS Inc., Chicago, 
IL). Results are expressed as mean ± SD unless otherwise stated. Baseline 
characteristics of the patient groups were compared using the one-way analysis of 
variance (ANOVA) for continuous variables, and the chi-square statistic was used 
for comparison of categorical variables. A probability level of random difference of 
P<0.05 was considered significant. 
RESULTS
Demographic data
Patients who underwent reoperative parathyroidectomy for persistent PHPT did not 
differ significantly in age and gender from patients who underwent initial surgery for 
sporadic PHPT. Laboratory data before operation did not differ significantly 
between the two patient groups (Table 1). 
Operative data and postoperative cure 
Bilateral neck exploration was more frequently performed in patients with persistent 
hyperparathyroidism undergoing reoperative parathyroidectomy (84%) than in 
patients with a single adenoma undergoing initial surgery (56%) (Table 1). 
At least one and up to three hyperactive parathyroid glands had been removed at 
initial surgery in patients with persistent hyperparathyroidism. The 18 pathological 
parathyroid glands removed at reoperative parathyroidectomy were removed from 
ectopic locations (n=8, 44%): intrathyroidal (n=4), thymus (n=2), mediastinum 
(n=1) and a location ventral to the trachea (n=1). Other glands were removed from 
expected anatomical locations in the right lower quadrant (n=4), right upper 
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quadrant (n=3), left lower quadrant (n=2), and left upper quadrant (n=1) of the 
neck. 
Table 1. Demographic, laboratory, operative and pathology data of patients who had 
a Tc99m-MIBI-SPECT scan prior to initial surgery for sporadic PHPT or prior to 
reoperative parathyroidectomy for persistent PHPT
Persistent PHPT Sporadic PHPT P value
(n=19) (n=23)
Age (years ± SD) 55 ± 12 59 ± 12 0.274
Sex (M/F) 5:14 2:21 0.127
Pre-operative laboratory data
s-Corrected Calcium (mmol/L) 2.88 ± 0.35 2.80 ± 0.23 0.399
s-PTH (pmol/L) 16.2 ± 9.3 24.5 ± 20.2 0.131
Post-operative laboratory data
s-Corrected Calcium (mmol/L)a 2.46 ± 0.28 2.29 ± 0.13 0.027
s-PTH (pmol/L)b 10.0 ± 11.7 4.0 ± 2.7 0.043
Operative data
Bilateral exploration 16 (84%) 13 (56%) 0.053
Unilateral exploration 3 (16%) 5 (22%) 0.625
Minimally invasive 0 5 (22%) 0.030
Pathology data
Adenoma 8 (42%) 19 (83%) 0.037
Hyperplasia 9 (47%) 4 (17%) 0.152
No pathological glands 2 (11%) 0 0.210
Gland diameter (cm ± SD) 1.21 ± 0.93 2.03 ± 1.40 0.062
s: serum, a reference range 2.15-2.55 mmol/L, b reference range 1.5-8 pmol/L
Complete cure was eventually achieved in 11 of the 19 patients (58%). Of the 
remaining 8 patients, 6 had no further surgery, 1 had 1 further operation, and 1 had 3 
further operations, which resulted in improvement in the severity of the 
hyperparathyroidism but not in complete cure as defined in our study. In all 8 
patients the decision to withhold further surgery was based on a combination of lack 
of severe symptoms, mild biochemical features of hyperparathyroidism, and the 
increased morbidity risk associated with further surgery in the context of prior 
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extensive neck exploration, which had to be extended to mediastinal exploration in 
some cases.
The 23 patients with PHPT who had a Tc99m-MIBI-SPECT scan prior to initial 
surgery for sporadic PHPT were all cured, and cure was sustained for a mean 
duration of 47 months (range 6-188 months) after PTx. Pathological parathyroid 
glands removed at surgery were predominantly located in the right (n=10, 43%) or 
left (n=7, 30%) lower thyroid quadrants, and only 1 pathological gland was located 
in the right upper quadrant of the neck. Five successfully removed ectopic glands 
had been in subcapsular thyroidal (n=2), intrathyroidal (n=1), or mediastinal (n=2) 
locations.
Histological data
On histological examination, 42% of the patients with persistent 
hyperparathyroidism had a second adenoma and 47% had hyperplastic parathyroid 
gland(s) (Table 1). A single adenoma was removed in 83% of the patients who 
underwent initial surgery for sporadic PHPT. The average diameter of a pathological 
parathyroid gland found at reoperative parathyroidectomy for persistent PHPT was 
smaller (1,21 cm) compared to the average size of glands found at initial surgery for 
sporadic PHPT (2,03 cm).  
Value of Tc99m-MIBI-SPECT scans prior to reoperative parathyroidectomy for 
persistent PHPT  
In total, 18 hyperactive parathyroid glands were removed at reoperative 
parathyroidectomy from 19 patients with persistent PHPT. One hyperactive 
parathyroid gland was removed in 16 of these patients, 2 glands in 1 patient, and no 
pathological glands could be found in the other 2 patients despite extensive bilateral 
neck and mediastinal explorations. Tc99m-MIBI-SPECT demonstrated increased 
radiotracer uptake, suggesting parathyroid hyperactivity in only 9 of the 19 patients 
(47%) (Figure 3). At reoperative parathyroidectomy 15 patients had a pathological
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Figure 3.  Flowchart of the answers to the three clinical questions addressed in 19 patients 
who had preoperative parathyroid localization studies with Tc99m-MIBI-SPECT prior to 
reoperative parathyroidectomy for persistent PHPT. 
19 patients who underwent 
revision surgery for persistent 
PHPT
15 patients with one or 
more hyperactive PT 
gland(s) in the neck
2 patient with a 
hyperactive PT gland in 
the mediastinum
2 patients with a negative 
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Question 2: “Which side of the neck should be explored, left or right?”
Answer 1: General sensitivity of the scan is 47% (9/19)
Answer 2: Ability of the scan to localize the gland to the correct side of the neck is 33% 
(5/15)
Question 3: “Is the scan able to accurately localize a pathological parathyroid gland?”
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gland removed from the neck region. Tc99m-MIBI-SPECT was able to identify the 
correct side of the neck in 5 of these 15 patients (33%) (Table 2; Figure 3). 
Tc99m-MIBI-SPECT was able to detect and accurately localize only 6 of the 18 
pathological glands removed at reoperative parathyroidectomy either from the neck 
or from ectopic localizations (33%) (Table 3; Figure 3). Two of these glands, an 
adenoma and a hyperplastic gland, were found in normal anatomical locations in the 
left upper and left lower thyroid quadrants, and 4 glands were found in ectopic 
locations in the neck, one adenoma was in the thymus, one adenoma and one 
hyperplastic gland were in the thyroid, and one adenoma was located ventral to the 
trachea, caudally in the neck. 
Of the 12 pathological glands not accurately localized by Tc99m-MIBI-SPECT, 
67% were hyperplastic glands and 33% were adenomas. Only 4 of the 12 glands 
missed at Tc99m-MIBI-SPECT were found in an ectopic location at surgery: one 
hyperplastic gland was in the thymus, one adenoma and one hyperplastic gland were 
in the thyroid gland, and one hyperplastic gland was in the mediastinum. 
Pathological glands with negative imaging were smaller, with a mean diameter of 9 
mm, ranging from 5-16 mm and had a histological predominance of chief cells. 
 
Value of Tc99m-MIBI-SPECT scans prior to initial surgery for sporadic PHPT   
All 23 patients with sporadic PHPT had one hyperactive parathyroid gland removed 
at initial surgery and achieved cure. However, Tc99m-MIBI-SPECT scan 
demonstrated increased radiotracer uptake, suggesting parathyroid hyperactivity in 
only 15 of the 23 patients (65%) (Figure 4). In 21 of the 23 patients the hyperactive 
parathyroid gland was removed from the neck. Tc99m-MIBI-SPECT was able to 
identify the correct side of the neck in 14 of these patients (67%) (Table 2; Figure 4). 
In 2 of the 23 patients a hyperactive gland was removed from the mediastinum, but 
Tc99m-MIBI-SPECT was able to detect only one of these glands (Figure 4). 
Tc99m-MIBI-SPECT was able to accurately localize 14 of the 23 pathological 
parathyroid gland removed at surgery (61%) (Table 3; Figure 4). Of the 14 glands 
accurately localized glands by Tc99m-MIBI-SPECT, 12 (86%) were adenomas 
located in the right lower thyroid quadrant in 9 cases (76%), in the left lower thyroid  
74  /  Chapter 3
quadrant in 2 cases (17%), and in the mediastinum in 1 case (7%). The remaining 2 
accurately localized glands were hyperplastic parathyroid glands located in the left 
lower thyroid quadrant. Of the 9 pathological glands that were not localized or that 
were inaccurately localized by Tc99m-MIBI-SPECT, 5 were found in the neck in 
expected anatomical locations at surgery and 4 were ectopically located: 3 
intrathyroidally and 1 in the mediastinum. Intrathyroidal parathyroid glands were 
found in 2 cases by visualization during extensive bilateral neck exploration and in 1 
case during unilateral neck exploration combined with intraoperative PTH (IOPTH) 
measurement. The mediastinal gland was found during thoracic extension of a full 
bilateral neck exploration during which no pathological parathyroid glands were 
found in the neck. 
 
Table 2. Predictive value of Tc99m-MIBI-SPECT for the localization of 
pathological parathyroid glands in the correct side of the neck 
 
  Sensitivity Specificity PPV NPV 
Before initial surgery     
for sporadic PHPT (n=23) 67% 100% 100% 75% 
Before reoperative parathyroidectomy     
for persistent PHPT (n=19) 33% 80% 63% 53% 
 
PPV: positive predictive value, NPV: negative predictive value 
 
Table 3.  Predictive value of Tc99m-MIBI-SPECT for the localization of 
pathological parathyroid glands in the exact region of the neck 
  Sensitivity Specificity PPV NPV 
Before initial surgery     
for sporadic PHPT (n=23) 61% 99% 93% 91% 
Before reoperative parathyroidectomy     
for persistent PHPT (n=19) 33% 95% 67% 84% 
 
PPV: positive predictive value, NPV: negative predictive value 
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Limitations of Tc99m-MIBI-SPECT imaging studies
Localization ability for pathological parathyroid glands in anatomically expected 
versus ectopic locations
Combining all patients included in this study, pathological parathyroid glands were 
most frequently found in the right (37%) and left (32%) lower thyroid quadrants 
(Figure 5). Thirteen of the 41 pathological glands removed at surgery (32%) were 
found in ectopic locations: intrathyroidally (n=7), in the thymus (n=2), in the 
mediastinum (n=3), and ventral to the trachea in the neck (n=1). An intrathyroidal 
parathyroid gland was accurately localized preoperatively in 2 of 7 cases (29%), a 
mediastinal gland in 1 of 3 cases (33%), a gland in the thymus in 1 of 2 cases (50%),
and a gland ventral to the trachea in one case (100%).
                                  
Figure 5. Combined number of pathological parathyroid glands identified at initial (n=23) 
and at revision surgery (n=18) in each of the four quadrants of the neck and the mediastinum. 
The sensitivity of Tc99m-MIBI-SPECT for localization in each of these four quadrants of the 
neck and the mediastinum is shown in parentheses.
Tc99m-MIBI-SPECT scan had a lower sensitivity for pathological parathyroid 
glands identified at surgery in the upper quadrants of the neck (2/9=22%), than for 
glands found in the lower quadrants of the neck (16/28=57%) (Figure 5). None of 
the 7 pathological parathyroid glands in the right upper thyroid quadrant could be 
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Figure 4. Flowchart of the answers to the 3 clinical questions addressed in 23 patients who 
had preoperative parathyroid localization studies using Tc99m-MIBI-SPECT prior to initial 
surgery for sporadic PHPT.
23 patients who underwent 
initial surgery for sporadic 
PHPT
21 patients with one 
hyperactive PT gland(s) in 
the neck
2 patients with a 








21 patients with one 
hyperactive PT gland(s) in 
the neck
7 negative scans14 positive scans, with 
hyperactivity on the correct 
side of the neck 
23 patients who underwent 
initial surgery for 
sporadic PHPT
23 patients in whom 1 
hyperactive PT gland(s) was 




in the correct 





in the wrong 






Question 1: “Does Tc99m- MIBI - SPECT detect any parathyroid hyperactivity?”
Question 2: “Which side of the neck should be explored, left or right?”
Answer 1: General sensitivity of the scan is 65% (15/23)
Answer 3: Ability of the scan to predict the exact localization of a hyperactive PT gland is 61%
Answer 2: Ability of the scan to localize the gland to the correct side of the neck is 67% (14/21)
Question 3: “Is the scan able to accurately localize a pathological parathyroid gland?”
(14/23)
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accurately localized pre-operatively. One of the 7 pathological glands in the right 
upper thyroid quadrant showed uptake in the right lower quadrant, and the other 6 
glands showed no radiotracer uptake on Tc99m-MIBI-SPECT.
Localization ability for adenomas versus hyperplastic pathological glands
In the present study, Tc99m-MIBI-SPECT scan was able to accurately localize 16 of 
26 adenomas (64%) and 4 of 16 hyperplastic glands (25%) found at surgery. 
Localization ability in relation to pathological parathyroid gland size
Pathological parathyroid glands with a diameter greater than 1.5 cm were more 
frequently accurately localized by Tc99m-MIBI-SPECT than glands with a diameter 
smaller than 1.5 cm. In patients undergoing initial surgery for sporadic PHPT, 
Tc99m-MIBI-SPECT had a sensitivity of 71% for glands with a diameter >1.5 cm 
compared to a sensitivity of 44% for glands with a diameter <1.5 cm. In patients 
who underwent reoperative parathyroidectomy for persistent PHPT, Tc99m-MIBI-
SPECT had a sensitivity of 50% for glands with a diameter >1.5 cm and a sensitivity 
of 14% for glands with a diameter <1.5 cm. 
Localization ability in relation to parathyroid pathology
In patients undergoing initial surgery, 81% of pathological glands, whether 
adenomatous or hyperplastic, had a predominance of chief cells and only 19% had a 
predominance of oxyphil cells. In patients undergoing reoperative 
parathyroidectomy for persistent PHPT, 59% of pathological glands had a
predominance of chief cells, 12% had a predominance of oxyphil cells and the 
remaining glands had a combination of cell types. In patients who underwent initial 
surgery for sporadic PHPT, Tc99m-MIBI-SPECT was more sensitive in localizing 
pathological parathyroid glands with a predominance of oxyphil cells compared to 
those with a predominance of chief cells (100% vs 47% respectively). This higher 
sensitivity for pathological parathyroid glands with a predominance of oxyphil cells 
could not be replicated in patients who underwent reoperative parathyroidectomy for 
persistent PHPT. 
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DISCUSSION
Our findings from this study underline the limitations of the Tc99m-MIBI-SPECT 
imaging technique in the accurate preoperative localization of residual pathological 
parathyroid glands before reoperative parathyroidectomy in patients with persistent 
hyperparathyroidism. Advances in imaging technology have promoted the 
development of more focused surgical approaches in the surgical management of 
primary hyperparathyroidism. The preoperative localization of a pathological 
parathyroid gland is, however, a prerequisite for a unilateral or minimally invasive 
surgical approach. Although more than 80% of patients with sporadic primary 
hyperparathyroidism will have a single adenoma, it has been estimated that 15-20% 
will have a double adenoma or four-gland hyperplasia (32,33). Ten percent of 
individuals may also have supernumerary glands (5-7 glands) (34-36), so that it is 
not surprising that some of these pathological glands may be missed at initial 
surgery. It has indeed been reported that 1-7% of patients with primary 
hyperparathyroidism will have persistent hyperparathyroidism after initial surgery 
(6,37,38). When this is the case, it becomes essential to accurately localize the 
residual hyperactive glands if morbidity from reoperative parathyroidectomy is to be 
significantly decreased (39).
Limited data suggest that the localizing value of Tc99m-MIBI-SPECT is much 
lower for the preoperative localization of residual active parathyroid glands before 
reoperative parathyroidectomy (28-30). Findings from the present study confirm this 
notion and emphasize that the ability of Tc99m-MIBI-SPECT to detect and to 
accurately localize residual hyperactive glands is significantly jeopardized in 
patients with persistent hyperparathyroidism before reoperative parathyroidectomy 
compared to its detection and localization ability for pathological parathyroid glands 
before initial surgery for sporadic PHPT. Several factors may play a role in this 
decrease in the scan’s ability to detect and accurately localize hyperactive 
parathyroid glands in persistent PHPT. Compared to patients with sporadic PHPT 
cured after initial surgery, patients with persistent hyperparathyroidism had a lower 
proportion of adenomas (44% vs. 74%), a higher proportion of hyperplastic glands 
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(55% vs. 26%), more ectopically located glands (44% vs. 22%), and smaller 
pathological gland size (1.21 cm vs. 2.03 cm). Published data do indeed suggest a
lower predictive value for Tc99m-MIBI-SPECT in cases of parathyroid hyperplasia, 
ectopic glands, and glands of small size (10,15,18,19,40,41). Patients with persistent 
HPTH are also at a higher risk from parathyromatosis due to potential spillage 
during sometimes multiple earlier surgical procedures.
Using Tc99m-MIBI imaging, the radiopharmaceutical uptake of pathological 
parathyroid glands depends not only on perfusion of the hyperactive gland but also 
on mitochondrial activity of the hyperactive cells. In the parathyroid gland, oxyphil 
cells have an abundance of mitochondria compared to that of chief cells. Studies 
focusing on the causes for negative Tc99m-MIBI-SPECT imaging suggest an 
influence of the presence of mitochondria-rich cells on outcome. Mihai et al. (18)
and Erbil et al. (42) found that Tc99m-MIBI-SPECT scans were more frequently 
positive than negative in the case of adenomas rich in mitochondria-abundant 
oxyphil cells. In contrast, Westerdahl and Bergenfelz (19) found no difference in the 
positive or negative imaging of predominantly oxyphil-rich adenomas.
Parathyroid adenomas are mainly composed of chief cells, and it could be argued 
that sestamibi may not be taken up by these pathological glands. This is not the case, 
however, as demonstrated by the frequent finding of both chief cells and oxyphil 
cells, although in different percentages, in parathyroid adenomas. When both types
of cells are found, the net number of mitochondria-rich cells would depend in large 
part on the size of the pathological gland. The same applies for hyperplastic glands. 
In keeping with published data, we also observe a clear relationship between gland 
size and localizing accuracy of Tc99m-MIBI-SPECT. The accuracy of a Tc99m-
MIBI-SPECT scan is thus determined mainly by size and amount of oxyphil cells
rather than by the predominance of a cell type or the adenomatous or hyperplastic 
nature of the gland.
Our findings from this study demonstrate that the ability of the widely used 
Tc99m-MIBI-SPECT to detect and accurately localize pathological parathyroid 
glands is significantly limited in patients with persistent hyperparathyroidism before 
reoperative parathyroidectomy. Although the precise cause for this remains unclear, 
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it is likely to be multifactorial, and probably includes disturbance in the local 
vascular supply by previous surgery, as well as differences in gland pathology and 
size ultimately affecting radiopharmaceutical uptake. It is also conceivable that a
previous scan may also have been unable to localize hyperactive parathyroid 
gland(s) in a specific individual prior to initial surgery. Because most patients in 
this series did not have preoperative scans before their initial surgery, however,
addressing the question of the general ability of Tc99m-MIBI-SPECT to localize a 
hyperactive parathyroid gland in a specific individual is impossible and represents a 
limitation of the study. 
Our data hold significant implications in the management of patients with 
persistent hyperparathyroidism. From the practical point of view, and in keeping 
with recent guidelines of the European Association of Nuclear Medicine (43), our 
data suggest that it is always worth performing a Tc99m-MIBI-SPECT scan as a 
first preoperative localization study in patients with either sporadic or persistent 
hyperparathyroidism. Should the scan fail to demonstrate increased uptake in neck 
or mediastinum, no effort should be spared to attempt further localization of 
residual hyperactive glands prior to surgery to minimize morbidity. For instance, it 
is possible to use the invasive but more reliable PTH venous sampling technique 
(our own unpublished observations), followed by high resolution 4 dimensional CT-
scan of the area of interest. Should the scan be able to lateralize the lesion to the 
right or left side of the neck, it would be reasonable to undertake more limited 
unilateral neck exploration under the umbrella of intraoperative PTH measurements. 
Whether the recently advocated use of double-tracer subtraction parathyroid 
scintigraphy (43) is able to provide better detection and localization accuracy for 
residual hyperactive parathyroid glands than Tc99m-MIBI-SPECT imaging in the 
difficult group of patients with persistent hyperparathyroidism remains to be 
established. 
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ABSTRACT
Introduction:
Localization studies are mandatory prior to revision surgery in patients with 
persistent hyperparathyroidism in order to improve surgical outcome and reduce the 
risk of lengthy explorations. However, in this case noninvasive localization studies 
are reported to have a poor sensitivity. The aim of our study was to determine the 
accuracy of selective PTH venous sampling (SVS) in localizing residual hyperactive 
parathyroid glands in patients with persistent or recurrent hyperparathyroidism.
Patients & Methods:
We retrospectively evaluated the localizing accuracy of 20 PTH SVS performed 
prior to revision surgery in 18 patients with persistent or recurrent primary 
hyperparathyroidism (n=11) or autonomous (tertiary) hyperparathyroidism (n=7). 
Tc99m-MIBI-SPECT was also performed in all patients prior to revision surgery. 
Operative and pathology data were obtained from hospital records. 
Results:
SVS was able to accurately localize 15 of the 20 pathological glands removed at 
revision surgery, representing a sensitivity of 75%. This sensitivity is significantly 
higher than that of Tc99m-MIBI-SPECT, which was only 30% (P=0.012).  
Conclusion: 
Our findings demonstrate that SVS is a valuable localization study in patients with 
persistent or recurrent hyperparathyroidism, with a sensitivity significantly higher 
than that of Tc99m-MIBI-SPECT. Our data suggest that SVS represents a useful 
addition to the pre-operative work-up of these patients prior to revision surgery.
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INTRODUCTION
In primary hyperparathyroidism (PHPT) parathyroidectomy is reported to have a 
cure rate of 94%-100% (1-10) with a complication rate of 0-2.7% in the hands of 
experienced surgeons (3,5,7-9). In contrast, revision surgery for persistent 
hyperparathyroidism poses a far greater challenge, due to distortion and scarring of 
surgical planes caused by previous interventions. In addition, the likelihood of 
supernumerary parathyroid glands, ectopic localizations and parathyromatosis 
(inadvertent seeding of parathyroid cells during previous surgeries) is also 
increased. For these reasons, preoperative localization studies are highly 
recommended prior to revision surgery for persistent hyperparathyroidism in order 
to decrease operating time, improve surgical outcome and reduce the risk of 
complications due to lengthy explorations (10-14). However, localizing residual 
hyperactive parathyroid tissue often represents an elusive task, particularly 
following previous surgery for PHPT. The most widely used localization study, 
Tc99m-MIBI-SPECT, has indeed been shown to hold significant limitations prior to 
revision surgery for persistent PHPT. Explanations for the poor localizing ability of 
Tc99m-MIBI-SPECT in persistent PHPT, as low as 50%, include the small size of 
residual pathological glands, higher probability of hyperplasia and potential 
distortion of the vascular supply to the residual hyperactive glands due to previous 
surgery (15-19).
Selective venous sampling (SVS) of parathyroid hormone (PTH) has been 
shown to be valuable in localizing hyperactive parathyroid glands (20-22), but this 
invasive technique has generally fallen out of favor since the introduction of non-
invasive radionucleotide tests, initially thallium-technetium subtraction scanning 
(23), and subsequently the more sensitive Tc99m-MIBI-SPECT (10). The 
diagnostic value of SVS is based on the assumption that regional drainage of each 
one of the 4 parathyroid glands is into the adjacent superior, middle and inferior 
thyroid veins, respectively (20). Despite potential anatomical variations, SVS is 
successful in predicting the side of a pathological parathyroid gland in 39-93% of 
patients with PHPT (20-22,24-31) and, more importantly, in 66-75% of patients 
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with negative noninvasive studies (21,27,32). The major limitation of SVS, 
however, is that it pinpoints the area of venous drainage of a hyperactive gland 
rather than its exact anatomical location. There may indeed be many variations in 
regional venous anatomy of the parathyroids due to embryological differences. 
While each parathyroid gland thus tends to drain ipsilaterally and inferiorly, 
contralateral drainage has also been described (20). Variations in regional venous 
drainage may also occur as a result of previous surgical interventions, usually due to 
ligation of draining veins. In previously published studies, the predictive value of 
SVS was judged to be positive when a positive gradient was documented on the 
side of the neck where a pathological gland was found at subsequent surgery 
(15,27,29). The aim of the present study was to evaluate whether SVS for PTH 
could contribute to a more accurate preoperative localization of residual hyperactive 
parathyroid tissue in patients with persistent hyperparathyroidism.
PATIENTS AND METHODS
Patients 
Using our hospital records, we selected all patients who had undergone Tc99m-
MIBI-SPECT and selective venous sampling for PTH prior to revision surgery for 
persistent or recurrent PHPT or autonomous tertiary hyperparathyroidism (THPT) 
due to end-stage-renal failure between February 1994 and January 2009. Eighteen 
patients who had undergone a total of 20 revision surgeries were considered eligible 
and were included in the study. Fifteen of the 18 patients (83%) had their initial 
parathyroidectomy at another hospital and were referred to our hospital for revision 
surgery. All revision surgeries were undertaken by two surgeons with considerable 
experience in endocrine surgery. 
Methods
Demographic data, operative data and pre- and post-operative laboratory data were 
obtained from patients’ hospital records. All Tc99m-MIBI-SPECT scans were 
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reviewed by an experienced nuclear medicine physician, blinded to the outcome of 
the subsequent revision surgery. 
In our study, cure was defined as sustained normal serum calcium and PTH 
concentrations more than 6 months after parathyroidectomy (33). Persistent 
hyperparathyroidism was defined as persistently elevated serum calcium and PTH 
concentrations in consecutive samples within and beyond 6 months after surgery 
(33).
Parathyroid selective venous sampling technique
Parathyroid venous sampling was performed by an experienced intervention 
radiologist as follows: a 5 Fr MP catheter, with a selective end hole, was introduced 
via a sheath in the right femoral vein under local anaesthesia and guided by 
fluoroscopy to each of the jugular, subclavian and brachiocephalic veins, the azygos 
vein and the vena cava superior and inferior. Blood samples were obtained from 
several levels along these veins at close distances (1-2 cm), covering the venous 
drainage of normal anatomical locations as well as potential ectopic locations of 
parathyroid glands. A total of 30-40 blood samples were collected in whole blood 
tubes with spray-coated potassium EDTA and immediately put on ice before 
transportation to the laboratory for PTH measurement. The various sampling sites 
and any anatomical variation in venous drainage system found at the time of 
sampling by injecting contrast (Iomeron 300, Bracco Imaging, Konstanz, Germany)
were accurately recorded during the procedure. 
At the end of the procedure, the catheter was withdrawn and pressure was 
applied at the point of entry in the femoral vein for approximately 10 minutes until 
haemostasis was achieved. Regular checks were undertaken for the following 1-2
hours after which the patient was discharged home. 
Blood samples were centrifuged and the separated serum was assayed in one 
batch using an immunochemiluminescent assay (Immulite 2500, Siemens, Deerfield, 
Il., USA). Using this assay, the normal range of serum iPTH concentration is 1.5-8
pmol/L. The measured PTH concentrations were plotted at the corresponding 
anatomical sites on the sampling map (Figure 1).
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Laboratory screening before the procedure included a coagulation screen and 
evaluation of renal and thyroid function to establish the safety of contrast 
administration. If anticoagulation was used, this was temporarily reversed and 
wherever possible NSAIDs and acetylsalicyl acid were discontinued for a few days 
before the procedure 
Similar to other venous catheterisation procedures, potential complications of 
SVS include hematoma formation, venous thrombosis, perforation of blood vessels, 
pseudo-aneurysm, wound infection and side-effects of use of contrast material 
including anaphylactic reactions and deterioration of renal function (20,34). Patients 
with a glomerular filtration rate of less than 45 ml/min who underwent SVS were 
prehydrated using normal 0.9% saline solution.   
A selective venous sampling for PTH was deemed to be positive when a gradient 
of >50% was found between PTH concentrations at a specific anatomical site of 
sample collection compared to peripheral blood samples obtained at the time of 
procedure (17,21).
For the purpose of the study, data of each selective venous sampling were 
reanalyzed by an experienced endocrinologist, blinded to the previously predicted 
localization and to the outcome of the surgical procedure.
Non-invasive pre-operative localization studies
The Tc99m-MIBI-SPECT scan was performed as follows: following intravenous 
injection of 500 MBq of Tc99m methoxy-isobutyle-isonitrile (MIBI), planar images 
of the head and neck region and chest were performed at a matrix size of 256 x 256 
(10 minutes per frame). Scintigraphy was performed as a dual-phase single tracer 
examination before each of the 20 revision surgeries. Images were acquired in the 
supine position, 15 minutes and 2 hours after injection of the radiopharmaceutical. A 
gamma camera (Toshiba GCA-7200, Tokyo, Japan) equipped with low-energy high 
resolution (LEHR) collimators was used for image acquisition. Single photon 
emission computed tomography (SPECT) was performed in a 128 x 128 matrix size, 
using a step angle of 4o and a step time of 35 seconds per step, 90 minutes after the 
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injection. The filtered back projection was used for image reconstruction, using a 
Butterworth filter (8 order, subset 12).
Figure 1: PTH concentrations (pmol/L) plotted on the sampling map demonstrating a 
gradient in the brachiocephalic vein, the superior vena cava and the azygos vein, suggesting a 
pathological parathyroid gland in the mediastinum, which corresponded with the subsequent 
operative finding of a pathological parathyroid gland in aorto pulmonary window (shaded 
area).
SVS in persistent PHPT  /  93
Analysis of data
For the purpose of the analysis, the neck was divided in 5 designated anatomical 
areas: four thyroid quadrants, and a fifth “elsewhere” area combining all possible 
ectopic localizations in the mediastinum (Figure 2). A true positive region was 
defined as a region from which a pathological parathyroid gland was removed at 
surgery, and in which the presence of hyperactive parathyroid tissue was suggested 
in the same region by the preoperative localization test. A true negative region was 
defined as a region in which no pathological parathyroid gland was found at surgery, 
and in which no presence of hyperactive parathyroid tissue was suggested in this 
region by the preoperative localization test. A false positive region was defined as a 
region in which no pathological parathyroid gland was found at surgery, although 
the presence of hyperactive parathyroid tissue was suggested in this region by the 
preoperative localization test. A false negative region was defined as a region from 
which a pathological parathyroid gland was removed at surgery, although no 
presence of hyperactive parathyroid tissue was suggested in this region by the 
preoperative localization test. 
True negative and false positive scans, sides or regions could only be
determined in patients who were cured after surgery by the finding and removal of a 
pathological parathyroid gland elsewhere in the neck or mediastinum (this latter 
condition precluding compromising the sensitivity and specificity by false-negative 
surgery).
Widely accepted definitions for sensitivity and specificity were used. Sensitivity 
was thus judged to be the power of the test to identify the presence of pathological 
parathyroid glands in an exact region of the neck. Specificity was judged to be the 
power of the test to recognize the absence of a pathological parathyroid gland in an 
exact region of the neck.
Statistical analysis
Statistical analysis was performed using the SPSS 16 software (SPSS inc., Chicago, 
IL., USA). Results are expressed as mean ± SE unless otherwise stated. The 
McNemar test was used to assess the difference in localization accuracy between 
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SVS and Tc99m-MIBI-SPECT scan. A probability level of random difference of 
P<0.05 was considered to be significant. 
Figure 2: Analysis of the ability of SVS and Tc99m-MIBI-SPECT scan to correctly localize a 
pathological parathyroid gland as confirmed by localization at surgery by dividing the neck 
into 5 anatomical areas (the four thyroid quadrants and a 5th area of all possible ectopic 
localizations in the mediastinum).
Ethical consideration
The methods used in this study were part of the clinical routine work-up of patients 
undergoing revision surgery in our hospital. The study was approved by the local 
Ethics Committee and all patients consented to the use of their data.
RESULTS
Pre-operative data
The study population consisted of 18 patients who underwent a total of 20 revision 
surgeries. Eleven patients had persistent or recurrent PHPT, which was sporadic in 9 
patients, due to a MEN-1 mutation in 1 patient and due to parathyroid carcinoma in 1 
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patient. Seven patients had persistent or recurrent autonomous tertiary 
hyperparathyroidism (THPT) due to end-stage renal failure. Patients had an average 
of 2 previous surgeries, during which an average of 3 pathological parathyroid 
glands were removed (Table 1). 
Operative and pathological data 
Surgical approach consisted of bilateral neck exploration in 10 cases, unilateral neck 
exploration in 8 cases and a sternotomy in 2 cases.  Bilateral neck exploration was 
extended to include mediastinal exploration via sternotomy in 8 cases in which no 
pathological glands could be found after extensive exploration of the neck.  
A single parathyroid adenoma was removed in 5 cases. In 3 of these 5 cases, this 
was a second adenoma, with an adenoma also removed at initial surgery. All of the 3 
second adenomas were found in normal anatomical locations, in the right (n=2) or 
left (n=1) lower quadrant of the neck. Cure was achieved in 2 of these 3 cases. In the 
other 2 cases, no pathological glands were removed at initial surgery, and both 
adenomas were identified in ectopic locations, in the mediastinum (n=1) and high on 
the left side of the neck on the prevertebral fascia (n=1). Both of these revision 
surgeries resulted in cure.
One or more hyperplastic gland(s) (n=14) were removed in 12 cases. The 
majority of hyperplastic glands were identified in normal anatomical locations, in 
the left upper quadrant (n=4), left lower quadrant (n=3), right upper quadrant (n=1) 
or right lower quadrant (n=3) of the neck. Three glands were removed from ectopic 
locations, 2 were in the mediastinum and 1 was intrathyroidal. Only 5 of these 12 
revision surgeries (42%) resulted in cure.
A metastasis of a parathyroid carcinoma was removed in 1 case, which resulted 
in cure lasting for more than 11 months. In the last two cases extensive bilateral 
neck exploration failed to identify pathological parathyroid glands. Cure was thus 
achieved in 10 of the 18 patients with persistent or recurrent hyperparathyroidism, 5 
after a second surgery, 4 after a third surgery and 1 patient with parathyroid 
carcinoma was normocalcaemic for almost 1 year after his sixth surgery but has 
since developed recurrent hyperparathyroidism.  
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Predictive value of Tc99m-MIBI-SPECT 
Tc99m-MIBI-SPECT scans performed before revision surgery were negative in 11 
of 20 cases. Scans were only able to detect and accurately localize 6 of 20 surgically 
removed pathological glands and had thus a sensitivity of 30%. 
Selective venous sampling for PTH
An average number of 36 ± 8 samples were collected during each of the 20 selective 
venous sampling procedures. A positive gradient in PTH concentration of >50% 
suggesting the presence of a hyperactive parathyroid gland was documented in all 20 
cases. The median of the highest PTH concentration found at sampling was 35 
pmol/L (range 16-2202 pmol/L) in patients with persistent or recurrent PHPT and  
182 pmol/L (range 39-790 pmol/L) in patients with persistent or recurrent THPT 
(P=0.8).  The average gradient was a 4-fold increase in PTH concentration (range 
1.5-9), which was not significantly different between patient groups (P=0.7). There 
were no complications reported for any of the 20 sampling procedures.
Sensitivity of SVS for localizing pathological parathyroid glands 
Selective venous sampling (SVS) for PTH was able to accurately localize 15 of 20 
pathological parathyroid glands removed at 20 revision surgeries. Ten of these 15 
glands: 7 hyperplastic glands and 3 adenomas, were found in normal anatomical 
locations in the left lower (n=3), right lower (n=4), and left higher (n=3) quadrants 
of the neck. Five of these 15 pathological parathyroid glands were found in ectopic 
locations: 4 in the mediastinum and 1 high in the left side of the neck on the 
prevertebral fascia. 
All 5 pathological parathyroid glands that were not accurately localized by SVS 
were hyperplastic in nature with an average size of 7 mm. Four of these glands were 
removed from normal anatomical locations and one was intrathyroidal. In only 2 of 
these 5 glands was a gradient found in the correct side of the neck, but not in the 
correct quadrant. 
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Table 1. Demographic, Laboratory, Operative and Pathology Data of patients who 
underwent Tc99m-MiBi-SPECT and SVS for PTH prior to revision surgery for 
persistent or recurrent PHPT or autonomous tertiary hyperparathyroidism (THPT)
11 patients 7 patients P value
with PHPT with THPT
(13 operations) (7 operations)
Age at time of SVS (years) 52 ± 3 49 ± 5 0.628
Sex (M/F) 4:7 3:4 0.528










Pathology data at previous operation
Adenoma 3/13 (23%) 2/7 (28%) 0.787
Hyperplasia 7/13 (54%) 5/7 (72%) 0.444
Carcinoma 1/13 (8%) 0 0.452
No pathological parathyroid glands 2/13 (15%) 0 0.274
Pre-operative laboratory data
Corrected s-Calcium (mmol/L) 2.72 ± 0.06 2.67 ± 0.08 0.623
s-PTH (pmol/L) 48.9 ± 31.8 50.6 ± 14.7 0.971
Selective venous sampling
Number of samples 36 ± 3 36 ± 2 0.966
Gradient of increase in PTH 4 ± 0.5 4 ± 1 0.745
Maximum PTH concentration (pmol/L) 214 ± 166 277 ± 106 0.797
Post-SVS operative data
Bilateral neck exploration 8/13 (62%) 2/7 (29%) 0.160
Unilateral neck exploration 4/13 (31%) 4/7 (57%) 0.251
Sternotomy alone 1/13 (8%) 1/7 (14%) 0.639
Neck exploration combined with sternotomy 4/13 (31%) 2/7 (29%) 0.919
Post-SVS pathology data
Adenoma 4/13 (31%) 1/7 (14%) 0.417
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Hyperplasia 7/13 (54%) 5/7 (72%) 0.444
Carcinoma 1/13 (8%) 0 0.452
No pathological parathyroid glands 1/13 (8%) 1/7 (14%) 0.639
PHPT: primary hyperparathyroidism, THPT: tertiary hyperparathyroidism due to end-stage renal failure, 
s: serum, PTH: parathyroid hormone, No: number
Sensitivity of SVS in relation to parathyroid gland pathology
SVS was able to accurately localize all 5 adenomas (100%), 9 of 14 hyperplastic
glands (64%) and one metastasis from a parathyroid carcinoma (100%) subsequently 
removed at surgery. 
Sensitivity of SVS for pathological parathyroid glands in anatomically expected 
versus ectopic locations
SVS was able to accurately localize 10 of the 14 pathological glands found in 
normal anatomical locations (71%) and 5 of the 6 pathological glands found in 
ectopic locations (83%): mediastinum n=4 and high on the left side of the neck on 
the prevertebral fascia n=1.
A gradient in both the distal brachiocephalic and the left jugular vein (n=2) 
accurately corresponded with the finding of a pathological parathyroid gland in the 
neck at surgery in the 2 cases (100%). A gradient in both the proximal 
brachiocephalic vein and the vena cava superior (n=3) accurately corresponded with 
a pathological gland in the right lower quadrant of the neck in 2 of 3 cases (67%) 
and in 1 case no pathological gland could be found despite extensive neck and 
mediastinal exploration. A gradient in the vena cava superior and the azygos vein 
accurately corresponded to the presence of a gland in the mediastinum in 2 of 2 
cases (100%). 
Sensitivity of SVS in relation to pathological parathyroid gland size
SVS was able to accurately localize 8 of 9 pathological glands (89%) with a 
diameter greater than 1.5 cm, but only 6 of 11 pathological glands (55%) with a
diameter smaller than 1.5 cm, 9 of which were hyperplastic (82%).
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Sensitivity of SVS for localizing pathological parathyroid glands compared to that of 
Tc99m-MIBI-SPECT 
Tc99m-MIBI-SPECT and SVS were both performed prior to the 20 revision 
surgeries, during which 1 pathological parathyroid gland was removed in 16 
patients, 2 pathological glands in 2 patients and none in 2 patients despite extensive 
neck and mediastinal exploration. Of these 20 surgically excised glands, 15 (75%) 
were accurately localized by SVS compared to only 6 (30%) by Tc99m-MIBI-
SPECT. SVS was thus able to accurately localize 10 of the 14 pathological glands 
(71%), which had been inaccurately localized or completely missed by Tc99m-
MIBI-SPECT, while Tc99m-MIBI-SPECT was only able to localize 1 of the 6 
pathological glands (17%) inaccurately localized by SVS. Localization accuracy was 
highest when the outcome of Tc99m-MIBI-SPECT and SVS was concordant (n=5) 
(Figure 3). The overall ability of SVS to accurately localize pathological glands was 
significantly higher than that of Tc99m-MIBI-SPECT (P=0.012).
DISCUSSION
The present study demonstrates that the ability of selective venous sampling for 
PTH to accurately localize residual hyperactive parathyroid glands in patients with 
persistent or recurrent hyperparathyroidism is significantly higher than that of the 
non-invasive Tc99m-MIBI-SPECT imaging technique. To date, Tc99m-MIBI-
SPECT and US of the neck are the most widely used imaging techniques with a 
sensitivity of up to 90% prior to initial surgery for PHPT (1-5,7,10,35). However, 
the sensitivity of these techniques has been reported to be as low as 50% before 
revision surgery for persistent PHPT (15-17).
Because of the invasive nature of SVS and the high costs of the procedure, SVS 
has been generally used only prior to revision surgery. In keeping with previous 
observations, the present study shows the better performance of SVS in the accurate 
detection of residual pathological parathyroid tissue prior to revision surgery 
compared to that of the widely used Tc99m-MIBI-SPECT (15-17). In our hands, 
SVS was indeed able to accurately localize 71% of the pathological glands missed 
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by Tc99m-MIBI-SPECT. Of significant relevance to the operating surgeon is the 
localizing sensitivity of 100% when concordance is achieved between SVS and 
Tc99m-MIBI-SPECT, compared to a sensitivity of only 30% when localization is 
only dependent on Tc99m-MIBI-SPECT. 
The disappointing low predictive value of the Tc99m-MIBI-SPECT imaging 
technique in patients with persistent PHPT is believed to be due to the usually small 
size of residual parathyroid glands and to their frequent hyperplastic nature (1,6,35-
38). Our findings suggest that the sensitivity of SVS is also decreased in the case of 
pathological parathyroid glands smaller than 1.5 cm compared to glands greater 
than 1.5 cm (55% vs. 89%), and in the case of hyperplastic compared to 
adenomatous residual glands (64% vs. 100%), hyperplastic glands being smaller 
than adenomatous ones (1.45 cm vs 2.3 cm, P=0.21). Although gland size could 
potentially influence the predictive value of SVS by determining the amount of 
PTH secreted by the hyperactive parathyroid gland, we were unable to demonstrate 
a correlation between the gradient in PTH concentration as measured at SVS and 
the size of the pathological parathyroid gland removed at surgery. 
One of the most frequently reported causes of persistent hyperparathyroidism is 
an ectopic mediastinal location of a pathological parathyroid gland (11,39). Our 
data and those of others demonstrate a high sensitivity of SVS ranging from 66% to 
100% for the localization of these ectopically located glands (17,40). In keeping 
with previous reports (22), we also observed that SVS was able to accurately 
localize all ectopically located pathological glands in the mediastinum by the 
finding of a gradient in the superior vena cava (SVC) alone, or by the finding of a 
simultaneous gradient in the SVC and in the azygos vein and/or in the 
brachiocephalic vein. A PTH gradient found only in the brachiocephalic vein 
remains, however, an interpretational challenge. In contrast to Nilsson et al. (22),
who suggested that a gradient in the proximal brachiocephalic vein or the SVC 
corresponded to a mediastinal parathyroid gland in all cases, we observed that a 
simultaneous gradient in the SVC as well as in the azygos vein was necessary for 
conclusive evidence for a hyperactive parathyroid gland in the mediastinum. A 
gradient in the distal brachiocephalic vein was less specific in the study reported by 
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Nilsson et al. (22), corresponding to a mediastinal gland in 86% of cases and to a 
cervical gland in 14% of cases. Our data suggest, however, that a gradient in the 
distal brachiocephalic vein corresponded to the localization of a pathological gland 
in the left side of the neck in 100% of cases.
In persistent or recurrent hyperparathyroidism, previous surgeries may disturb 
venous anatomy which jeopardizes the localizing ability of radiotracer techniques, 
such as Tc99m-MIBI-SPECT, and sometimes leads to challenging interpretation of 
venous sampling data. Notwithstanding, our findings demonstrate that in patients 
with persistent or recurrent hyperparathyroidism the ability of SVS for PTH to 
detect and accurately localize pathological parathyroid glands is significantly higher 
than that of the widely used Tc99m-MIBI-SPECT imaging technique. In 
experienced hands the SVS procedure is safe and devoid of complications. 
Concordance of both techniques leads to a reassuring sensitivity of 100%. Our data 
from this study clearly suggest that SVS for PTH should be reinstated as a valuable 
tool in the armamentarium of localization studies in the pre-operative work-up of 
patients with persistent or recurrent hyperparathyroidism. 
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ABSTRACT
The term hungry bone syndrome refers to the rapid, profound and prolonged
hypocalcaemia associated with hypophosphataemia, hypomagnesaemia and 
functional hypoparathyroidism, which follows parathyroidectomy in patients with 
severe hyperparathyroidism and preoperative high bone turnover. It is a relatively
uncommon, but serious adverse effect of parathyroidectomy in patients with severe 
primary hyperparathyroidism and skeletal manifestations. We conducted a literature 
search of all available studies reporting a "hungry bone syndrome" in patients who 
had a parathyroidectomy for primary hyperparathyroidism, to identify patients at 
risk and address the pitfalls in their management. The severe hypocalcaemia is
believed to be due to increased influx of calcium into bone, due to the sudden 
removal of the effect of high circulating levels of PTH on bone resorption and 
activation frequency, in the face of continuing bone formation, although there is no 
good documentation for this. Various risk factors have been suggested for the 
development of a hungry bone syndrome, including older age, weight/volume of the 
resected parathyroid glands, radiological evidence of bone disease and vitamin D 
deficiency. The syndrome is reported in 25-90% of patients with radiological 
evidence of hyperparathyroid bone disease versus only 0-6% of patients without 
skeletal involvement. There is insufficient data-based evidence on the best means to 
treat, minimize or prevent this severe complication of parathyroidectomy.
Treatment is aimed at replenishing the severe calcium deficit by using high doses of 
calcium supplemented by high doses of active metabolites of vitamin D. Adequate 
correction of magnesium deficiency and normalization of bone turnover are 
required for resolution of the hypocalcaemia which may last for a number of 
months after successful surgery. Pre-operative treatment with bisphosphonates has 
been suggested to reduce postoperative hypocalcaemia, but there are to date no 
prospective studies addressing this issue.
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INTRODUCTION
Patients with primary hyperparathyroidism (PHPT) who undergo 
parathyroidectomy demonstrate a rapid decrease in serum calcium levels after
successful removal of one or more hyperactive parathyroid gland(s). This decrease 
in serum calcium levels is usually mild and maximal 2 to 4 days post-operatively, 
independently of the size of hyperactive glands or pathological diagnosis (1-8).
Persistence of hypocalcaemia for more than 4 days after parathyroidectomy may be 
due to intentional or accidental removal of all parathyroid glands, devascularization 
or trauma to residual parathyroid glands, but is also often due to long-term 
suppression of residual non-pathological parathyroid glands (1,2,8,9).
The term “hungry bone” syndrome has been coined to the profound (serum 
calcium <2.1 mmol/l) and prolonged (longer than 4th day post-operatively) 
hypocalcaemia, which follows parathyroidectomy for severe hyperparathyroidism.
This is usually associated with skeletal manifestations, reflected by pre-operative
indices of high bone turnover, osteitis fibrosia cystica and/or "brown tumours". The 
severe hypocalcaemia is believed to be due to the greatly increased skeletal 
utilisation of calcium, thought to occur as a result of removal of the effect of high 
circulating PTH levels on bone with immediate arrest of bone resorption in the face 
of continuing and enhanced bone formation, although there is no good 
documentation for this.
Literature data on the hungry bone syndrome are scarce despite the still 
significant prevalence of this clinical problem and despite the challenges associated 
with its management. This has prompted us to perform a systemic review of the 
literature on this topic. To this effect, we performed a structured literature search in
Medline, Embase and the Cochrane Library for studies reporting a "hungry bone 
syndrome" in patients who had undergone parathyroidectomy for primary 
hyperparathyroidism. 
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METHODS
We searched PubMed, EMBASE, Cochrane Library, Web of Science, CINAHL and 
Science Direct, using the following search strategy: (("hypocalcaemia"[ti] OR 
"hypocalcemia"[MeSH Terms] OR "hypocalcemia"[ti] OR Hypocalcemic[ti] OR 
Hypocalcaemic[ti]) AND (hyperparathyroidism OR parathyroid adenoma OR 
parathyroid cancer OR "Parathyroid Neoplasms"[Mesh] OR parathyroidectomy OR 
hyperparathyroid* OR parathyroidectom* OR "Hyperparathyroidism/surgery"
[Mesh]) AND (postoperative OR post-operative OR Postoperative Complications 
OR Postoperative Care OR pretreatment OR pre-treatment OR prevention OR 
preventive)) OR ("hungry bone" OR "hungry bones")). We restricted our search to 
publications in the ”English language” and on ”Human subjects”. We also checked 
the references of relevant articles for additional articles. Abstracts of meetings and 
unpublished results were not included in the study. The last search was performed 
on January 17, 2012.
RESULTS
Systematic literature search 
The initial search resulted in a total of 364 articles, 144 of which were excluded
based on title and abstract, so that a total of 220 potentially relevant papers were 
retrieved for full assessment (Figure 1). Eligibility criteria included articles 
reporting a hungry bone syndrome after surgery for primary hyperparathyroidism in 
adult humans. Exclusion criteria were hypocalcaemia due to any other cause, non-
complicated post-operative course, hungry bone syndrome in secondary or tertiary 
hyperparathyroidism and hungry bone syndrome in children. Comments or Letters 
to the Editor and articles only displaying a radiological picture were also excluded.
One hundred and sixty nine of the 220 publications were excluded based on these
exclusion criteria. Consequently, our search strategy ultimately resulted in 51
publications meeting the inclusion criteria of hungry bone syndrome after surgery 
for primary hyperparathyroidism in adult humans.
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Figure 1. Flowchart of articles included in the systematic review
Pathophysiology of hungry bone syndrome
Bone remodelling consists of a series of cellular events on the bone surface, the 
function of which is to remove damaged bone through the process of osteoclastic 
bone resorption, and replacing it with new bone through the process of osteoblastic 
bone formation. The process of bone resorption which lasts about 2 weeks is 
followed by a reversal phase of  2-3 weeks, before new bone is formed, which lasts 
about 3 months. The remodeling space is the total amount of bone that at any time 
has been resorbed by osteoclasts but not yet reformed by osteoblasts during the 
coupled remodeling process, because of the delay between resorption and 
formation. This space depends on the activation frequency of new remodeling sites, 
which is considerably increased in primary hyperparathyroidism, and on the 
average difference between the amount of bone resorbed and not yet reformed at 
each remodeling site, which is largely unchanged in hyperparathyroidism. In severe 
hyperparathyroidism. The increase in bone resorption leads to mineral depletion of 
bone and significantly contributes to the hypercalcaemia characteristically observed 
in patients with hyperparathyroidism (10-14). In patients with hyperparathyroidism 
and pre-operative high rates of bone turnover, successful parathyroidectomy curbs 
364 identified articles 
using search strategy
144 articles excluded 
on the basis of title 
and abstract 
74 articles based on  patients 
with secondary or tertiary
hyperparathyroidism
58 articles based on patients 
without hyperparathyroidism
12 articles based on children
220 articles potentially 
relevant retrieved for 
more detail
169 articles excluded 
on the basis of text
169 articles based on PHPT 
patients but no hypocalcemia 
or hungry bone disease
51 articles included in 
the review
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osteoclastic resorption, leading to a decrease in the activation frequency of new 
remodeling sites and to a decrease in remodeling space, leading to a consequent 
gain in bone mass.
The duration of the hungry bone syndrome is defined as the duration of post-
operative hypocalcaemia or time required for normalization of serum calcium 
following successful parathyroidectomy, which parallels normalisation of bone 
turnover and may last for up to 9 months, but exceptionally longer in cases of 
parathyroid carcinoma following radical excision of the tumour. In our experience, 
the duration of the hypocalcaemia is determined by the height of the increased bone 
turnover pre-operatively as well as by the time required for recovery of normal 
function of residual non-pathologic parathyroid tissue (unpublished personal 
observations).
Clinical manifestations of hungry bone syndrome
Severe hypocalcaemia (serum calcium concentration ≤ 2.1 mmol/l) is associated 
with neuromuscular irritability, clinically manifested by carpopedal spasms, perioral 
paresthesiae, tingling extremities, Chvostek sign and Trousseau sign (15-26).
Patients can also develop generalized convulsions, which can ultimately lead to 
pathological fractures (27,28), and ultimately if remaining uncorrected to coma and 
even death. Congestive heart failure, which is reversible after normalization of 
serum calcium concentration, has also been reported (15,29).
Prevalence of hungry bone syndrome after parathyroidectomy
Data on the prevalence of hungry bone syndrome have been scarce and conflicting 
after original publications in the eighties from a large case series suggesting that the 
syndrome develops post-operatively in up to 13% of patients with primary 
hyperparathyroidism (1,3,30). Recent case series from Asia reported much higher 
prevalence rates of 24-87% (31-34), whereas a case serie from Saudi Arabia 
documented a prevalence rate of only 4% (35).
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Risk factors for the development of a hungry bone syndrome 
Age at time of surgery 
Older age at the time of surgery is a risk factor for hungry bone syndrome (1). 
Brasier et al. (1), showed in a group of 198 PHPT patients, that patients who 
developed hungry bone syndrome were 10 years older than patients with an 
uncomplicated post-operative course (61 ± 3 vs. 51 ± 1, P<0.05).  
 
Table 1. Pre-operative laboratory data  
    Patients who Patients who did P- 
Laboratory investigation Author  developed HBS not develop HBS value 
s-Calcium (mmol/l)  Brasier(1) 3.00 ± 0.05  2.88 ± 0.03 <0.05 
 Spiegel(36) 3.25 ± 0.05 3.00 ± 0.03 <0.001 
 Heath(39) 3.94 ± 0.38 2.95 ± 0.15 <0.01 
 Lee(37) 3.00 ± 0.1 3.00 ± 0.08 0.7 
s-PTH (pmol/l) Brasier(1) 10.2 ± 2.00 5.7 ± 0.3 <0.05 
 Lee(37) 30.7 ± 10 32.9 ± 6 0.2 
s-alkaline phosphatase (U/l) Brasier(1) 68 ± 15  38 ± 2 <0.05 
 Heath(39) 51 ± 37 12 ± 6 <0.01 
  Lee(37) 248 ± 48 169 ± 31 0.1 
 
HBS: hungry bone syndrome, s: serum 
 
Laboratory investigations prior to surgery 
Patients who developed hungry bone syndrome had higher pre-operative levels of 
serum calcium (3.00 ± 0.05 vs. 2.88 ± 0.03 mmol/l, P<0.05 and 3.25 ± 0.05 vs. 3.00 
± 0.03 mg/dl, P<0.001 and 3.94 ± 0.38 vs. 2.95 ± 0.15 mmol/l, P<0.01) and almost 
2-fold increased levels of PTH (10.2 ± 2 vs. 5.7 ± 0.3 pmol/l, P<0.05) and of 
alkaline phosphatase (68 ± 15 vs. 38 ± 2 IU/l, P<0.05 and 12 ± 6 vs. 51 ± 37 U/dl, 
P<0.01) compared to patients who had an uncomplicated post-operative course 
(Table 1) (1,4,36). However, Lee et al. (37) were not able to demonstrate a 
significant difference in pre-operative serum calcium levels (3.00 ± 0.1 vs. 3.00 ± 
0.08 mg/dl, P=0.7), PTH (30.7 ± 10 vs. 32.9 ± 6 pmol/l, P=0.2) or of alkaline 
phosphatase (248 ± 48 vs. 169 ± 31 IU/l, P=0.1) levels between 9 patients who 
developed hungry bone syndrome post-operatively and 14 patients who did not.  
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Serum magnesium and albumin levels were found to be significantly decreased 
in patients who subsequently developed a hungry bone syndrome (1.5 ± 0.1 vs. 1.7 
± 0.04 mEq/l, P<0.001 and 3.9 ± 0.1 vs. 4.3 ± 0.04 g/dl, P<0.001, respectively) (1).  
There were no data available on the predictive value of pre-operative bone 
markers other than alkaline phosphatase, such as procollagen type 1 amino-terminal 
propeptide (P1NP, a marker of bone formation) and beta-crosslaps (β-CTX, a 
marker of bone resorption).  
Depleted vitamin D status (low levels of 25(OH)D and 1,25(OH)2D) has been 
suggested to be a risk factor for the development of hungry bone syndrome, by 
some, but not all, authors (1,38,39) 
 
Radiological bone disease prior to surgery 
Radiological evidence of PHPT-related bone disease has been reported to be an 
important risk factor for the development of a hungry bone disease 
(4,16,17,26,27,31,40), which also reflects prolonged exposure of the skeleton to 
high circulating PTH levels. Fourteen of 18 available case reports on hungry bone 
syndrome indeed report skeletal abnormalities, such as subperiostal erosions, lytic 
lesions, brown tumours, and multiple fractures (15-19,21-27,29,41-45). Osteitis 
fibrosa cystica was observed in 47-100% of patients who develop hungry bone 
syndrome (31,36). Hungry bone syndrome was reported in 25-90% of patients with 
radiological evidence of PHPT-related bone disease versus in 0-6% of patients 
without skeletal involvement (31,39,40). 
 
Volume and weight of resected pathological parathyroid gland(s) 
A large study in 198 patients with PHPT demonstrated that the volume and weight 
of the removed adenomas were significantly greater in patients who developed 
hungry bone syndrome compared to patients who had an uncomplicated post-
operative course (5 ± 1 vs. 1 ± 0.2 cm3, P<0.05 and 4 ± 1 vs. 2 ± 0.2 gram, P<0.05, 
respectively) (1). Zamboni et al. (46) confirmed this finding, by demonstrating that 
11  of  16  patients  with  a  single  adenoma  of  > 2 gram developed transient post-  
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operative hypocalcaemia versus only 3 of 21 patients with a single adenoma of <1 
gram (P<0.001).  
There are no available data on the relation between histological 
characterizations of the resected  pathological glands (adenoma vs. hyperplasia) and 
the development of hungry bone syndrome.  
 
Biochemical changes associated with hungry bone syndrome 
A rapid decrease in serum PTH levels to a mean of 1.7 ± 0.4 pmol/l follows 
successful parathyroidectomy in all cases of primary hyperparathyroidism (1). 
Serum calcium levels drop to levels <2.1 mmol/l within the first 3-4 days, but 
decrease further after the fourth postoperative day in patients with hungry bone 
syndrome (1). Serum phosphate levels decrease post-operatively and remain so for 
the duration of the syndrome (1,17,27,31,37,38,41,47,48). Hypomagnesaemia is 
frequently encountered (36). Serum alkaline phosphatase levels increase 
significantly post-operatively and remain elevated for sometimes up to 9 months 
after surgery (1,17,27,31,38,40,41,43,44,49).  
Agarwal et al. (31) also reported increased levels of osteocalcin, a marker of 
bone formation, and decreased urine crosslaps, a marker of bone resorption, in 51 
patients one week after surgery, with serum osteocalcin levels normalising only 6 
months after successful parathyroidectomy (31). In 3 of 51 patients with extreme 
osteopenia, bone turnover markers remained elevated for 1 year after successful 
parathyroidectomy (31).  
 
Radiological changes associated with hungry bone syndrome 
Removal of the excessive circulating levels of PTH shuts off bone-resorptive 
activity and leads to a rapid increase in bone mineral density. Case reports show an 
increase in bone mineral density of the lumbar spine of 17% at 10 weeks, 10% at 6 
months and 27-65% at 1 year after parathyroidectomy (7,44,49,50) and an increase 
in bone mineral density of the greater trochanter of 33% at 6 months and of 35-
131% at 1 year after surgery (7,50).  
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Bone mineral density increased post-operatively by a remarkable 332% within 1 
year in Indian patients with overt skeletal disease and/or osteitis fibrosa cystica 
(31). Follow-up radiographs show recovery of subperiosteal resorption and 
remineralisation of "brown tumours", osteolytic lesions and fracture sites 
(7,16,27,31). Scintigraphy shows an increased uptake 1 month after 
parathyroidectomy, known as "flare phenomenon", which reflects a healing 
response due to a significant increase in bone formation with a high influx of 
calcium into the skeleton (16,19). A moderately increased uptake can still be seen 8 
months after parathyroidectomy (18) and a decrease in the number of lesions and a 
normalization of uptake in the remaining lesions one year after parathyroidectomy 
(16).
Management of hungry bone syndrome
The treatment of a hungry bone syndrome is aimed in the short term primarily at 
replenishing the depleted skeletal calcium stores following withdrawal of the effect 
of high circulating levels of PTH on the skeleton. The first case reports of a hungry 
bone syndrome, which appeared in the late 70’s, described the difficulties 
encountered in the management of this severe complication of parathyroidectomy 
before active metabolites of vitamin D and their synthetic analogues became 
available for use in the clinic (15,22,26,27). Severely decreased serum calcium 
levels of  ≤1.3 mmol/l were reported despite treatment with very high doses of 
calcium, magnesium and cholecalciferol (15,26,27). However, difficulties in the 
management of hungry bone syndrome are still being reported, also after active 
metabolites of vitamin D and their synthetic analogues became available for use in 
the clinic (23).
The amount of elemental calcium supplementation required to treat the severe 
hypocalcaemia varies between 8 and 12 grams per day (17,21,23,29,41,44,45).
Initially calcium is supplemented intravenously, followed by oral preparations, with 
lower doses of calcium being possible because of concomitant use of active 
metabolites of vitamin D, in the form of calcitriol or alfacalcidol (2 to 4 ug per day) 
(17,21-23,38,43-45), and after replenishing magnesium stores as required. The 
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amount of magnesium required to correct hypomagnesaemia is not always reported 
and supplementations has been variably given in the form of intravenous 
magnesium chloride or sulphate or oral magnesium sulphate 
(15,17,19,22,26,38,44). In 11 of 18 cases serum magnesium level was not 
mentioned and in 1 of 18 cases serum magnesium levels were within the normal 
range (16,18,21,23-25,27,29,41-43,45).  
 
Treatment options to prevent hungry bone syndrome 
Pre-operative treatment with vitamin D 
Depleted vitamin D status has been postulated to be a risk factor for the 
development of hungry bone syndrome and it has generally been recommended to 
supplement vitamin D to normalize 25(OH) vitamin D levels, although there are so 
far no available data to support the premise that this would contribute to the 
prevention of hungry bone syndrome (1,38).  
 
Pre-operative treatment with bisphosphonates 
Two case reports of patients with a short history of PHPT, but with extensive 
hyperparathyroid-related bone disease, who were treated with either pamidronate 
i.v. 30 mg on 2 consecutive days or with a single infusion of 60 mg once, 
demonstrated that serum calcium decreased pre-operatively and that patients needed 
much less (1500 mg of elemental calcium orally per day) or no calcium 
supplementation post-operatively (7,51). One case report showed that a patient with 
a history of severe PHPT for > 8 years who received alendronate for 6 years, in 
addition to a total of 180 mg pamidronate i.v. pre-operatively, did not develop a 
hungry bone syndrome post-operatively (52).  
In a retrospective study, Lee et al. (37) also demonstrated that none of 6 patients 
who had received bisphosphonates pre-operatively (either clodronate 300-
1600mg/day or pamidronate 60mg/day) developed hungry bone syndrome post-
operatively, compared to 9 of 17 patients who had not received bisphosphonates 
pre-operatively (Table 2). There were no significant differences in pre-operative 
mean serum calcium (3.00 ± 0.15 vs 3.01 ± 0.04 mmol/l), PTH (34.8 ± 11 vs 33.4 ±  
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10 pmol/l) or alkaline phosphatase (224 ± 50 vs. 174 ± 60 U/l) levels between 
groups. A retrospective case serie of 46 patients with severe bone disease, who were 
treated with intravenous zolidronate pre-operatively also reported a low frequency 
of hungry bone syndrome of only 4% (35). Another retrospective case serie of 6 
patients with radiological characteristics of osteitis fibrosa cystica, who were pre-
operatively  treated with bisphosphonates (alendronate 20-30mg/day for 4-6 weeks 
or a single dose of pamidronate 90 mg i.v. or ibandronate 150 mg i.v.) reported that 
none of the patients needed intravenous supplementation of calcium post-
operatively (50). 
In contrast, a case report of a patient with severe, prolonged and extensive bone 
involvement (florid metabolic bone changes on X-ray), has shown that a single dose 
of 60 mg pamidronate i.v. combined with calcitriol 1-2 ug/day was able to 
significantly decrease (but not normalize) serum alkaline phosphatase levels (1600 
U/l to 420 U/l), but not able to completely prevent a hungry bone syndrome (43). 
Four others cases have also shown that treatment of severe hyperparathyroidism 
with alendronate (70 mg/week), pamidronate (twice 90 mg i.v. or 5 times 15 mg 
i.v.) or zolendronate (twice 4 mg i.v.) was unable to completely prevent a hungry 
bone syndrome (23,38,44,45).  
 
Pre-operative treatment with active metabolites of vitamin D 
Boyle et al. (53) showed that pre-operative treatment of severe hyperparathyroidism 
with 2 µg/day of 1,25(OH)2D for 1-10 weeks significantly decreased pre-operative 
alkaline phosphatase levels in 3 of 7 patients with prominent radiologically apparent 
bone cysts, and 3 other patients required intravenous calcium to a total of less than 1 
g in the first 12 post-operative days. In contrast, Heath et al. (4) showed that 6 
patients with PHPT and radiological evidence of bone involvement, who were 
treated pre-operatively with 2 µg/day of 1,25(OH)2D for 1 week, were as likely to 
develop hungry bone disease as patients with PHPT and radiological evidence of 
bone involvement who did not receive active vitamin D pre-operative (2 of 6 vs. 1 
of 6, respectively).  
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DISCUSSION
Hungry bone syndrome is characterized by a rapid, profound and persistent 
hypocalcaemia associated with functional hypoparathyroidism, which follows 
parathyroidectomy in patients with severe primary hyperparathyroidism and
preoperative high bone turnover. The duration of the hungry bone syndrome is the 
time taken to remineralize the skeleton, which is also mirrored by normalization of 
bone turnover markers, healing of radiological features of osteitis fibrosa cystica 
and brown tumours and by significant gains in bone mass. 
Hungry bone syndrome should be distinguished from the relatively common 
short- or longer-term hypocalcaemia encountered after thyroid surgery due to 
temporary or permanent hypoparathyroidism and from the temporary 
hypocalcaemia often observed after parathyroidectomy for primary 
hyperparathyroidism with no or marginally increased bone turnover pre-operatively,
which resolves spontaneously or readily after supplementation of active vitamin D 
until recovery of parathyroid function. In the context of primary 
hyperparathyroidism, a prerequisite for developing a hungry bone syndrome is a 
severely increased bone turnover state prior to surgery. A period of functional 
hypoparathyroidism may be followed by a period of increased PTH levels, more 
often encountered and exacerbated by associated vitamin D deficiency. These 
increased PTH levels are however unable to correct the hypocalcaemia, which will 
only resolve after adequate mineralization of the skeleton and normalization of bone 
turnover, often requiring huge doses of active metabolites or analogues of vitamin 
D and of calcium supplements, for periods sometimes exceeding 12 months after 
successful surgery. 
Our literature search suggests that over the last 2 decades the prevalence of 
hungry bone syndrome has decreased in the Western World, most likely due to the 
early detection of still asymptomatic primary hyperparathyroidism by routine 
calcium screening before the advent of clinically evident bone disease, such as 
osteitis fibrosa cystica (38,49), although exact numbers are missing. 
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One of the identified risk factors for a post-operative hungry bone syndrome is 
the older age at the time of surgery, with age being associated with vitamin D 
deficiency, a decrease in 1α-hydroxylase activity, and lower dietary calcium intakes 
(1), all 3 factors contributing to a negative calcium balance and clinical bone 
disease (4). It has indeed been shown that patients with osteitis fibrosa cystica, have 
lower levels of 1,25(OH)2D than expected, due to high levels of serum calcium 
which directly inhibit renal 1α-hydroxylase production, but may also result in renal 
impairment and further decrease in 1α-hydroxylase activity (54). A testable 
hypothesis for the development of bone disease, and for the development of a
hungry bone syndrome, relates to the possibility that low circulating levels of 
1,25(OH)2D with resultant decreased fractional absorption of calcium, leads to 
undermineralization of the skeleton (1,4). Low levels of 1,25(OH)2D may thus 
represent a measurable risk factor for the development of a hungry bone syndrome,
independently of age, although 25(OH)D deficiency has been proposed to be the 
more significant risk factor (38).
Pre-operative serum alkaline phosphatase levels reflect the state of bone 
turnover and, therefore, the degree of osteoclast activity and of bone resorption. It 
has been suggested that pre-operative serum alkaline phosphatase concentrations 
may predict the degree and duration of hypocalcaemia after successful 
parathyroidectomy (55). Radiological evidence of bone disease, in the form of 
osteitis fibrosa cystica, subperiostal bone erosions or resorption or bone cysts, has
also been stated to be a risk factor for the development of hungry bone disease 
(4,15-17,26,27,31,40). Pathological risk factors include the volume and weight of 
the removed adenoma(s), which have been found to be significantly greater in 
patients who developed a hungry bone syndrome compared to patients who had an 
uncomplicated post-operative course (1,3).
Treatment of the hungry bone syndrome is aimed in the short term primarily at 
replenishing the circulating calcium deficit, resulting from the increased utilisation 
of calcium arising from the abrupt cessation of bone resorption by the removal of 
the stimulatory effect of PTH in the face of continuing bone formation to refill the 
multiple resorption cavities. In the longer term, treatment is aimed at restoring 
Hungry bone syndrome in PHPT  /  125
calcium homeostasis by substituting the temporarily missing stimulatory effect of 
PTH on the 1α-hydroxylase enzyme by providing the active form of vitamin D to 
ensure adequate intestinal absorption of calcium. Doses and duration of treatment 
are guided by serum calcium levels and achievement of normalisation of bone 
turnover (3,15,20,26-28,49), which can sometimes exceed 12 months after 
successful surgery.  
It is estimated that 10 grams of calcium daily is on average necessary to restore 
and maintain serum calcium within the normal range (15,17,21-23,29,41). Lower 
doses of calcium are possible because of concomitant use of active metabolites of 
vitamin D, in the form of calcitriol or alfacalcidol (2 to 4 ug per day) (17,21-
23,38,43-45), or very occasionally higher doses (unpublished personal 
observations). The reason for this is post-operative low PTH levels which can last 
for up to 6 months after parathyroidectomy, resulting in lack of stimulation of the 
1α-hydroxylase enzyme. 
When calcium-containing solutions are given intravenously, administration into 
large veins or via a central venous catheter is recommended to minimize the risk of 
local irritation or tissue necrosis, by accidental extravasation in surrounding tissues. 
Parenteral calcium could be initially administered intermittently, for example in the 
form of one or two 10 ml ampoules of 10% calcium gluconate diluted in 50-100 ml 
of 5% dextrose infused slowly over 10 minutes. Continuous administration of a 
diluted solution of ten 10 ml ampoules of 10% calcium gluconate in 1 litre of 5% 
dextrose or 0.9% saline is often subsequently required to prevent recurrence of 
hypocalcaemia. This is given at an initial infusion rate of 50 ml/hour, slowing down 
as required, aiming at maintaining serum calcium at least at the lower end of the 
reference range. Electrocardiographic monitoring is recommended as dysrhythmias 
may occur in case of too rapid correction of the hypocalcaemia (56)  
Of the available oral calcium preparations calcium carbonate has the highest % 
of elemental calcium (40%), followed by citrate salts (20%). If a patient cannot 
tolerate these calcium supplements, other calcium preparations are available, 
although they do not contain sufficient elemental calcium per tablet and compliance 
may be affected by the large number of tablets required to be taken orally to achieve  
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the same calcium level: calcium lactate (13%), calcium gluconate (9%) and calcium 
glubionate (6.6%) (20). Oral calcium therapy should be initiated as soon as 
practical, but should always be combined with active vitamin D metabolites or 
analogues such as calcitriol or alfacalcidol to ensure adequate intestinal absorption 
of the administered oral preparation. 
Treatment of hypomagnesaemia depends on the degree of magnesium 
deficiency. When high doses of magnesium are required, this should only be given 
intravenously in adequate dilutions of magnesium sulphate, and not orally or 
intramuscularly. Lower doses of magnesium can be supplemented as magnesium 
oxide orally or magnesium sulphate intramuscularly. Hypocalcaemia does not 
resolve until the magnesium deficiency has been corrected (3,15,26-28,49).
The severity of a hungry bone syndrome is dictated by the degree of bone 
resorption pre-operatively, the highest pre-operative bone turnover being associated 
with the most severe and prolonged hungry bone syndrome. Preventive measures 
for a hungry bone syndrome should thus aim at reducing bone turnover pre-
operatively. This should be first achieved by correcting any prevailing vitamin D 
deficiency. Depleted vitamin D status has been postulated to be associated with an 
increased risk of developing postoperative hypocalcaemia and hungry bone 
syndrome (57-60). Preliminary data suggest that pre-operative correction of vitamin 
D deficiency may decrease levels of PTH and bone turnover, without exacerbating
hypercalcaemia (57,60,61). Although the effect of preoperative vitamin D treatment 
on postoperative hypocalcaemia has not been evaluated by randomized controlled 
intervention studies in primary hyperparathyroidism, it is our experience that a 
preoperative replete vitamin D status is associated with a decreased likelihood of a 
severe or prolonged hungry bone syndrome.  
Bisphosphonates are potent antiresorptive agents widely used in the 
management of bone disorders associated with increased bone turnover, such as 
Paget's disease of bone or metastatic bone disease. These agents inhibit osteoclastic 
bone resorption, decrease activation frequency of remodeling sites, resulting in 
refilling of remodeling space and increased mineralization of bone.
Bisphosphonates have been shown to reduce bone turnover in severe 
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hyperparathyroid bone disease (38,62,63). In this context preoperative 
bisphosphonate treatment would have a potential beneficial effect on the severity 
and duration of a hungry bone syndrome by significantly decreasing or normalising 
bone turnover before surgery is attempted (38,64). In contrast, short-term 
preoperative treatment may exacerbate postoperative hypocalcaemia by just 
reducing bone resorption, without allowing time for a coupled decrease in bone 
formation. There are as yet no prospective studies or randomized control trials 
addressing the use of bisphosphonates in the prevention or limitation of duration of
a hungry bone syndrome. There are, however, case reports and small case series of 
patients with extensive hyperparathyroid-related bone disease (35,37,54,64) or with 
longstanding severe PHPT (52) who received pamidronate pre-operatively and did 
not develop a hungry bone syndrome post-operatively (23,27,35-37). Other case 
reports have shown that pamidronate combined with calcitriol decreased serum 
alkaline phosphatase levels, but was unable to completely prevent a hungry bone
syndrome in patients with severe, prolonged and extensive bone involvement 
(23,38,43-45). However, in these case reports, the duration of pre-operative 
treatment with bisphosphonates and of active vitamin D was deemed to be too short
and the dosage to low, since serum alkaline phosphatase levels had not normalized 
before surgery (23,38,43-45).
Because low levels of 1,25(OH)2D are a risk factor for the development of post-
operative hungry bone syndrome (1,39), it has also been hypothesized that pre-
operative supplementation of 1,25(OH)2D could shorten symptomatic 
hypocalcaemia and hospital course (1,53,54). Data on the results of 1,25(OH)2D
supplementation are, however, conflicting (4,53). A major limitation of the studies 
looking at prevention of hungry bone syndrome, using either bisphosphonates or 
1,25(OH)2D supplementation or both, is the lack of patient randomization. 
CONCLUSION
Hungry bone syndrome is a relatively uncommon, but serious complication of 
parathyroidectomy for severe primary hyperparathyroidism associated with high 
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bone turnover. There are no clear guidelines for the management of the hungry bone 
syndrome but treatment is aimed at replenishing the severe calcium deficit and at 
correcting the effects of the functional hypoparathyroidism by using high doses of 
calcium and active metabolites of vitamin D. Adequate correction of magnesium 
deficiency and normalization of bone turnover are required for resolution of the 
hypocalcaemia which may last for a number of months after successful surgery. 
Adequate pre-operative treatment with bisphosphonates may reduce the severity 
and duration of postoperative hypocalcaemia. Further prospective studies are 
needed to optimize pre- and postoperative treatment strategies in patients with 
primary hyperparathyroidism and skeletal manifestations, at high risk for a hungry 
bone syndrome.
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ABSTRACT
Objective: In vitro and in vivo studies in animal models have shown that 
parathyroid hormone (PTH) inhibits the expression of the SOST gene, which 
encodes sclerostin, an osteocyte-derived negative regulator of bone formation. We 
tested the hypothesis that chronic PTH excess decreases circulating sclerostin in 
humans. 
Design: We studied 25 patients with elevated serum PTH concentrations due to 
primary hyperparathyroidism (PHPT) and 49 patients cured from PHPT after 
successful parathyroidectomy (PTx; euparathyroid controls (EuPTH)).
Methods: We measured plasma PTH and serum sclerostin levels and the serum 
markers of bone turnover alkaline phosphatase, P1NP, and β-CTX. 
Results: As expected by the design of the study, mean plasma PTH was 
significantly higher (P<0.001) in PHPT patients (15.3 pmol/l; 95% confidence 
interval (CI): 11.1-19.5) compared with that of EuPTH controls (4.1 pmol/l; 95%
CI: 3.6-4.5). PHPT patients had significantly lower serum sclerostin values 
compared with those in EuPTH subjects (30.5 pg/ml; 95% CI: 26.0-35.1 vs 45.4 
pg/ml; 95% CI: 40.5-50.2: P<0.001) and healthy controls (40.0 pg/ml; 95% CI: 
37.1-42.9: P=0.01). Plasma PTH concentrations were negatively correlated with 
serum sclerostin values (r=-0.44: P<0.001). Bone turnover markers were 
significantly correlated with PTH, but not with sclerostin.
Conclusion: Patients with primary hyperparathyroidism have significantly lower 
serum sclerostin values compared with PTx controls with normal PTH 
concentrations. The negative correlation between PTH and sclerostin strongly 
suggests that SOST is downregulated by PTH in humans.
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INTRODUCTION
Parathyroid hormone (PTH) exerts its calciotropic action by acting directly on bone 
and kidney and indirectly on the intestine to increase the transport of calcium to the 
circulation. The skeletal effect of PTH is to increase the rate of remodeling (1), and 
it is generally believed that this effect is achieved by the binding of PTH to its 
specific receptor (PTHR1) on stromal/osteoblastic cells of the bone marrow. This in 
turn stimulates the production of RANK ligand and decreases that of its decoy 
receptor osteoprotegerin (OPG) (2-5). However, recent in vitro and animal studies 
suggest that some of the effects of PTH on bone are also exerted by specific binding 
of the hormone to PTHR1 in osteocytes, resulting in inhibition of the expression of 
the SOST gene (6-9). This gene encodes sclerostin, a protein exclusively expressed 
in osteocytes in the skeleton (10), which decreases bone formation by binding to 
LRP5/6, resulting in inhibition of the Wnt signaling pathway in osteoblasts (11,12).
Whether chronic PTH excess has similar effects on sclerostin secretion in 
humans as in animal models has not so far been investigated. In this study, we 
tested the hypothesis that chronic hypersecretion of PTH, as seen in patients with 
hyperparathyroidism, may decrease sclerostin secretion, and that PTH may thus 
represent a potential regulator of sclerostin production in humans. To this effect, we 
measured sclerostin in serum of patients with untreated primary 
hyperparathyroidism (PHPT) and in a control group of patients with PHPT after 
establishment of cure following parathyroidectomy (PTx). 
PATIENTS AND METHODS
Patients
Thirty-four consecutive patients with PHPT that was untreated, persistent, or 
recurrent following PTx, and 54 patients cured after successful PTx (euparathyroid 
controls, EuPTH) were studied. Inclusion criteria included willingness to participate 
in the study, no impairment in renal function (serum creatinine levels <120 µmol/l), 
adequate vitamin D status (25-hydroxy vitamin D (25-OHD) levels >50 nmol/l),
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and no use of bone and mineral metabolism modifying agents such as 
bisphosphonates, calcimimetics, or glucocorticoids.
We defined PHPT as plasma PTH concentrations above the upper limit of the 
normal laboratory reference range (>8 pmol/l) in the presence of increased serum 
calcium concentrations (>2.55 mmol/l).
Patients with EuPTH were included when cure was confirmed by post-operative 
normalization of serum PTH and calcium concentrations, which was sustained for at 
least 6 months after PTx.
As per inclusion criteria, nine patients were excluded from the PHPT group, 
three because of impaired renal function and six because of the use of 
bisphosphonates, and six were excluded from the EuPTH group because of the use 
of bisphosphonates.
The study was approved by the Medical Ethics Committee of the Leiden 
University Medical Center, and informed consent was obtained from all patients.
Serum biochemistry
Serum calcium was adjusted for albumin binding; phosphate and creatinine were
measured by semi-automated techniques. Serum alkaline phosphatase (ALP) 
activity was measured using a fully automated P800 modulator system (Roche BV). 
P1NP (a marker of bone formation) and β-CTX (a marker of bone resorption) were 
determined using the E-170 system (Roche BV). Plasma PTH was measured using 
the Immulite 2500 (Siemens diagnostics, Breda, The Netherlands) and serum 25-
OHD was measured using the LIAISON 25-OHD TOTAL assay (DiaSorin 
S.A./N.V., Bruxelles, Belgium)
Sclerostin measurement
Sclerostin was measured in serum by an electrochemiluminescence assay (MSD 96-
well MULTI-ARRAY Human Sclerostin Assay, Gaithersburg, MD, USA) in which 
two polyclonal antibodies were raised against the whole sclerostin molecule. The 
sclerostin standard for the assay was produced in a NS0-derived myeloma cell line, 
and the purity was checked by SDS-PAGE gel with silver stain. In our hands, the 
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intra- and inter-assay coefficient of variation values were 4.9 and 7% respectively, 
the detection limit was ± 1 pg/ml, and the detection range was 1-10.000 pg/ml.   
Sclerostin was measured in the serum of 77 healthy subjects (30 male and 47 
female, aged 20-77 years). All had normal serum calcium concentration, renal 
function, and bone turnover and none were using bisphosphonates, the calcimimetic 
cinacalcet, or glucocorticoids. Sclerostin was detected in serum of all healthy 
subjects: mean 40.0 pg/ml (95% CI = 37.1-42.9 pg/ml), range 12.4-68.19 pg/ml, 
while it was undetectable in serum of three patients with sclerosteosis.  
 
Statistical analysis 
Data were analyzed using SPSS 16.0 (SPSS Inc. Chicago, IL, USA). Between-
group differences in baseline characteristics and serum biochemistry were assessed 
by Student’s t-test. Pearson correlation coefficients were calculated to assess 
correlations between PTH (after logarithmic transformation), sclerostin, and 
biochemical markers of bone turnover. A probability level of random difference of 





There were no differences in age, gender, weight, or body mass index between 
patients with PHPT and EuPTH controls (Table 1). 
 
Table 1. Subject characteristics 
  PHPT EuPTH P value* 
Male : Female 10:15 13:36 0.41 
Age (years) 59.6 ± 16.7 62.4 ± 10.9 0.44 
Weight (kg) 80.0 ± 18.2 81.1 ± 15.3 0.78 
BMI (kg/m²) 27.0 ± 6.0 28.1 ± 4.6 0.42 
Values are given as mean ± standard deviation, BMI = body mass index,  * PHPT vs EuPTH 
 
As expected by the inclusion criteria, mean serum calcium and PTH 
concentrations were significantly higher and those of  phosphate significantly lower 
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in the PHPT group compared with the EuPTH group in which PTH concentrations 
were detectable in all patients. There were no differences in serum 25-OHD or 
creatinine concentrations between the two groups.
Patients with PHPT had significantly higher levels of biochemical markers of 
bone formation (P1NP) and bone resorption (β-CTX) compared with EuPTH 
controls. Combining all patients, there was a significant positive correlation 
between plasma PTH concentrations and the concentrations of all three measured 
biochemical markers of bone turnover (ALP: r=0.23, P=0.047; P1NP: r=0.45, 
P<0.001; β-CTX: r=0.54, P<0.001). There was also a significant correlation 
between PTH and P1NP (r=0.51, P=0.009) in the PHPT group, but not between 
PTH and ALP (r=0.35, P=0.085), or PTH and β-CTX (r=0.31, P=0.13). In the 
EuPTH group alone, PTH was not correlated with any of the biochemical markers 
of bone turnover (Table 2). 
Table 2. Biochemical measurements
PHPT EuPTH Reference range P value*
Calcium homeostasis
PTH (pmol/l) 15.3 ± 10.7 4.1 ± 1.6 1.5 - 8.0 <0.001
Calcium (mmol/l) 2.61 ± 0.13 2.26 ± 0.12 2.15 - 2.55 <0.001
Phosphate (mmol/l) 0.92 ± 0.14 1.14 ± 0.24 0.90 - 1.50 <0.001
25 (OH) D (nmol/l) 53.1 ± 34.3 53.9 ± 20.2 30 -120 0.90
Creatinine (μmol/l) 80.2 ± 18.1 76.8 ± 14.7 44 - 80 0.39
Bone turnover
ALP (U/l) 87.0 ± 23.0 75.7 ± 23.6 40 - 120 0.055
P1NP (ng/ml) 45.9 ± 16.9 34.0 ± 15.5 16 - 80 0.004
β-CTX (ng/ml) 0.32 ± 0.15 0.17 ± 0.11 0.01– 0.66 <0.001
* PHPT vs EuPTH
Serum sclerostin
Mean serum sclerostin level of patients with PHPT (30.5 pg/ml, 95% CI: 26.0-35.1) 
was significantly lower than that of patients with EuPTH and healthy controls (45.4 
pg/ml, 95% CI: 40.5-50.2; P<0.001, and 40.0 pg/ml, 95% CI: 37.1-42.9; P=0.01,
respectively; Figure 1). There was no significant difference in mean sclerostin 
values between EuPTH and healthy subjects (P=0.13).
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There was no significant correlation between PTH and sclerostin concentrations 
within each individual group of patients but there was a significant negative 
correlation between sclerostin and PTH when all patients were pooled together (r=
-0.44, P<0.001: Figure 2).
There was no significant relationship between serum sclerostin and biochemical 
markers of bone turnover in patients with PHPT or in all patients combined. 
Figure 1. Serum sclerostin levels in PHPT, EuPTH and healthy subjects. *** P <0.001, ** P
=0.01 (Student’s t-test).
DISCUSSION
Data from our study demonstrates that in humans, chronic PTH excess, as observed 
in patients with PHPT, is associated with a significant decrease in circulating 
sclerostin and that there is a significant negative correlation between PTH and 
serum sclerostin levels. Taken together, these results suggest that, similar to animal 
models (6-9), PTH has a regulatory role on sclerostin production in humans also.
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Sclerostin, a glycoprotein expressed by osteocytes in bone and encoded by the 
SOST gene, has emerged in recent years as an important regulator of bone formation 
in humans as well as in animals (13,14). Inactivating mutations of the SOST gene 
leading to sclerostin deficiency have been shown to be associated with the rare 
skeletal disorder sclerosteosis, which is characterized by a marked increase in bone 
mass (13). Deletion of the Sost gene in mice has also been shown to increase bone 
formation, bone mass, and bone strength (14) demonstrating an evolutionary 
conservation of the function of sclerostin in the regulation of bone formation. 
Moreover, inhibition of sclerostin secretion by an MAB to sclerostin has been 
shown to increase bone formation and bone mass in rodents, primates, and humans 
(14-16). Conversely, transgenic mice overexpressing Sost have low bone mass and 
impaired biomechanical competence (17). The mechanism of action of sclerostin to 
decrease bone formation involves inhibition of the Wnt signaling pathway (11,12),
although its precise molecular mechanism and factors controlling its secretion are 
yet to be determined. Recent animal studies have shown that mechanical loading 
and high PTH levels downregulate the expression of Sost in osteocytes and decrease 
the production of sclerostin resulting in stimulation of bone formation (8,18).
Human studies of sclerostin regulation have lagged behind due to lack of 
noninvasive techniques to determine sclerostin production. A number of assays 
have been recently developed for the measurement of sclerostin in blood. In our 
study, we used a sclerostin assay that proved to have excellent performance 
characteristics in our hands with a wide detection range. Sclerostin was detectable 
in serum in all healthy subjects studied, suggesting that the protein is secreted and 
enters the circulation, while it was undetectable in three patients with sclerosteosis 
in whom it was measured. The difference in absolute values with other commercial 
assays is not clear and may be related to different methodologies. We chose to study 
patients with PHPT in order to mimic as closely as possible the effect of chronic 
PTH excess on sclerostin, as previously studied in animals (6,8). In addition, we 
chose to use as controls, patients with PHPT cured after PTx to exclude potential 
confounding factors, other than PTH excess. 
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Figure 2. Relationship between circulating sclerostin and PTH levels. r=-0.44 , P<0.001 
(Pearson’s correlation). PTH levels were log transformed because of skewness. 
We show here that serum sclerostin levels are significantly decreased in patients 
with chronic PTH excess due to PHPT compared to EuPTH and healthy subjects
although there was an overlap of values between groups. PTH has been shown to 
decrease SOST transcription in vitro (6,7), and continuous and intermittent chronic 
administration of PTH to rodents is associated with decreased Sost mRNA and 
sclerostin expression in osteocytes (6,7,9). Moreover, transgenic mice expressing a 
constitutively active PTH receptor in osteocytes exhibit decreased expression of 
sclerostin and increased Wnt signaling associated with increased bone mass (8).
Additional evidence for an interaction between PTH and Sost/sclerostin was 
recently provided by a study showing that the anabolic actions of PTH on bone was 
blunted in Sost-overexpressing mice (19). In keeping with the notion of a regulatory 
role of PTH for sclerostin production, our data show a significant correlation 
between circulating PTH and sclerostin. These data extend those of Mirza et al.
(20), who recently reported a negative relationship between serum PTH and
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sclerostin in healthy postmenopausal women, and those of  Drake et al. (21), who 
showed that intermittent PTH treatment decreased serum sclerostin levels in 
postmenopausal women. Put together, these data suggest that SOST regulation by 
PTH is also conserved between humans and rodents.
As expected in the presence of chronic PTH excess, patients with PHPT had 
increased bone turnover as indicated by increased biochemical parameters of bone 
formation and resorption. There was a significant relationship between circulating 
PTH concentrations and serum P1NP and β-CTX. However, we did not find a 
significant relationship between biochemical parameters of bone turnover and 
serum sclerostin, either in patients with PHPT or the combined group of PHPT and 
EuPTH subjects. This lack of correlation between sclerostin and bone turnover 
markers was previously reported in healthy postmenopausal women (20) but not in 
elderly women (22). The functional significance of circulating sclerostin is as yet 
not established. 
The actions of PTH on bone are complex and involve a variety of signaling 
pathways in bone marrow stroma cells, osteoblasts, and osteocytes (23,24). Despite 
the significant progress in our understanding of the actions of PTH on bone, it
should be appreciated that the cellular and molecular actions of PTH, which 
determine the action of the hormone on bone remodeling and bone balance, have 
only been partially unraveled and studies are needed to further elucidate these 
actions.
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ABSTRACT
Introduction: Fibroblast growth factor 23 (FGF23) and parathyroid hormone 
(PTH) are major players in the bone-parathyroid-kidney axis controlling phosphate 
homeostasis. In patients with primary hyperparathyroidism (PHPT) data on the 
relationship between PTH and FGF23 are scarce and not always concordant. 
Objective: The aim of our study was to evaluate the relationship between PTH and 
FGF23 in patients with PHPT and in euparathyroid patients cured after successful 
parathyroidectomy (PTx).
Patients & Methods: Twenty-one patients with PHPT and 24 patients in long-term 
cure after successful PTx (EuPTH) were studied. All patients underwent 
biochemical evaluation of renal function, parathyroid status, vitamin D status, bone 
turnover markers, and serum intact FGF23 levels.
Results: Mean serum FGF23 concentration was significantly higher in PHPT than 
in EuPTH patients (50.8 ± 6.1 pg/mL vs. 33.1 ± 2.6 pg/mL, P=0.01). FGF23 levels 
significantly correlated with PTH levels (r=0.361, P=0.02), also after correction for 
1,25(OH)2D levels (r=0.419, P=0.01). FGF23 levels showed a significant negative 
correlation with 1,25(OH)2D, which was more pronounced in PHPT than in EuPTH 
patients (r= −0.674, P=0.001, vs. r= −0.509, P=0.01). 
Conclusion: Our findings suggest that in PHPT, FGF23 levels are increased 
independent of 1,25(OH)2D levels. The more pronounced negative relationship 
between FGF23 and 1,25(OH)2D in the presence of high circulating PTH levels 
suggest that the increase in FGF23 levels may be an adaptive mechanism to 
counteract the PTH-induced increase in 1,25(OH)2D levels, although not 
completely overriding it. 
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INTRODUCTION
Parathyroid hormone (PTH) and the active metabolite of vitamin D (1,25(OH)2D) 
are prime regulators of calcium homeostasis but also have significant effects on 
phosphate homeostasis by respectively downregulating or upregulating the sodium 
phosphate co-transporters in the proximal tubules of the kidneys and in enterocytes 
of the intestinal tract (1-8). However, the major player of the bone-kidney axis 
controlling phosphate homeostasis has been shown to be fibroblast growth factor 23 
(FGF23). FGF23 acts as a phosphaturic factor by the same mechanism of action as 
PTH, downregulating the cotransporters NaPi2a and NaPi2c in the kidney after 
binding to its receptor, FGFR-1, in the presence of Klotho (9-11). FGF23 also 
decreases 1,25(OH)2D synthesis in the proximal tubules by direct inhibition of the 
1α-hydroxylase enzyme (9,10,12).
FGF23 is predominantly produced and secreted by osteocytes in bone (9,10).
This process is positively regulated by 1,25(OH)2D, via a vitamin D response 
element (VDRE) in the fgf23 promoter (9,13-15). The process is also regulated by 
serum phosphate, although the exact mechanism by which this is achieved remains 
unclear. Extracellular phosphate does not appear to directly stimulate FGF23
mRNA levels or fgf23 promoter activity in osteoblastic cultures (9,14). Data on the 
effect of changes in phosphate intake on FGF23 concentrations are inconsistent, 
with different responses observed with short-term or long-term alterations in 
phosphate intake (16-20). It has also been shown that early and rapid changes in 
renal phosphate excretion occur following a high-phosphorus meal, independent of 
FGF23, PTH, secreted frizzled-related protein (sFRP-4), or 1,25(OH)2D, 
suggesting the presence of an intestinal “phosphate sensor”, although its exact 
biochemical nature is not known (21-25).
The PTH/PTHrP receptor (PTHR1) is present on osteocytes (26) and 
constitutive activation of this receptor has been shown to upregulate FGF23
mRNA expression in vitro (27,28). Administration of PTH (1-34) in mice and in 
healthy individuals is associated with an increase in 1,25(OH)2D and in serum 
FGF23 levels and with a decrease in serum phosphate levels (13,28,29). In 
contrast, although intermittent administration of PTH to postmenopausal women 
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with osteoporosis induced an increase in 1,25(OH)2D and in FGF23 levels, this 
was not associated with a decrease in serum phosphate levels (30). Taken together, 
these data suggest that PTH is a regulator of FGF23 synthesis and that this is likely 
to be independent of serum phosphate concentrations. 
In patients with primary hyperparathyroidism (PHPT), data on the relationship 
between PTH and FGF23 are scarce and not always concordant. Compared to 
healthy controls, circulating FGF23 levels have been found to be elevated in 
patients with PHPT before parathyroidectomy (31,32) and to decrease immediately 
post-operatively (32), supporting the notion that PTH stimulates FGF23 secretion. 
However, this post-operative normalization of FGF23 levels was not observed in all 
studies (31,33), or was observed only transiently post-parathyroidectomy, with 
FGF23 levels returning to the originally high pre-operative values 7 days after 
surgery (32). The latter data suggest a possible alteration in FGF23 regulation, 
independent of PTH levels, in patients with PHPT. The aim of our study was to 
address the relationship between PTH and FGF23 in patients with primary 




Twenty-one consecutive patients with primary hyperparathyroidism, which was 
untreated, persistent or recurrent after PTx, and 24 consecutive euparathyroid 
patients who had a successful PTx for sporadic PHPT at the Leiden University 
Medical Center (LUMC) were invited and agreed to take part in the study of a 18 
months period. All patients were under regular follow-up at the Outpatient Clinic of 
the Department of Endocrinology and Metabolic Diseases of the LUMC, with 
patients with persistent hyperparathyroidism being followed more closely than 
those cured after PTx, who were mostly seen at 1- or 2-year intervals.
The diagnosis of PHPT was established on the basis of a serum PTH 
concentration above the upper limit of the normal laboratory reference range (>8
pmol/L) in the presence of a high or inappropriately normal serum calcium 
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concentration (>2.55 mmol/L). Eight of these latter patients had PTH 
concentrations of 13.6 ± 2.2 pmol/L, (range 8.4-27.4 pmol/L) in the presence of a 
normal serum calcium (serum calcium 2.46 ±  0.02, range 2.38-2.52 mmol/L), in 
the absence of vitamin D deficiency (25(OH)D3 55.6 ± 7.2, range 35-93 nmol/L). 
Four of these eight patients had a genetically confirmed MEN-1 mutation, the other 
four patients had evidence for a parathyroid adenoma on localization studies and 
became hypercalcemic under vitamin D supplementation.  
A diagnosis of cure was based on sustained normal serum calcium and PTH 
concentrations more than 6 months after PTx. 
All patients and controls had to have a creatinine clearance >60 ml/min to be 
included in the study to preclude the confounding effect of renal impairment on 
FGF23 levels. All patients and controls had a 25(OH) vitamin D3 level of >30 
nmol/L except for 5 patients who had levels between 25 and 28 nmol/L. These five
patients were, however, hypercalcaemic (2.72 ± 0.02, range 2.67-2.80 mmol/L) 
with increased PTH levels (serum PTH 23.5 ± 9.0, range 8.6-54.3 pmol/L) and high 
normal 1,25(OH)D2 levels (serum 1,25(OH)D2 142 ± 20, range 87-205 pmol/L), 
which was the reason to withhold the vitamin D supplementation.
Serum Biochemistry 
Serum concentrations of calcium (reference range 2.15-2.55 mmol/L), albumin 
(reference range 34-48 g/L), phosphate (reference range 0.90-1.50 mmol/L), and 
creatinine (reference range 44-80 μmol/l) were measured using semi-automated 
techniques. Creatinine clearance was calculated using Modification of Diet in Renal 
Disease (MDRD) formula. Serum alkaline phosphatase (ALP; reference range 40-
120 U/L) was measured using a fully automated P800 modulator system (Roche 
BV). Serum P1NP (a marker of bone formation) and β-CTX (a marker of bone 
resorption) were determined using the E-170 system (Roche BV). Serum 
concentrations of intact PTH (reference range 1.5-8 pmol/L) were measured using 
the Immulite 2500 (Siemens diagnostics, Breda, Holland). Serum 25-
hydroxycholecalciferol (25(OH)D3; reference range 30-120 nmol/L) was measured 
using the LIAISON® 25-OH Vitamin D TOTAL assay (DiaSorin S.A./N.V., 
Bruxelles, Belgium) and 1,25(OH)2 vitamin D was measured using LIAISON® 
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1,25-OH2 Vitamin D TOTAL assay (DiaSorin S.A./N.V.). .Serum intact FGF23 
(reference range 18-50 pg/mL (34)) was measured using an immunometric assay 
(Kainos Laboratories, Inc., Tokyo, Japan; intra-assay coefficient of variation (CV) 
6% and inter-assay CV 10%). 
Statistical analysis
Statistical analysis was performed using the SPSS 16.0 software (SPSS, Inc., 
Chicago, IL, USA). Results are expressed as mean ± S.E.M. unless otherwise 
stated. Chi-square test and Student’s t-test were used as appropriate for categorical 
variables and continuous variables. Pearson correlation coefficients were calculated 
to assess correlations between FGF23, PTH, 1,25(OH)2D, creatinine clearance, 
phosphate and calcium. Serum PTH, FGF23, and 1,25(OH)2D levels are shown in 
Table 1 in absolute values, but were log transformed before statistical correlation 
and regression analysis to correct for skewness. The relationship between several 
biochemical variables and FGF23 was investigated by backward regression 
analysis. A probability level of random difference of P<0.05 was considered 
significant. 
The study was approved by the local ethics committee and informed consent 
was obtained from all patients prior to inclusion in the study.
RESULTS
Patients with PHPT did not differ significantly in age, gender, weight, body mass 
index (BMI) and renal function from those in long-term cure after successful PTx 
(EuPTH; Table 1).  
Mean serum calcium and PTH concentrations were significantly higher and 
mean serum phosphate and 25(OH) vitamin D3 concentrations were significantly 
lower in the PHPT group compared with the EuPTH group. However, serum 
1,25(OH)2D concentrations and the bone turnover markers, ALP, P1NP and CTX, 
were significantly increased in the PHPT group compared with the EuPTH group 
(Table 1). 





Figure 1: Relationship between serum FGF23 and PTH levels (Pearson’s correlation). PTH 
and FGF23 levels were log transformed because of skewness. 
 
 
Mean serum FGF23 concentration was significantly higher in patients with 
PHPT than in EuPTH patients (50.8 ± 6.1 pg/mL vs. 33.1 ± 2.6 pg/mL, P=0.01; 
Table 1). There was a significant positive relationship between PTH and FGF23 
levels when PHPT and EuPTH were analyzed together (r=0.361, P=0.02; Figure 1), 
and this relationship was sustained and more pronounced after correction for 
1,25(OH)2D levels (r=0.419, P=0.01). There was no significant relationship 
between PTH and FGF23 when PHPT and EuPTH patients were analyzed 
separately (r=0.187, P=0.4, vs. r=0.114, P=0.6, respectively).   
There was also no significant relationship between PTH and 1,25(OH)2D levels 
in either PHPT patients (r= −0.269, P=0.3) or EuPTH patients (r=0.016, P=0.9) or 
when both groups were analyzed together (r=0.061, P=0.7). 
In patients with PHPT, there was a significant negative correlation between 
FGF23 and 1,25(OH)2D levels (r= −0.674, P=0.001; Figure 2). This relationship 
remained significant, albeit less marked, in EuPTH patients (r= −0.509, P=0.01; 
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significant when all patients were pooled together (r= −0.393, P<0.01). Using 
backward stepwise regression analysis, we also demonstrate that FGF23 levels 
exhibit significant and independent associations with PTH and 1,25(OH)2D levels 
(β=0.372, P=0.015, and β= −0.429, P=0.003 respectively; Table 2).
Table 1. Demographic and laboratory data in 21 patients with PHPT and 24 
patients in sustained cure after successful parathyroidectomy.
PHPT (n=21) EuPTH (n=24) Ref. range
P
value
Gender (men:women) 6:15 8:16 0.738
Age (years) 57 ± 3 63 ± 2 0.144
Height (cm) 172 ± 2 170 ± 1 0.279
Weight (kg) 79 ± 6 74 ± 2 0.425
BMI (kg/m2) 27 ± 2 26 ± 1 0.664
Serum biochemistry
      MDRD (ml/min per 1.73 m2) 90 ± 5 84 ± 3 >60 0.376
      Corrected calcium (mmol/l) 2.59 ± 0.03 2.27 ± 0.02 2.15-2.55 0.000
      Phosphate (mmol/l) 0.89 ± 0.04 1.10 ± 0.04 0.9-1.5 0.000
      PTH (pmol/l)a 15.2 ± 2.4 3.9 ± 0.3 1.5-8.0 0.000
      PTH (median (IQR)   11.7 (9.4-14.6) 3.7 (2.6-5.5) 1.5-8.0 0.000
      25(OH)D3 (nmol/L) 48 ± 4 60 ± 4 30-120 0.030
      1.25(OH)2D (pmol/l)a 163 ± 14 125 ± 7 40-140 0.020
      1,25(OH)2D (median (IQR)) 150 (119-203) 125 (95-144) 40-140 0.020
      FGF23 (pg/mL) a 50.8 ± 6.1 33.1 ± 2.6 18-50 0.012
      FGF23 (median (IQR)) 44.0 (36.1-59.6) 29.2 (24.8-40.6) 18-50 0.006
      ALP (U/l) 93 ± 5 71 ± 4 40-120 0.002
      P1NP (ng/ml) 41.4 ± 4.4 27.4 ± 2.4 16-80 0.010
      β-CTX (ng/ml) 0.31 ± 0.04 0.12 ± 0.01 0.01-0.66 0.000
PHPT: primary hyperparathyroidism, EuPTH: euprathyroid controls, MDRD: glomerular filtration rate,
IQR: interquartile ranger, a Log transformedbefore correlation analysis
There was no significant relationship between FGF23 concentrations and 
creatinine clearance or serum phosphate concentrations in either PHPT patients 
(r=0.085, P=0.7, and r=0.349, P=0.09, respectively) or EuPTH patients (r= −0.398, 
P=0.06 and r= −0.247, P=0.3, respectively). Also using backward stepwise 
regression analysis, creatinine clearance and serum phosphate levels failed to 
emerge as significant modulating factors for FGF23 levels in this model (β=
−0.033, P=0.811 and β= −0.068, P=0.642 respectively; Table 2).
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There was also no significant relationship between FGF23 levels and all three 
markers of bone turnover, serum ALP activity, P1NP, or CTX concentrations, in 
either PHPT or EuPTH patients after correction for PTH and 1,25(OH)2D levels. 
Table 2. Result of multiple regression analysis, demonstrating a significant 
association between FGF23, PTH and 1,25(OH)2D
Predictor B S.E.M. β t P value
PTH 0.895 0.353 0.372 2.534 0.015
1.25(OH)2D −0.192 0.061 −0.429 −3.124 0.003
Phosphate −7.9595 16.996 −0.068 −0.468 0.642
MDRD −0.039 0.160 −0.033 −0.241 0.811
DISCUSSION
Data from our study show that patients with primary hyperparathyroidism have 
higher levels of FGF23 than cured controls, and that this increase is independent of  
1,25(OH)2D levels. We further demonstrate a significant negative relationship 
between FGF23 and 1,25(OH)2D levels, that is more pronounced in patients with 
PHPT, suggesting that FGF23 at least partially antagonizes the stimulatory effects 
of PTH on the 1α-hydroxylase enzyme, although not totally overriding it. 
Data on FGF23 levels in PHPT and in the euparathyroid state following 
successful PTx are scarce and not always concordant. Two studies (31,33)
demonstrated no significant difference in pre- and post-PTx FGF23 levels, but a 
further study (32) showed a return of FGF23 levels to high pre-operative levels 
several days after PTx. The authors of this latter paper (32) suggested that one of 
the reasons for these discrepant results may be the post-operative use of active 
vitamin D metabolites or analogues in their patients, which had not been taken into 
consideration in the interpretation of their results. To our knowledge, FGF23 levels 
have never been previously evaluated in long-term euparathyroid patients after 
successful PTx. Our findings from this study suggest that the increase in FGF23 
levels observed in PHPT is reversible when the euparathyroid state is achieved by 
cure after successful PTx, providing that renal function is not impaired.  
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Although the cross-sectional design of our study does not allow the definitive 
determination of a causal relationship between PTH and FGF23, our data are in 
keeping with recently published data in parathyroidectomized rats, in which a direct 
relationship between PTH and FGF23 independent of 1,25(OH)2D is demonstrated 
in the presence of high but not low levels of PTH (35). 
 
 
Figure 2: Relationship between serum FGF23 and 1,25(OH)2D levels in 21 patients with 
primary hyperparathyroidism (PHPT: white dots) and 24 patients in long-term cure after 
parathyroidectomy for PHPT (EuPTH: black dots). FGF23 and 1,25(OH)2D levels were log 
transformed because of skewness. 
 
In the presence of high PTH and FGF23 levels in patients with PHPT, it is 
intruiging that a significant number of these patients do not develop 
hypophosphatemia despite chronic exposure to the two phosphaturic hormones, 
PTH and FGF23. In keeping with previous observations (13,30), indeed only 11 of 
our 22 patients with PHPT (50%) had phosphate levels below the lower limit of 
normal (<0.90 mmol/l). This suggests that in PHPT, factors other than PTH, FGF23 
or their combined effect may play a role in phosphate homeostasis. A clear 
contender is 1,25(OH)2D. The net effect of 1,25(OH)2D on gut, kidney, bone and 
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transporter expression in the intestinal tract (1,7) and NaPi2 co-transporter (NaPi3)
gene in the kidney, and by directly reducing PTH synthesis and secretion by the 
parathyroid (29).
In our study, patients with PHPT had significantly increased 1,25(OH)2D levels 
compared with euparathyroid patients, but also demonstrated significantly increased 
FGF23 levels. A new hypothesis has been recently proposed to explain the need for 
two phosphaturic hormones, PTH and FGF23, with the former repressed and the 
latter induced by 1,25(OH)2D (36). The suggested negative feedback loop includes 
FGF23-induced inhibition of 1,25(OH)2D synthesis. It has been proposed that these 
counter-regulatory effects of FGF23 on the bone-kidney axis have the physiological 
task of securing the maintenance of serum phosphate levels, thus providing 
protection against the hyperphosphatemia-related soft tissue and vascular 
calcifications (37-40). A possible explanation for the antagonizing effect of FGF23 
on 1α-hydroxylase enzyme may be the shorter half-life of PTH compared with 
longer half-life of FGF23 (41).
Our findings from this study extend our insight into the role of FGF23 in 
pathological states by showing that in primary hyperparathyroidism, FGF23 
production is increased in the presence of high circulating PTH levels and that this 
increase is reversible after the euparathyroid state is achieved following successful 
PTx. The more pronounced negative relationship between FGF23 and 1,25(OH)2
vitamin D in patients with PHPT suggests that in these patients the increase in 
FGF23 levels may be an adaptive mechanism to counteract the PTH-induced
1,25(OH)2D levels, although not completely overriding it. 
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ABSTRACT
A 29-year-old men presented to his primary-care physician with nausea, severe 
weight loss and muscle weakness. He had a hard, fixed neck swelling. He was 
severely hypercalcaemic with 10-fold increased parathyroid hormone (PTH)
concentrations. A diagnosis of primary hyperparathyroidism was established and 
the patient was referred for parathyroidectomy. At neck exploration, an enlarged 
parathyroid gland with invasive growth into the thyroid gland was found and 
removed, lymph nodes were cleared and hemithyroidectomy was performed. A 
suspected diagnosis of parathyroid carcinoma was confirmed histologically. Serum 
calcium and PTH levels normalized post-operatively, but hyperparathyroidism 
recurred within 3 years of surgery. Over the following 17 years, control of 
hypercalcaemia represented the most difficult challenge despite variable success 
achieved with repeated surgical interventions, embolisations, radiofrequency 
ablation of metastases and treatment with calcimimetics, bisphosphonates and 
haemodialysis using low-dialysate calcium. In this paper, we report the challenges 
and pitfalls we encountered in the management of our patient over nearly two 
decades of follow-up and review recent literature on the topic.  
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INTRODUCTION
Parathyroid carcinoma is a rare disorder, accounting for 0.1 to 5.0% of all cases of 
primary hyperparathyroidism (1-5). The disease presents at a mean age of 50 years 
and is equally likely to occur in males as in females (2-6) (Table 1). Clinical and 
biochemical manifestations are those of severe primary hyperparathyroidism often 
with renal and skeletal complications (2-5,7). A palpable neck mass can be felt in 
30-76% of patients (3,5,8,9). Parathyroid carcinoma is associated with germline and 
somatic mutations in the HRPT2 gene (3,10) and with irradiation of the neck for 
other pathologies (3,11).
A diagnosis of parathyroid carcinoma is suggested by the presence of intra-
operative features of local invasion and the diagnosis is confirmed by the World 
Health Organization histopathological criteria for parathyroid carcinoma. These 
include the presence of vascular invasion, perineural space invasion, capsular 
penetration with growth into adjacent tissues and/or metastasis (12).
Although parathyroid carcinoma is a slow growing tumor, it inevitably 
metastasises and is invariably fatal due to the eventual inability to control 
hypercalcaemia. Survival is estimated to range from 50% to 86% at 5 years and 
35% to 70% at 10 years (1-6,13,14). The most effective treatment for parathyroid 
carcinoma is radical surgery with en bloc removal of the lesion together with the 
ipsilateral thyroid, thyroid isthmus and lymph nodes (2,3,5,13,15). Surgery is also 
the treatment of choice in case of local recurrence or development of metastases 
(5,7,16), although radiotherapy (2-5,8,9), chemotherapy (3,5,9,17,18), embolisation 
(19) or radio frequency (RF) ablation (19-21) may also be attempted.
We report here the nearly two decades’ odyssey of a male patient with multiple 
metastases from parathyroid carcinoma, describing in the process the challenges 
and pitfalls we encountered in the management of this difficult malignancy. We 
also review all original case reports and case series on parathyroid carcinoma, 
fulfilling the WHO criteria and with a follow-up of at least 6 months after initial 
parathyroidectomy, which were published in the English literature since the last 
large review on this topic in 2001 (3). The literature search was conducted in 
PubMed using the keywords ("Parathyroid Neoplasms" OR "Parathyroid 
carcinoma" OR "Parathyroid cancer" OR "Parathyroid cancers") AND ("Case 
Reports" OR "case report" OR “case” OR “cases”). The last search was conducted 
on June 2, 2010. Patients with changes suggestive of carcinoma in the context of 
autonomous (tertiary) hyperparathyroidism were excluded because of the 
controversy in diagnosing malignancy in this case. Of an initial 872 publications, 
only 45 fulfilled the WHO criteria for parathyroid carcinoma and follow-up as per 
our search criteria, and were selected for further analysis.   
CASE REPORT
A 29 year old man presented to his primary care physician with a 2-month history 
of severe weight loss (20kg) associated with polyuria, polydipsia, nausea, muscle 
weakness, difficulty in concentrating and debilitating tiredness. On physical 
examination, he was clinically dehydrated and had a palpable hard, fixed swelling 
in the left side of the neck. He was using no medication and had no significant past 
or family history. Laboratory investigations revealed a severe hypercalcaemia of 4.9 
mmol/l (normal range 2.15-2.55 mmol/l), a decreased creatinine clearance of 45 
ml/min (normal >120ml/min) and a 10-fold increased serum intact parathyroid 
hormone (PTH) concentration: 88 pmol/l (normal <8 pmol/l). These findings 
suggested a diagnosis of severe primary hyperparathyroidism probably due to 
parathyroid carcinoma. No further investigations were requested; the patient was 
intensively rehydrated and referred for parathyroidectomy. At neck exploration, an 
enlarged parathyroid gland (3.5x3x3.5 cm) invading the ipsilateral thyroid lobe was 
found and removed from the left side of the neck (Figure 1). A left 
hemithyroidectomy was also performed. The diagnosis of parathyroid carcinoma 
was confirmed histologically by the finding of capsular and vascular invasion. 
Serum calcium and PTH concentrations normalized within a few days of surgery 
associated with a significant improvement in renal function. A second surgery was 
performed within 1 month of the first surgery to ensure complete removal of all 
malignant tissue and provide a negative surgical margin. The patient was started on 
a course of radiotherapy, which had to be discontinued before completion because 
of severe pharyngitis and esophagitis. 
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A recurrence of hyperparathyroidism was documented on routine laboratory 
control 3 years after parathyroidectomy. This was mild, with a serum calcium 
concentration of 2.74 mmol/l, a PTH concentration of 8.4 pmol/l and a stable 
creatinine clearance of 75 ml/min. The patient was completely asymptomatic. 
Tc99m-MIBI-SPECT and ultrasonography identified a lesion in the left side of the 
neck, which was found to be a local recurrence of the primary tumor at extensive 
bilateral neck exploration. The recurrent tumor had invaded the esophagus, part of 
which was excised and reconstructed using tissue from the sternocleidomastoid 
muscle. The edges of the excised specimen were tumor free and resected draining 
lymph nodes were clear of tumor tissue. DNA analysis of the resected recurrent 
tumor demonstrated a somatic HRPT2 mutation, c.165delC located on exon 2 (64).
Despite the radical nature of the surgery, mild hyperparathyroidism persisted post-
operatively, suggesting the presence of residual probably metastatic tumor tissue. 
No further localization studies or surgery were planned principally because of the 
patient’s reluctance to undergo further surgery but also because of the mild nature 
of the hyperparathyroidism. Closer clinical monitoring was arranged.  
Over the following 4 years, serum calcium and PTH concentrations and bone 
turnover markers slowly increased, and periods of dehydration were associated with 
transient worsening of renal function, which remained, however, on the whole 
stable despite persistent hypercalciuria and development of nephrocalcinosis. 
Progressive bone loss, predominantly cortical, was also documented and treatment 
with the non-nitrogen-containing bisphophonate clodronate was started, resulting in 
normalisation of bone turnover and stabilisation of BMD measurements. 
Rehydration and treatment with bisphosphonates eventually failed in controlling 
hypercalcaemia and bone loss. Localisation studies were undertaken to identify the 
source of PTH production. Ultrasound (US), selective venous sampling for PTH 
(SVS) and CT scan of the neck succeeded in localizing a small dense lesion in the 
left supraclavicular region. CT scan of the thorax also revealed a small solitary 
lesion of 1 cm radius in the inferior lobe of the right lung (Figure 2A). The patient 
refused to undergo a thoracotomy, but did agree to a fourth neck exploration at 
which a lymph node metastasis was excised from the left supraclavicular region 
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(Figure 1). Although less severe, hyperparathyroidism persisted post-operatively, as 
expected due to the unresected lung metastasis. Two attempts at embolisation of the 
lung metastasis failed to reduce tumor load. In contrast radiofrequency ablation 
(RFA) of the lesion, although complicated by an episode of severe pleuritis, was 
very successful in achieving biochemical remission, with serum PTH concentrations 
decreasing from 265 pmol/l to <1 pmol/l (Figure 2), suggesting that the metastasis
targeted with RFA was the only source of PTH secretion. However, remission was 
not permanent and PTH levels started to rise within 9 months of RFA. The patient 
finally agreed to undergo a right inferior lobectomy (Figure 3), which was 
complicated by multiple small cerebral infarcts resulting in right hemianopia, 
dysphasia, acalculia and transient epilepsy. Disappointedly, there was also only 
partial improvement in serum calcium and PTH concentrations, which continued to 
increase within 2 months of lobectomy (Figure 3).
Further localisation studies, in the form of Tc99m-MIBI-SPECT and a CT scan 
of the neck and thorax, were unable to localise any residual pathological 
parathyroid tissue suggesting the presence of (micro) metastasis. The now available 
calcimimetic cinacalcet was prescribed eventually at a maximum dose of 90 mg 
twice daily, which decreased PTH concentrations from 120 pmol/l to 85 pmol/l, 
stabilized calcium concentrations to about 2.80 mmol/l and stabilized creatinine 
clearance at 51 ml/min. In the course of the following year serum calcium and PTH 
concentrations further increased, however, despite maximal doses of cinacalcet and 
intermittent intravenous bisphosphonates. 
Repeat Tc99m-MIBI-SPECT and CT scan of the thorax, now demonstrated a 
new large (4x3x2cm) subcarinal mediastinal metastasis, which was successfully 
excised using a transpericardial approach (Figure 4). The elimination of the source 
of PTH secretion was associated with a very severe hungry bone syndrome for 
which the patient needed intensive care for over 2 months, requiring very large 
doses of iv administered calcium (up to 14 g/day) and maximal doses of active 
vitamin D metabolites. Remission lasted for more than 1 year, after which PTH 
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the upper mediastinum on CT scan of the thorax. There was also suggestion of a 
second subcarinal lesion at the site of the previously excised metastasis.
Figure 2. Radiological (A. pre-RF ablation, B. after RF ablation) and biochemical changes 
after RF ablation of the lung metastasis, demonstrating a severe drop in serum PTH 
concentrations, which persisted for almost a year.
In view of the complications associated with his previous surgeries, the patient 
was at that stage again reluctant to undergo any further surgery. Within the next few 
months PTH steadily increased associated with uncontrollable hypercalcaemia and 
deteriorating renal function eventually requiring haemodialysis using a very-low-
dialysate calcium concentration. Localisation studies confirmed the 2 previously 
identified pretracheal and subcarinal mediastinal lesions. The pretracheal lesion was 
accessible from the neck and was radically removed by a cervical approach (Figure 
1). There were no post-operative complications and serum PTH concentration 
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subcarinal mediastinal metastasis. Surgical removal of this metastasis would have 
required a third thoracotomy, which would be associated with too high an operative 
risk, especially in view of the patient’s poor clinical condition. Excision of the 
metastasis by mediastinoscopy was also not considered to be an option because of 
multiple scarring due to previous surgeries. The patient remains on haemodialysis 
and is still treated with cinacalcet, with intermittent courses of intravenous 
bisphosphonates. The patient was not considered to be a candidate for PTH 
immunisation (36,65), because of surgical clearance of cervical and mediastinal 
lymph nodes, poor general immune status and recurring infections. 
Figure 3: Radiological and biochemical changes following lobectomy of the lung metastasis, 
which resulted in only partial improvement in serum calcium and PTH concentrations. 
REVIEW OF THE LITERATURE 2001-2010
Sixty-two new cases have been reported in the literature since the last published 
review in 2001 (3), and data of these cases are summarised in Table 1. The median 
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men and women reported. Data on initial presentation were available in 43 of the 62 
patients (69%), 37 of which were symptomatic (86%). Polyuria and polydipsia were 
reported in 9 patients (21%), constipation in 7 (16%), tiredness in 13 (30%), bone 
and joint pain in 17 (40%), muscle weakness in 7 (16%), nausea and vomiting in 10 
(23%) and weight loss in 7 patients (16%). Seventeen patients (40%) had renal 
stones and 6 patients (14%) had sustained a documented fracture. A palpable neck 
mass was reported in 22 of 27 patients in whom this was checked (81%).  
Similar to the review of 2001, surgery is still the most frequently chosen therapy 
for the initial treatment of parathyroid carcinoma, but also for the treatment of 
recurrent or metastatic parathyroid carcinoma (Table 1). It is of note that the use of 
both chemotherapy and radiotherapy has decreased over the last 10 years, likely due 
to several reports and reviews which showed disappointing results (2-5). The last 
case report on the use of chemotherapy and radiotherapy dates from 2005 and 2008, 
respectively (Table 1). In contrast to the review of 2001, reports on the use of the 
newer techniques, embolisation (n=1), radiofrequency ablation (n=3) and PTH 
immunisation (n=1), have recently been published, although the number of cases 
reported is still very limited. Use of the calcimimetic, cinacalcet, has increased over 
the last few years after the first report in 2007, while the use of bisphosphonates has 
remained stable. 
The median follow-up reported in the 62 cases is relatively short at 3 years 
(range 0.5-20 years), considering that the average time to a first recurrence is also 
approximately 3 years (1,3). This could explain why only 27 of the 62 patients 
(44%) developed a local recurrence and/or distant metastasis and 9 patients (15%) 
died as a result of parathyroid carcinoma during the reported follow-up period.  
DISCUSSION
To our knowledge, we report here one of the longest survival and follow-up in one 
center of a patient with recurrent metastatic parathyroid carcinoma. Although 
parathyroid carcinoma is a slow growing tumor, it is associated with a relatively 
high incidence of local recurrence (40-82% within 5 years) (1-3,5,6,13). Metastasis 
 1 
tend to occur later in the course of the disease with spread to cervical nodes (30%), 
lung (40%) and liver (10%), via both lymphatic and hematogenous routes (3). 
Survival is estimated to range from 35% to 70% at 10 years (1-6,13,14), with an 
average survival of 6 years after local recurrence, and of 4,5 years after the 




Figure 4: CT scan of the thorax demonstrating a large (4x3x2 cm) subcarinal mediastinal 
lymph nodded metastasis (white arrow) (A+B), which was successfully excised using a 
transpericardial approach (C). 
 
In patients with parathyroid carcinoma, determinants of survival include delay 
in diagnosis, the presence of locally invasive features, distant metastasis at 
diagnosis and the radical nature of initial surgery (3,6,13,14). A further important 
determinant of survival and disease-free survival is the due care taken at initial 
surgery to avoid rupturing the capsule of the gland to prevent local seeding of tumor 
tissue (3). Initial surgery has been reported not to be radical in up to 48% of patients 
because of failure to establish the diagnosis of parathyroid carcinoma pre- or intra-  
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operatively (6,14). This was also the case in our patient at initial surgery, despite 
very suggestive clinical features of parathyroid carcinoma, in the form of severe 
hyperparathyroidism in a young male patient, palpable neck swelling and intra-
operative features of local invasion. A second surgery had to be performed within 
one month of the first to ensure complete removal of all malignant tissue and to 
provide a negative surgical margin.
The main determinant of survival in all patients remains, however, the eventual 
inability to control hypercalcaemia (2,5), and its association with fatal renal and 
cardiovascular complications (1,2,5,7). End-stage renal failure has been reported in 
up to 84% of patients due the deleterious effects of severe persistent hypercalcaemia 
on kidney function (2,5,7). A persistently elevated circulating PTH level is also 
associated with increased bone turnover and bone loss predominantly at cortical 
sites and with increased risk of fractures. In parathyroid carcinoma, the main goal of 
treatment is control of hyperparathyroidism by eradicating the source of PTH 
secretion (7,16).
Although the morbidity associated with re-exploration of the neck is estimated 
to be 6-17% (7), that of re-exploration of the mediastinum or lungs is clearly much 
higher. In our patient, the recurrent laryngeal nerve had to be unavoidably sacrificed 
during the second surgical intervention due to invasive growth of remnants of the 
primary tumor, resulting in transient loss of voice and permanent hoarseness. 
Subsequent lung surgery was associated with severe trombo-embolic complications. 
The increasing morbidity attached to repeated surgical interventions has led to 
the search for other treatment options, such as radiotherapy, chemotherapy, RF 
ablation, embolisation, use of the calcimimetic cinacalcet and PTH immunisation. 
Although parathyroid tumors are relatively resistant to radiotherapy (2-5), this 
management approach showed some promise as adjuvant treatment for microscopic 
residual disease (8,9). In our patient, the prescribed course of radiotherapy could not 
be completed due to the development of severe side effects in the form of 
pharyngitis and esophagitis.
Embolisation of localized and/or ectopic parathyroid adenomas has been 
reported to have only limited success (19,66-68), and in metastatic parathyroid 
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carcinoma, embolisation has only been described in combination with RF ablation 
in one patient (19). In our patient, the outcome of twice attempted embolisation of a 
lung metastasis was disappointing, largely because it was not technically possible to 
selectively embolise the arterial branch that fed the lung metastasis. 
The outcome of combined embolization and RF ablation in a patient with liver 
metastasis due to parathyroid carcinoma (19), and the effectiveness of RF ablation 
in various types of cancer (69) has led us to consider RF ablation in our patient. 
This approach was indeed very successful in eradicating PTH production by the 
metastasis, as has also been subsequently reported in 2 patients with parathyroid 
carcinoma and lung metastases (20,21). The beneficial effect was unfortunately 
transient, lasting only 9 months after the procedure, when PTH production was 
documented to resume from the same site. 
In parathyroid carcinoma, attempts at reducing tumor load are not always 
successful, in which case control of serum calcium by other means becomes central 
to prevent the deleterious effects of hypercalcaemia on various organ systems. 
Intensive rehydration, use of medications such as bisphosphonates and 
calcimimetics and use of dialysis represent diverse means to control hypercalcaemia 
and are often used in combination. Bisphosphonates decrease the skeletal efflux of 
calcium from bone by suppressing osteoclast-mediated bone resorption and overall 
bone turnover (3). These agents, however, have no effect on renal tubular 
reabsorption of calcium so that they improve hypercalcaemia but do not normalise
serum calcium (3,70). Cinacalcet is a calcimimetic, which reduces parathyroid 
hormone secretion by binding to the calcium-sensing receptor on parathyroid cells, 
increasing the sensitivity of these cells to extracellular calcium concentrations 
(15,71,72). These agents are widely used in the management of secondary and 
tertiary hyperparathyroidism in renal failure and have been also recently registered 
for the management of primary hyperparathyroidism, including that due to 
parathyroid carcinoma. In our patient, combined treatment with bisphosphonates 
and cinacalcet resulted in reasonable control of the hypercalcaemia initially, but 
eventually failed to do so, even when used at maximal doses. Dialysing against low-
dialysate calcium became necessary in order to better control the hypercalcaemia.
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The very high operative risks associated with a third thoracotomy, the patient’s 
poor lung function and current metabolic status despite regular dialysis, preclude 
the option of further surgery to remove the identified source of PTH secretion. PTH 
immunisation is being explored as a potential non-invasive option, although 
experience with this approach is still limited and the patient’s general condition may 
not permit its use (36,65,73).
Although we are rapidly running out of options in the management of our 
patient, we believe that we have nonetheless managed to secure for him a longer 
albeit not disease-free survival. This clinical case with a follow up spanning over 17 
years illustrates that the long-term management of patients with metastatic 
parathyroid carcinoma remains indeed a daunting task, despite all recent imaging, 
surgical and medical advances.
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Parathyroid carcinoma is associated with mutations in the HRPT2/CDC73 gene and 
with decreased parafibromin and calcium-sensing receptor (CASR) expression, but 
in some cases establishing an unequivocal diagnosis remains a challenge. The aim 
of our study was to evaluate the prognostic value of CASR and parafibromin 
expression and of HRPT2/CDC73 mutations in patients with an established 
diagnosis of parathyroid carcinoma. 
Patients & Methods:
Data on survival and disease-free survival were obtained from hospital records of 
23 patients with an established diagnosis of parathyroid carcinoma in whom CASR 
and parafibromin expression and HRPT2/CDC73 mutation analysis were available 
from paraffin-embedded pathological specimens. Kaplan-Meier curves were used 
for survival analysis. 
Results:
Downregulation of CASR expression, global loss of parafibromin staining and a 
HRPT2/CDC73 mutation were respectively found in 7 (30%), 13 (59%) and 4 
(17%) patients, and were associated with, respectively, 16-fold, 4-fold and 7-fold 
increased risk of developing local or distant metastasis. 
Conclusion:
These findings suggest that, although downregulation of CASR expression, global
loss of parafibromin staining and mutations in the HRPT2/CDC73 gene are tools of 
proven value to assist in establishing a diagnosis of parathyroid carcinoma, their 
absence does not exclude it. Notwithstanding, we demonstrate a significant added 
value of these markers as strong determinants of increased malignant potential and 
thus as negative prognostic markers in this malignancy.
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INTRODUCTION
Parathyroid carcinoma is a rare disorder, accounting for 0.1-5.0% of all cases of 
primary hyperparathyroidism (PHPT) (1-6). The disease presents at a mean age of 
50 years and, contrary to sporadic hyperparathyroidism, is equally likely to occur in 
men and women (1,3-5,7). Clinical manifestations are those of severe PHPT, often 
associated with renal and skeletal complications (1,3-5,8). A neck mass is palpable 
in 30-76% of patients (1,5,9,10). The diagnosis of parathyroid carcinoma is 
suspected by intra-operative features of local invasion and confirmed by the World 
Health Organization (WHO) histopathological criteria for parathyroid carcinoma. 
These include vascular invasion, perineural space invasion, capsular penetration 
with growth into adjacent tissues and/or metastasis (11). Despite the availability of 
these histopathological criteria, the diagnosis of parathyroid carcinoma remains a 
challenge in some cases, and markers such as mutations in the tumor-suppressor 
gene HRPT2/CDC73 (12-15), and global loss of expression of its protein, 
parafibromin (16,17), are proven valuable tools frequently used to assist in 
establishing a diagnosis of this malignancy.  
Mutations in the HRPT2/CDC73 gene, which encodes for the protein 
parafibromin (18), are associated with the hyperparathyroidism-jaw tumor 
syndrome (HPT-JT; OMIM 607393). Patients with a HPT-JT syndrome have a 15-
24% chance of developing parathyroid carcinoma, and loss of heterozygosity of 
chromosome 1q, the location of the HRPT2/CDC73 gene, is reported to be found in 
55% of parathyroid carcinomas (1,17,19-21).
The calcium-sensing receptor (CASR) regulates not only the synthesis and 
secretion of PTH, but also the proliferation of the parathyroid glands. We have 
previously reported that 31% of parathyroid carcinomas had irregular or absent 
staining for CASR compared to only 1% of sporadic adenomas (21). We have also 
demonstrated, using gene expression analysis, a significant downregulation of the 
CASR in patients with sporadic carcinoma or familial HPT-JT syndrome compared 
with patients with sporadic PHPT, PHPT due to MEN-1 or MEN-2 mutations or 
PHPT due to lithium use (22). Downregulation of CASR has been previously 
shown to be a negative prognostic factor in colon carcinoma (23-25), but there are 
no available data on the prognostic value of downregulation of CASR in 
parathyroid carcinoma. There are also no available data on the prognostic value of 
loss of parafibromin staining in the presence of a HRPT2/CDC73 mutation.  
The aim of our study was to evaluate the prognostic value of downregulation of 
CASR expression, loss of parafibromin staining and the presence of mutations in 




We identified 29 patients who had initial surgery for parathyroid carcinoma in 
various hospitals in the Netherlands in the period 1985-2000. All resected tumors 
were screened for somatic and/or germline mutations in the HRPT2/CDC73 and the 
MEN-1 genes, and immunohistochemical staining for parafibromin and CASR was 
performed on all 29 pathological specimens in the Department of Pathology of the 
Leiden University Medical Center (LUMC) (21). Four patients were lost to follow-
up, one patient died (normocalcaemic) of a myocardial infarction 4 months after 
initial parathyroidectomy and one patient did not meet the histopathological WHO 
criteria for parathyroid carcinoma and were excluded from the final analysis. A total 
of 23 patients were thus included in the study. The study was approved by the local 
Ethics Committee of the LUMC. 
Methods
Clinical data were obtained from the hospital records of the 23 patients included in 
the study, with special emphasis on time to development of local recurrence and/or 
distant metastasis and when applicable time and cause of death. Data on initial 
clinical presentation were available in 16 of the 23 patients (70%) including 
physical examination of the neck in 14 of the 23 patients (61%). Serum 
biochemistry before initial surgery was available in 20 of the 23 patients (87%) and 
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hypercalcemia was documented in all patients, although exact concentrations were 
not available in 3 patients. Operative and pathology data were available in all 23 
patients.
End points of the study
The primary end point of the study was the development of local recurrence and/or 
distant metastasis. Recurrence was defined as recurrence of an increase in serum 
calcium and parathyroid hormone (PTH) concentrations after a period of 
normalization of at least 6 months after initial surgery. Local recurrence was 
defined on the basis of a surgically removed lesion from a site adjacent to the 
primary tumor that was histologically confirmed to be parathyroid carcinoma. 
Distant metastasis was defined as radiologically and/or surgically and histologically 
proven distant metastasis diagnosed at least 6 months after successful excision of a 
primary tumor.  
The secondary end point of the study was death related to parathyroid 
carcinoma, which was defined as death due to PTH-related uncontrollable 
hypercalcemia. Patients who died from other causes in the setting of normocalcemia 
were censored at the time of death.
Histopathological diagnosis of parathyroid carcinoma
The histopathological diagnosis of parathyroid carcinoma was established using the 
WHO criteria for this malignancy. These include vascular invasion, perineural 
space invasion, capsular penetration with growth into adjacent tissues and/or 
metastasis (11). The presence of a trabecular pattern, fibrous bands and/or multiple 
mitoses were considered to be minor criteria. All pathological specimens were re-
evaluated in our Department of Pathology using the WHO criteria and only those 
fulfilling these criteria were included in the analysis. 
Pathological analysis
Pathological analysis of the primary tumor has been reported in detail in previous 
publications (14,21). In brief, formalin-fixed, paraffin-embedded (FFPE) specimens 
Figure 1: Staining with hematoxylin-eosin for CASR expression (A/C) and 
immunohistochemical (IHC) staining of CASR (B/D) in 2 patients with parathyroid 
carcinoma (patient 7 (A/B) and patient 1 (C/D)) showing maintained membranous CASR 
expression in patient 7 (A/B) and loss of membranous CASR expression in Patient 1 (C/D).  
Magnification x 25.
of the primary parathyroid carcinomas of all 23 patients were screened for 
HRPT2/CDC73 and MEN-1 gene mutations (14), and all were 
immunohistochemically stained for parafibromin and CASR (Figures 1 and 2) 
(17,21). Downregulation of CASR expression was defined as irregular or absent 
staining pattern for CASR on the membrane of parathyroid tumor cells. Focal loss 
of parafibromin staining was previously defined as the absence of nuclear staining 
in variably sized regions. Global loss of parafibromin staining was defined as the 
absence of nuclear staining in all tumor tissue. The three identified germline 
HRPT2/CDC73 mutations were positioned on exon 2 (c.176C>T, pSer59Phe, 
patient no. 1), exon 7 (c.687_688delAG, p.Arg229fsX, patient no. 23) and exon 7 
(c.691_692insT, p.Trp231fsX35, patient no. 21), respectively (14). The two 
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identified somatic HRPT2/CDC73 mutations were positioned on exon 1 (c128G>A, 
pTrp43fsX, patient no. 21) and exon 2 (c.165delC, pTyr55fsX, patient no. 6), 
respectively (14). The three identified somatic MEN-1 mutations were positioned on 
exon 2 (c.168_171delCAAC, pAns57fsX61, patient no. 16), exon 3 (c.631G>T, 
pVall211Phe, patient no. 5) and exon 9 (c.1256delG, pGly419fsX26, patient no.14), 
respectively (14). The mutation specifics have been partly curated, that is, updated 
according to the latest published literature, in the Cosmic Database of the Sanger 
Institute (www.sanger.ac.uk/genetics/CGP/cosmic).
Figure 2: Immunohistochemical staining of parafibromin in a patient with parathyroid 
carcinoma (patient 23) showing global loss of parafibromin staining in the nuclei of 
parathyroid carcinoma cells (A) and in the nuclei of parathyroid carcinoma cells located 
intravascular (B). In contrast, the nuclei of the endothelial cells of the vascular wall stained 
positive for parafibromin (B). Magnification x 100.
Statistical analysis
Statistical analysis was performed using the SPSS 16 (SPSS inc., Chicago, IL, 
USA) software. Results are expressed as mean ± s.d. unless otherwise stated. The 
chi-square test and Student’s t-test were used for categorical variables and 
continuous variables. Disease-free survival (time to first local recurrence and/or 
distant metastasis) and overall survival (time to death related to parathyroid 
carcinoma) was determined by the Kaplan-Meier method and P-values were 
calculated by the log-rank test. Cox regression analysis was used to determine 
hazard ratios (HRs). 
RESULTS
Demographic data
A total of 12 women and 11 men, with a mean age of 51 ± 16 years at the time of 
diagnosis, were studied (Table 1). At initial presentation, polyuria and polydipsia 
were present in 50%, tiredness in 31%, muscle- or bone pain in 25%, constipation 
in 13% of patients and a neck swelling was palpable in 11 of 14 patients (79%). 
Mean serum calcium concentration was 3.28 ± 0.55 mmol/l (reference range 2.15-
2.55 mmol/l), mean PTH level was 75 ± 57 pmol/l (reference range 1.5-8 pmol/l), 
mean alkaline phosphatase concentration was 386 ± 297 U/l (reference range 40-
120 U/l) and creatinine clearance was <60 ml/min in 59% of patients. 
Surgical data 
Of the 23 patients, 17 (74%) had bilateral neck exploration and the remainder 
unilateral neck exploration. Parathyroidectomy was combined with 
hemithyroidectomy in 12 patients (52%) because of thyroid invasion (n=11) or pre-
operatively identified thyroid pathology (n=1). Invasive growth of the tumor was 
observed intra-operatively in 14 of 21 patients (67%), including invasion of the 
thyroid (n=8), the recurrent laryngeal nerve (n=2), the esophagus (n=1), both the 
thyroid and esophagus (n=1) and unspecified tissue (n=2) (Table 1). 
Histopathological data
On pathological evaluation, cystic features were observed in 6 of the 23 tumors 
(26%) and fibrotic bands were present in 19 of the 23 tumors (83%). There was no 
mitotic activity in 7 of the 23 tumors (30%), sporadic mitotic activity was observed 
in 10 (44%) and >1/10 high-power field (HPF; more than 1 mitotic figure per HPF) 
was observed in 6 patients (26%). Invasion of blood vessels was documented in 21 
primary tumors (91%). Four patients had local lymph node metastases.
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Disease-free survival and survival
Median duration of follow-up after initial parathyroidectomy was 10 years, (range 
1-20 years). Of the 23 patients, 7 (30%) developed local recurrence of the tumor 
after a median duration of 3 years (range 1-7 years) after initial parathyroidectomy. 
One or more distant metastasis developed in 11 patients (48%) after a median 
duration of 2 years (range 0.5-13 years): lung metastasis (n=10), lymph node 
metastasis (n=5), bone metastasis (n=2), liver metastasis (n=1) and brain metastasis 
(n=1). Disease-free survival was 96, 60 and 40%, respectively, at 1, 5 and 10 years 
after initial parathyroidectomy.
Of the 23 patients, 13 (57%) had died at the time of the study. In 11 of these 
patients (85%), death was related to severe uncontrollable hypercalcemia. Death 
was unrelated to parathyroid carcinoma in the other two patients, who died 
respectively of septic shock and of a cerebrovascular accident, in the setting of 
normocalcemia. Overall survival rates were 91, 74 and 65%, respectively, at 1, 5 
and 10 years after initial parathyroidectomy. 
There was no significant difference in survival and disease-free survival 
between patients who had a hemithyroidectomy and those who did not (61 vs. 58%, 
P=0.7 and 81 vs. 67%, P=0.8, respectively).    
Downregulation of CASR expression
Of the 23 patients, 7 (30%) demonstrated downregulation of CASR expression in 
the resected primary tumor (Figure 3). Of these 7 patients, 5 also had somatic and/or 
germline HRPT2/CDC73 or MEN-1 mutations. Patients with downregulation of 
CASR expression demonstrated more global than focal parafibromin loss compared 
to patients with normal CASR expression (6/6 vs. 7/16, P=0.02). At the time of 
initial surgery, positive lymph nodes were also more frequently found in patients 
with downregulation of CASR expression compared to patients with normal CASR 
expression (3/5 vs. 1/16, P<0.01). 
Of the 7 patients with downregulation of CASR expression, 6 developed local 
recurrence and/or distant metastasis compared with only 8 of the 16 patients with 
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normal CASR expression (log-rank test, P=0.1). The time to development of a local 
recurrence and/or distant metastasis was significantly shorter in patients with 
downregulation of CASR expression compared with patients with normal CASR 
expression (1±1 years vs. 9±5 years, P<0.01). In addition, 5 of the 7 patients with 
downregulation of CASR expression and 6 of 16 patients with normal CASR 
expression had parathyroid carcinoma-related death a mean of 2±2 years and 10±5 
years, respectively, after initial surgery.                               
Both the 5-year disease-free survival and the 5-year overall survival were lower 
in patients with downregulation of CASR expression compared to patients with 
normal CASR expression (81% vs. 0% and 94% vs. 29%, respectively, Figure 3). 
Downregulation of CASR expression was associated with a 16-fold increased risk 
of developing a local or distant metastasis (HR 16; 95% CI 3-87;  P<0.01; Table 2)
and a 3-fold increased risk of death (HR 2.9; 95% CI 0.8-9.7; P=0.09).
Figure 3. Significant decrease in 5-year disease-free survival in patients with downregulation 
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Loss of parafibromin 
Parafibromin loss was determined in the resected primary tumor in all 23 patients. 
A total of 14 specimens showed global loss (Figure 2) and 9 showed focal loss of 
parafibromin staining. Of the 14 patients with global parafibromin loss, 11
developed a local recurrence and/or distant metastasis compared with 3 of 9 patients 
with focal parafibromin loss (log-rank test P=0.03). Also, 8 of 14 patients with 
global parafibromin loss and 3 of 9 patients with focal parafibromin loss had a 
parathyroid carcinoma-related death (log-rank test P=0.27). Both the 5-year 
disease-free survival (89 vs. 41%) and the 5-year overall survival (100 vs. 57%)
were lower in patients with global parafibromin loss compared with patients with 
focal parafibromin loss (Figure 4). Global parafibromin loss was associated with a 
fourfold increased risk of developing local recurrence and/or distant metastasis (HR 
4.3; 95% CI 1.2-15.9; P=0.03; Table 2) and with a twofold increased risk of death 
(HR 2.0; 95% CI 0.5-7.8; P=0.3).
Figure 4: Significant decrease in 5-year disease-free survival in patients with global loss of 
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HRPT2/CDC73 mutation 
Of the 23 patients with parathyroid carcinoma, 2 had a germline HRPT2/CDC73
mutation, one had a somatic HRPT2/CDC73 mutation and one patient had both a 
germline and a somatic HRPT2/CDC73 mutation (Table 1). All 4 patients with an
HRPT2/CDC73 mutation developed a local recurrence and/or distant metastases 
compared to only 10 of the 19 patients without this mutation (log-rank test: 
P=0.08). Time to development of recurrence/metastasis was shorter in patients with 
an HRPT2/CDC73 mutations compared with patients without this mutation (1±1 
year vs. 8±5 years, P<0.01). Two of the 4 patients with an HRPT2/CDC73 mutation 
and 9 of 19 patients without this mutation had a parathyroid carcinoma-related 
death. Both the 5-year disease-free survival (73 vs. 0%) and the 5-year overall 
survival (79 vs. 50%) were lower in patients with an HRPT2/CDC73 mutation 
compared with patients without this mutation (Figure 5). HRPT2/CDC73 mutations 
were associated with a 7-fold increased risk of developing local recurrence and/or 
distant metastasis (HR 7.4; 95% CI 1.8-30.6, P<0.01; Table 2).
                 
Figure 5: Significant decrease in 5-year disease-free survival in patients with germline 
and/or somatic HRPT2/CDC73 mutation compared with patients without a mutation in the 



























Of the 23 patients with parathyroid carcinoma, 3 had a somatic MEN-1 mutation 
(Table 1). Patient 16 had intra-operative findings of invasion of the thyroid gland 
and pathological features of vaso-invasion, but did not develop local or distant 
metastases during 9 years of follow-up. Patient 14 had a palpable neck swelling at 
presentation, intra-operative findings of invasion, pathological features of vaso-
invasion and developed lymph node, lung and bone metastases 11 months after 
initial parathyroidectomy. There was no response to chemotherapy and the patient 
died of uncontrollable hypercalcemia soon after the diagnosis of metastases. Patient 
5 also had a palpable swelling in the neck, intra-operative findings of invasion, 
pathological features of vaso-invasion, a positive lymph node and developed lung 
and brain metastases 18 months after initial parathyroidectomy. The patient died of 
uncontrollable hypercalcemia 24 months later. In these 3 patients with somatic 
MEN-1 mutations the 5-year disease-free survival and the 5-year overall survival 
were lower compared with patients without this mutation (respectively, 64 vs. 33% 
and 80 vs. 33%). Somatic MEN-1 mutations were associated with a 2-fold increased 
risk of developing a local recurrence and/or distant metastasis (HR 1.7; 95% CI 0.4-
7.8, P=0.5; Table 2) and a 3-fold increased risk of death (HR 3.3; 95% CI 0.7-16.6, 
P=0.15).
Combined effect of negative prognostic factors
Of 23 patients, 14 had one or more negative prognostic factors, but only 4 of the 
patients had a combination of an HRPT2/CDC73 mutation, global loss of 
parafibromin staining as well as downregulation of CASR expression. Both the 5-
year disease-free survival and the 5-year overall survival were lower in patients 
with one or more negative prognostic factors compared with patients without one of 
these factors (89 vs. 41% and 100 vs. 57%, respectively; Figure 6). Patients with 
one or more negative prognostic factors had a 4-fold increased risk of developing 
local recurrence and/or distant metastasis (HR 4.3; 95% CI 1.2-15.9, P=0.03; Table 
2) and a 2-fold increased risk of death (HR 2.0; 95% CI 0.5-7.8, P=0.3). 
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Figure 6: Significant decrease in 5-year disease-free survival in patients with one or more of 
the studied prognostic factors (germline and/or somatic HRPT2/CDC73 mutation, global loss 
of parafibromin staining or downregulation of CASR expression) compared with patients 
without one of these prognostic factors (89 vs. 41%).
DISCUSSION
Data from our study in patients with a WHO-based diagnosis of parathyroid 
carcinoma suggest that downregulation of CASR expression, global loss of 
parafibromin staining and the presence of germline and/or somatic HRPT2/CDC73
mutations are strong negative determinants of prognosis in patients with this
malignancy, with clear associations with decreased disease-free survival and overall 
survival. 
Although downregulation of CASR expression was present in only 7 of 23 
patients, this molecular alteration was associated with a 16-fold increased risk of 
developing local recurrence and/or distant metastasis. This suggests that this tumor 
marker represents a significant determinant of prognosis in parathyroid carcinoma. 
The CASR holds an important function in the control of calcium homeostasis by the 
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inhibition of PTH secretion, PTH gene expression and thus PTH synthesis, and of 
parathyroid cell proliferation (23). Mutations in the CASR gene that result in a loss 
of function of the CASR, such as seen in familial benign hypercalcemia, increase 
the calcium-dependent set-point for inhibition of PTH release from the parathyroid 
cell (26). However, no mutations in the CASR gene have been so far identified in 
patients with parathyroid carcinomas (27). It also remains unclear whether 
increased parathyroid cell proliferation leads to decreased CASR expression as 
observed in autonomous hyperparathyroidism in chronic renal failure, or whether 
decreased CASR expression leads to increased parathyroid cell proliferation and 
increased malignant potential in patients with parathyroid carcinoma (21,23).
Notwithstanding, evaluating CASR expression may not only be used as a 
prognostic tool in the management of patients with parathyroid carcinoma, but may 
also serve the purpose of determining whether calcimimetics may play a role in the 
therapeutic management of these patients. In one patient in our series (patient no. 6) 
demonstrating loss of CASR expression in his primary tumor, the calcimimetic 
cinacalcet, prescribed at a maximum dose of 90 mg twice daily, was indeed unable 
to decrease PTH or calcium levels to any extent (personal observation).
Table 2: Association between prognostic factors and the development of 
local recurrence and/or distant metastasis
HR (95% CI) P value
Downregulation of CASR expression 16.3 (3.0-87.3) 0.000
HRPT2/CDC73 mutation 7.4 (1.8-30.6) 0.005
Global loss of parafibromin 4.3 (1.2-15.9) 0.028
One or more of these prognostic factors 4.3 (1.2-15.9) 0.028
HRPT2/CDC73 mutations are known to be associated with the HPT-JT
syndrome. These mutations have also been found in 67-100% of patients with 
parathyroid carcinoma selected on the basis of local recurrence or distant metastasis
(12,13,15). In contrast, in our study, in which patients were selected on the basis of 
the WHO histopathological criteria for parathyroid carcinoma, rather than on the 
basis of the presence of a local recurrence and/or of distant metastasis, we could 
only demonstrate a germline and/or somatic HRPT2/CDC73 mutation in 4 of the 23 
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patients (17%). These were 4 of 14 patients who developed a local recurrence 
and/or distant metastasis during follow-up (29%), suggesting that factors other than 
mutations in the HRPT2/CDC73 gene may also play a role in the tumorigenesis of 
parathyroid carcinoma. One of the limitations of our study is that we may not have 
identified all mutations in the HRPT2/CDC73 gene. The low mutation frequency in 
our population may thus be due to technical reasons, because of the nature of the 
paraffin-embedded tissue studied, leading to the inability to completely screen all 
DNA sequences of the HRPT2/CDC73 gene or screen the DNA for large somatic or 
germline genomic deletions (14). However, exons 1, 2 and 7, which harbor up to 
85% of all somatic HRPT2/CDC73 mutations (12,15,18,28,29), were completely 
screened in all patients. Silencing of HRPT2/CDC73 due to promoter 
hypermethylation was also not studied, although this may not be relevant, as it was 
recently documented that hypermethylation does not play a role in loss of this gene
(30). Although the numbers are small, our data do suggest that the presence of 
mutations in the HRPT2/CDC73 gene are associated with a significant decrease in 
disease-free survival and also survival, albeit the latter not significantly. These data 
suggest that mutations in this gene determine the malignant potential of a 
parathyroid carcinoma and may thus be used as a prognostic tool in this 
malignancy. 
In patients with parathyroid carcinoma, most of the identified HRPT2/CDC73
mutations are predicted to prematurely truncate the parafibromin protein
(12,13,16,28), which often lead to loss of parafibromin staining. Parafibromin is 
known to be involved in cell transcription, proliferation, differentiation and 
apoptosis, although, the exact mechanism by which this protein increases the 
malignant potential of parathyroid carcinoma remains to be established (28). In our 
population, all patients with germline and/or somatic HRPT2/CDC73 mutations had 
global loss of parafibromin staining. We also found global loss of parafibromin 
staining in 10 patients in whom no mutations were identified, possibly pointing at 
the difficulties in capturing all mutations in our study population. In keeping with 
previous studies, which showed that loss of parafibromin staining was more 
frequently observed in patients who developed a local recurrence and/or distant 
metastasis compared with patients who did not (62-96% vs. 22-50%) (16,17,28), we 
indeed observed that patients with global loss of parafibromin staining had a short 
disease-free survival and survival. In contrast, focal loss of parafibromin staining 
did not appear to influence the clinical outcome. Moreover, in our experience 
scoring of focal loss of parafibromin staining is difficult to use in daily practice, 
because of commonly encountered regional differences in immunohistochemical 
staining. In this case, it is the general staining pattern that is taken in consideration 
for decision making. Our data support the premise that focal loss of parafibromin 
staining might not be as useful as global loss of parafibromin staining as a 
diagnostic or prognostic tool in parathyroid carcinoma. Gill et al. (31) indeed 
proposed a scoring system in which focal loss would be considered positive, and 
concluded that complete absence of nuclear staining for parafibromin is diagnostic 
of parathyroid carcinoma or HPT-JT syndrome-related (benign) tumor.
MEN-1 mutations are frequently found in familial (95%) and also in sporadic 
adenomas (20-30%), but so far only 4 cases of somatic MEN-1 mutations and 3 
clinically suspected germline MEN-1 mutations have been reported in patients with 
parathyroid carcinoma (14,32-34). In our population, 3 patients demonstrated a 
somatic MEN-1 mutation. In all three patients, a diagnosis of parathyroid carcinoma 
was established on the basis of intra-operative findings of invasive growth (100%), 
vaso-invasion (100%) and distant metastasis (67%). These findings suggest that 
patients with a somatic MEN-1 mutation are at risk of developing parathyroid 
carcinoma and that somatic MEN-1 mutations could have a role in parathyroid 
carcinogenesis. 
Among many other markers, downregulation of CASR expression, global loss 
of parafibromin staining and mutation in the HRPT2/CDC73 gene are tools to assist 
in establishing a diagnosis of parathyroid carcinoma. Our data demonstrate a 
significant added value of these tumor markers as strong negative determinants of 
the malignant potential of parathyroid carcinomas. We therefore advocate the use of 
these prognostic tools in the management of patients with this malignancy. Findings 
from our study strengthen the link between molecular alterations and clinical course 
of patients with parathyroid carcinoma. 
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ABSTRACT
Background: Persistent hyperparathyroidism is rare after surgery for sporadic 
hyperparathyroidism, occurring in only 0-6% of cases. The management of these 
patients is complex, with a generally poor cure rate despite repeated surgery. The 
aim of our study was to identify the challenges and pitfalls encountered in the 
complex management of patients with persistent hyperparathyroidism after initial 
parathyroidectomy.
Methods: Using Leiden University Medical Centre hospital records, we identified
20 patients with sporadic primary hyperparathyroidism who had undergone 33 
revision surgeries for persistent hyperparathyroidism. Patients with a MEN-1, MEN-
2 or CASR mutation or carcinoma were excluded. Clinical, operative and histology 
data were collected for the period covering the course of the disease.
Results: The most common causes of persistent hyperparathyroidism were a missed 
ectopic gland at initial surgery (33%) and missed multiglandular disease (15%). 
Parathyromatosis was documented in 9% of patients. Pre-operative localisation
studies had poor sensitivity: ultrasound 18%, Tc99m-MIBI-SPECT 25%, CT 30%,
MRI 20%. In contrast, selective venous sampling for PTH had a sensitivity of 50%
and a specificity of 89%. The decrease in intraoperative PTH was significantly less 
marked in patients in whom hyperparathyroidism persisted compared to those who 
achieved cure (63 ± 26 vs. 89 ± 11%, P=0.003). The risk of complications increased 
with each subsequent surgery: 20% after first, 50% after 2nd and 67% after 3rd 
surgery.
Conclusion: Persistent PHPT represents a significant management challenge 
largely due to the poor predictive value of pre-operative localisation studies and to 
the risk of complications, which increases with each subsequent revision surgery. 
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INTRODUCTION
In primary hyperparathyroidism (PHPT) cure is reported in 93 to 100% of cases
after parathyroidectomy, also when a minimally invasive approach is opted for (1-
4). Removal of all hyperactive parathyroid tissue is of significant clinical relevance, 
since patients who achieve cure show significant post-operative increase in bone 
mass (5,6), no recurrence of nephrolithiasis (5,6) and improvement in various 
parameters of quality of life (7,8).
Persistent hyperparathyroidism is defined as residual biochemical features of
hyperparathyroidism in the form of increased serum calcium and PTH 
concentrations documented directly post-operatively or within the first 6 months 
after removal of one or more hyperactive parathyroid glands at initial surgery and 
persisting thereafter (4). Persistent PHPT is most commonly due to a pathological 
gland missed at initial surgery, which is often small (<1.5 cm) and hyperplastic in 
nature (9,10), or rarely due to parathyromatosis from gland spillage during previous 
surgery (11). It is of note that the diagnosis of persistent hyperparathyroidism may 
be overlooked or delayed after parathyroidectomy, particularly in the case of 
multiple gland disease due to transient normalization of serum calcium and PTH 
concentrations due to suppression of the activity of smaller glands by the dominant 
first resected large gland. Pathological small parathyroid glands may indeed take up 
to 6 months to recover and become hyperactive in their own right (4).
Initial bilateral neck exploration or the more limited surgical approaches are 
associated with very few complications in the hands of experienced surgeons 
(12,13). In contrast, re-exploration for persistent hyperparathyroidism is associated 
with a 3-fold increase in morbidity due to scarring and disruption of the normal 
patterns of drainage due to previous surgery (14,15). In this case, pre-operative 
localisation studies are imperative in order to reduce operating time and the risk of 
complications. However, the value of standard localisation studies has been shown 
to be significantly curtailed in patients with persistent PHPT, predominantly 
because of the high frequency of hyperplastic, ectopically located and small sized 
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parathyroid glands (16-18). Management of patients with persistent 
hyperparathyroidism represents therefore a recurring challenge.
The aim of our study was to evaluate the demographic, clinical, biochemical,
operative and pathology data of a series of patients with persistent
hyperparathyroidism who had had one or more revision surgeries after initial 
parathyroidectomy, identifying in the process the challenges and pitfalls 
encountered in their complex management.
PATIENTS AND METHODS
Study population
Using our hospital records, we identified 20 patients who had undergone a total of 
33 revision surgeries for persistent PHPT in the Leiden University Medical Center.
Eighteen of the 20 patients (90%) had had their initial parathyroidectomy at another 
hospital. All revision surgeries were undertaken by two surgeons with considerable 
experience in endocrine surgery. Patients with a MEN-1, MEN-2 or CASR mutation 
were not included in the study.
Methods
All available demographic data, clinical data, data on pre-operative localisation
studies, operative data, including data on intra-operative PTH measurements, pre-
and post-operative laboratory data and histopathological data were obtained from 
the patients’ hospital records. 
All pre-operative localisation studies, including Tc99m-MIBI-SPECT and 
selective venous sampling for PTH (SVS), followed by CT-scan to confirm 
localisations suggested by Tc99m-MIBI-SPECT or SVS, were reviewed and 
analysed as previously reported (19,20).
Bilateral neck exploration consisted of visualization of all four parathyroid 
glands, leading to either excision of a single enlarged parathyroid gland, or to 
subtotal or total parathyroidectomy with auto-transplantation if more than one 
parathyroid gland was found to be enlarged. If no parathyroid glands could be 
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visualized or no enlarged gland was found, the surgeon proceeded to dissection of 
the ipsilateral anterior compartment extending from the level of the hyoid bone 
superiorly to the suprasternal notch inferiorly and to a hemithyroidectomy on the 
side of the missing parathyroid. Less invasive neck exploration was only undertaken 
in patients with positive preoperative localisation studies and was guided by intra-
operative PTH (IOPTH) monitoring in the majority op patients. IOPTH monitoring 
consisted of two initial baseline PTH measurements with an interval of 15-20
minutes, followed by 5 measurements at 3-minute intervals after excision of the 
pathological parathyroid(s). Surgery was considered successful if IOPTH decreased 
by more than 50% within 7 minutes of excision of a pathological parathyroid 
gland(s).
Histological preparations obtained at surgery conducted in our hospital 
(including all last revision surgeries) were independently reviewed by an
experienced pathologist. A diagnosis of sporadic parathyroid adenoma was based on 
the presence of a benign encapsulated neoplasm mostly consisting of one cell type 
with an adjacent rim of normal glandular tissue, usually involving a single gland 
(21). A diagnosis of parathyroid hyperplasia was based on an absolute increase in 
parathyroid parenchymal cell mass resulting from proliferation of a mixture of the 
different parathyroid cells, present in multiple parathyroid glands in the absence of a 
known stimulus for PTH hypersecretion such as renal failure or vitamin D 
deficiency (21).
Laboratory data on serum calcium and PTH concentrations as measured more 
than 6 months post-operatively were used to indicate cure or persistence of 
hyperparathyroidism.
Statistical analysis
Statistical analysis was performed using the SPSS 16 software (SPSS inc., Chicago, 
IL, USA). Results are expressed as mean ± SD unless otherwise stated. Chi-square 
test and Student’s t-test were used as appropriate for categorical variables and 
continuous variables. A probability level of random difference of P<0.05 was 
considered to be significant. 
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Ethical consideration
The methods used in this study were part of the clinical routine work-up of patients 
undergoing revision surgery in our hospital. The study was approved by the Local 
Ethics Committee of the Leiden University Medical Center and all patients 
consented to the use of their data.
RESULTS
The study population consisted of 20 patients, 4 male and 16 female, with an 
established diagnosis of PHPT, which persisted for a mean of 5 ± 7 years (range 0-
24) after initial parathyroidectomy (PTx). Duration since first presentation with 
clinical and biochemical features of hyperparathyroidism was 12 ± 9 years (range 2-
35) and all patients had had at least 1 revision surgery (range 1-5).
Findings before initial surgery
Nine of the 20 patients (45%) presented with nephrolithiasis, two with height loss 
because of documented vertebral fractures, two with generalized bone and muscle 
pain, one with polyuria and polydipsia, one with severe weight loss and in one 
patient the diagnosis was made during a hospital admission for acute pancreatitis. In 
the last 4 cases, the diagnosis was established by the incidental finding of 
hypercalcemia on general medical screening in 3 cases, and in the process of an 
endocrine work-up for thyroid disease in the last case.
At the time of diagnosis, only 1 of the 20 patients was asymptomatic. Although 
symptoms related to hypercalcemia such as polyuria, polydipsia and constipation
were present in only 5 patients (25%), 47% had non-specific symptoms such as 
muscle or bone pain and tiredness was reported by 41% of patients (Table 1).
Mean preoperative serum calcium concentration was 2.86 ± 0.21 mmol/L and 
mean PTH level was 13 ± 6 pmol/L. Renal impairment (creatinine clearance <60 
ml/min) was documented in 25% of patients. 
At presentation, renal stones were documented on ultrasound of the kidneys in 
58% of patients and 29% had osteoporosis on Dual energy X-ray absorptiometry 
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(DXA). Six of the 20 patients (30%) had parathyroid localisation studies before 
initial PTx, using a Tc99m-MIBI-SPECT scan and/or an ultrasound scan of the 
neck.
Eleven of the 20 patients (55%) had initially undergone bilateral neck 
exploration, 25% had unilateral neck exploration and the type of surgery was not 
specified in 4 cases. Initial surgery was guided by intra-operative PTH (IOPTH) 
monitoring in only 2 patients (13%). In 3 of 20 patients (15%) surgery was 
combined with a hemithyroidectomy, because of pre-operatively identified thyroid 
pathology in 1 patient and because of a negative bilateral neck exploration which 
raised suspicion of an intrathyroidal parathyroid gland in the other 2 patients. In 
both cases an intrathyroidal pathological parathyroid gland was indeed found and 
removed. In one of the 20 patients (5%) surgery was combined with a total 
thymectomy, because of a negative bilateral neck exploration with suspicion of an 
intrathymic parathyroid gland, although no pathological gland was found at this 
location (Table 1).
A single adenoma was removed at surgery in 9 of 20 patients (45%), an ectopic 
pathological parathyroid gland in 2 cases, one or more hyperplastic glands were 
removed in one case and no pathological glands were found in 8 cases.
Surgery was complicated by recurrent laryngeal nerve paralysis in 2 cases, in 
one of which it was transient, and by cellulitis of the neck in one case.
Findings at revision surgery
Prior to first revision surgery, 6 of the 20 patients (30%) had symptoms of 
hypercalcemia such as polyuria, polydipsia and constipation, 30% had symptoms of 
muscle or bone pain and 40% complained of tiredness. Prior to second revision 
surgery, polyuria and polydipsia was reported by 1 of 8 patients, constipation by 1 
of 8 patients, muscle or bone pain by 1 of 8 patients and tiredness by 3 of 8 patients. 
Renal impairment (creatinine clearance of <60ml/min) was documented in 3 of 15 
patients (20%) prior to first revision surgery and in 1 of 7 patients (14%) prior to 
second revision surgery. Ultrasound of the kidneys was performed in 18 of 20
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Table 1. Demographic, operative and pathology data in 20 patients with persistent 
PHPT following surgery
Prior to initial At second At third
PTx (n=20) PTx (n=20) PTx (n=8)
Gender (Men:Women) 4:16 4:16 2:6
Age (years) 52 ± 12 (35-70) 57 ± 11 (36-71) 57 ± 11 (36-72)
Biochemistry prior to initial surgery
      s-calcium (mmol/L) 2.86 ± 0.21 2.73 ± 0.16 2.94 ± 0.29
      PTH (pmol/L) 13 ± 6 17 ± 6 18 ± 13
      phosphate (mmol/L) 0.77 ± 0.14 0.84 ± 0.14 0.90 ± 0.26
      alkaline phosphatase 181 ± 176 98 ± 43 140 ± 79
      creatinine clearance  (ml/min) 66 ± 15 68 ± 16 75 ± 18
      u-calcium (mmol/24 hours) 11.0 ± 6.5 11.2 ± 7.2 14.3 ± 8.1
Clinical presentation
      Polyuria & polydipsia 4/17 (24%) 3/18 (17%) 1/7 (14%)
      Constipation 1/17 (6%) 3/18 (17%) 1/7 (14%)
      Tiredness 7/17 (41%) 8/18 (44%) 3/7 (43%)
      Muscle or bone pain 8/17 (47%) 6/18 (33%) 1/7 (14%)
Complications
      Renal impairment 3/12 (25%) 3/15 (20%) 1/7(14%)
      Nephrolithiasis/Nephrocalcinosis 11/19 (58%) 8/18 (44%) 4/7 (57%)
      Osteoporosis 2/7 (29%) 5/9 (56%) 3/6 (50%)
      Fractures 0/20 1/18 (6%) 0/7
Type of surgery
     Bilateral neck exploration 11/16 (69%) 12/18 (67%) 5/8 (63%)
      Unilateral neck exploration 5/16 (31%) 4/18 (22%) 3/8 (38%)
      Sternotomy alone or combined 0/16 2/18 (11%) 1/8 (13%)
      Combined with thyroidectomy 3/16 (19%) 5/18 (28%) 1/8 (13%)
      Combined with thymectomy 1/16 (6%) 2/18 (11%) 3/8 (38%)
      Use of IOPTH monitoring 2/16 (13%) 8/18 (44%) 6/8 (75%)
      No data available 4//20 2/20 0/8
Pathology
      Adenoma 10/19 (53%) 8/20 (40%) 2/8 (25%)
      Hyperplasia 2/19 (11%) 5/20 (25%) 5/8 (63%)
      No pathological glands found 7/19 (37%) 7/20 (35%) 1/8(12%)
Outcome of surgery
      Cure 0/20 8/20 (40%) 4/8 (50%)
      Persistence 20/20 (100%) 12/20 (60%) 4/8 (50%)
s: serum, u: urine, IOPTH: Intra-operative PTH measurement
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patients (90%) before first revision surgery and nephrolithiasis was demonstrated in 
8 (44%), all of whom also had  evidence for nephrolithiasis before initial surgery.
Ultrasound data were available in 7 of 8 patients (88%) before second revision 
surgery and demonstrated persistent nephrolithiasis in 4 patients (57%). One patient 
had developed this complication de novo after persistence of PHPT for 30 years 
after failed revision surgery.
BMD measurements were available in 9 of 20 patients (45%) who underwent 
first revision surgery, and demonstrated osteoporosis in 5 (55%), osteopenia in 3 
(33%) and a normal BMD in 1 case. Prior to second revision surgery BMD was 
measured in 6 of 8 patients (75%) and demonstrated osteoporosis in 3 (50%) and
osteopenia in the other 3 (50%). Only one postmenopausal patient sustained a 
fracture of the wrist, prior to first revision surgery. None of the patients had 
sustained a clinical vertebral fracture at any time since diagnosis. 
The 20 patients underwent a total of 33 revision surgeries. Twenty of the 33
revision surgeries were bilateral neck explorations (61%), 9 (27%) were unilateral 
neck explorations, a sternotomy was performed in 2 cases and the type of surgery 
was not specified in the last 2 cases. Surgery was combined with a 
hemithyroidectomy in 8 of the 33 cases (24%) and in 6 of 33 cases (18%) with a
thymectomy. The decision to perform a hemithyroidectomy was based on the intra-
operative finding of an intrathyroidal node in 3 cases, negative bilateral neck 
exploration with suspicion of an intrathyroidal parathyroid gland in 4 cases, and the 
incidental finding of a small papillary thyroid carcinoma in one case.
Nineteen of the 33 revision surgeries (58%) were guided by IOPTH 
measurements. A decrease in PTH levels of more than 50% was observed in all 10 
patients who achieved cure after revision surgery, but also in 7 of the 9 patients who 
had persistence of PHPT after revision surgery. However, the decrease in PTH 
levels was significantly greater in patients who achieved cure after revision surgery 
compared to patients with persistence after revision surgery (89 ± 11% vs. 63 ± 
26%, P=0.003; Figure 1). A decrease in PTH concentration of more than 50% was 
also reached faster, albeit not significantly, in patients who achieved cure after 
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revision surgery compared to patients with persistence of HPTH after revision 
surgery (6 ± 4 minute vs. 10 ± 7 minutes, P=0.09).
Figure 1: IOPTH measurement during revision surgery in patients with persistent PHPT who 
were cured post-operatively (black bars) compared to those in whom hyperparathyroidism
persisted post-operatively (gray bars). 
Four of the 20 first revision surgeries (20%) were associated with 
complications: fever (n=1), hypoparathyroidism (n=1), infected hematoma (n=1)
and recurrent laryngeal nerve paralysis (n=1) (Figure 2). Four of the 8 second 
revision surgeries (50%) were associated with one or more complications; recurrent 
laryngeal nerve paralysis (n=1), transient recurrent laryngeal nerve paralysis (n=1), 
hungry bone syndrome (n=1) and hypoparathyroidism (n=1). Two of 3 third 
revision surgeries (67%) were complicated by a wound infection. The patient who 
also underwent fourth and fifth revision surgery had an uncomplicated fourth 
revision surgery, but the fifth revision surgery was complicated by permanent 
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Figure 2: Complications documented after 33 revision surgeries in patients with persistent 
PHPT.
At first revision surgery a single and first adenoma was removed in 5 cases
(25%), a second adenoma in 3 cases (15%), one or more hyperplastic parathyroid 
glands in 5 cases (25%) and no pathological parathyroid tissue was found in 7 cases
(35%) (Figure 3). At second revision surgery a single and first adenoma was 
removed in 1 case (13%), one or more hyperplastic glands in 5 cases (63%), and 
seeded cell aggregations from parathyromatosis in 2 cases (25%). At third revision 
surgery one or more hyperplastic glands were removed in 1 case and cell 
aggregations from parathyromatosis in 2 cases. One patient also underwent a fourth 
and fifth revision surgery, during which remnants of hyperplastic autotransplantated 
parathyroid tissue and cell aggregations from parathyromatosis were respectively 
excised. 
After first revision surgery 8 of 20 patients (40%) were cured and 12 of 20 
patients (60%) had persistence of PHPT (Figure 3). Eight of the 12 patients who 
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were not cured by first revision surgery underwent a second revision surgery.
Surgery was not undertaken in the other 4 patients, because of mild asymptomatic 
hyperparathyroidism in 2 cases, reluctance of 1 patient to undergo further surgery 
because of recurrent laryngeal nerve paralysis at previous surgery, and in the last
patient surgery was not advocated because of 2 negative bilateral neck explorations 
and persistently negative localisation studies except for SVS, which suggested a
mediastinal localisation of hyperactive parathyroid tissue, although this was not 
confirmed by CT-scan of the region. After second revision surgery 4 of 8 patients 
were cured (50%) and 4 of 8 patients (50%) had persistence of PHPT. Three of the 
4 patients with persistence of PHPT went on to have a third revision surgery
exclusively on the basis of a positive PTH sampling, with otherwise negative
localisation studies, which failed to result in cure in all 3 cases. Only 1 of these 3 
patients underwent a fourth and fifth revision surgery, neither of which again 
resulted in cure. These last three patients are currently being treated with the 
calcimimetic cinacalcet and an oral bisphosphonate with reasonable control of 
serum calcium and PTH concentrations and no further bone loss.
Pathology of excised hyperactive parathyroid tissue in persistent PHPT
At revision surgery, an adenoma was found in 9 of 33 revision surgeries (27%), 
which was a single adenoma in 6 cases (ectopic n=4, intrathyroidal n=1, normal 
anatomical location n=1), and a second adenoma in 3 cases (normal anatomical 
location n=2, intrathyroidal n=1). 
A hyperplastic gland was found in 10 of 33 revision surgeries (30%), in the 
context of a missed multiglandular disease (MGD) in 5 cases, an ectopically located 
gland in 3 cases and an intrathyroidally located gland in 2 cases. In one patient the 
autotransplanted parathyroid tissue that was implanted in the sternocleidomastoid 
muscle had become hyperplastic, also showing invasive growth in the muscle, for 
which the patient had to undergo 2 explorations to remove all identifiable 
hyperplastic parathyroid tissue.
Ectopic parathyroid glands (n=7) were found in the thymus (n=3), mediastinum 
(n=1), caudally in the neck ventral to the trachea (n=1), caudally in the neck near the 
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aortic arch (n=1), and high on the left side of the neck on the prevertebral fascia 
(n=1).
Spillage of hyperactive parathyroid tissue leading to parathyromatosis occurred 
during initial surgery in 1 patient, during first revision surgery in 1 patient and 
during fourth revision surgery in 1 patient. Hyperparathyroidism persisted in these 3 
patients despite a total of 6 revision surgeries. 
Table 2. Predictive value of localisation studies prior to revision surgery
Sensitivity Specificity PPV NPV
Tc99m-MIBI-SPECT (n=35) 25% 96% 60% 83%
Ultrasound of the neck (n=16) 18% 29%
CT-scan (n=11) 30 81% 30% 81%
MRI-scan (n=7) 20% 100% 50% 80%
Selective venous sampling for PTH (n=14) 50% 89% 50% 85%
PPV: Positive predictive value, NPV: Negative predictive value
Predictive value of pre-operative localisation studies in persistent PHPT
One or more localisation studies were performed prior to 27 of 33 revision surgeries 
compared to only 6 of 20 performed prior to initial surgeries. An ultrasound of the 
neck (US) was performed prior to 6 of 20 initial surgeries (30%) and prior to 10 of 
33 revision surgeries (30%). US had a sensitivity of 67% prior to initial surgery and 
of 18% prior to revision surgery. Tc99m-MIBI-SPECT was performed prior to 5 of 
20 initial surgeries (25%) and prior to 26 of 33 revision surgeries (79%). Tc99m-
MIBI-SPECT failed to localise hyperactive parathyroid glands in the 5 patients in 
whom it was performed prior to initial surgery, and had a localising sensitivity of 
only 25% prior to revision surgery. A CT scan was performed in only 1 of the 20 
patients before initial surgery and prior to 10 of 33 revision surgeries (30%), in 
which case it was mainly performed to confirm localisation suggested by Tc99m-
MIBI-SPECT, SVS or both. CT scan had a general sensitivity of 30% (Table 2). An 
MRI scan was performed before 1 of the 20 initial surgeries and prior to 6 of 33 
revision surgeries. MRI scan had a general sensitivity of 20%. Selective venous 
sampling (SVS) for PTH was not performed before initial surgery but SVS data 
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were available prior to 15 of the 33 revision surgeries and had a localisation
sensitivity of 50% (Table 2). 
DISCUSSION
Data from our case series of 20 patients with persistent PHPT suggest that their 
management is complex and associated with a number of pitfalls. The most 
common causes of persistent HPTH were a missed ectopic gland at initial surgery 
(33%) and missed multiglandular disease (15%). The more challenging surgical 
complication of parathyromatosis was observed in 9% of patients. Pre-operative 
localisation studies had poor sensitivity: US 18%, Tc99m-MIBI-SPECT 25%, CT 
30%, MRI 20%. In contrast, selective venous sampling for PTH had a sensitivity of 
50% and a specificity of 89%, although it failed to accurately localise hyperactive 
tissue in 43% of patients. The decrease in intraoperative PTH was significantly less 
marked in patients in whom hyperparathyroidism persisted compared to those who 
achieved cure (63 ± 26 vs. 89 ± 11%, P=0.003). The risk of complications, 
particularly that of recurrent laryngeal nerve palsy, increased with each subsequent 
surgery: 20% after first, 50% after 2nd and 67% after 3rd surgery.
In primary hyperparathyroidism, surgery is the treatment of choice resulting in 
cure in the vast majority of patients. We have previously demonstrated that the most 
commonly encountered sporadic hyperparathyroidism does not recur if cure is 
established 6 months after parathyroidectomy (4). The prevalence of persistent 
hyperparathyroidism is thus low, with only a small number of patients
demonstrating persistence of clinical and biochemical features of 
hyperparathyroidism after initial surgery.
The main challenge in the management of persistent PHPT lies in the decreasing 
value of localisation studies after initial and each subsequent revision surgery.
Tc99m-MIBI-SPECT has a lower predictive value in patients with persistent PHPT, 
likely to be due to disturbance in local vascular supply by previous surgery, but also 
due to differences in gland pathology and size in persistent hyperparathyroidism,
ultimately affecting radiopharmaceutical uptake. It is of interest that Tc99m-MIBI-
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SPECT performed prior to initial surgery failed to identify hyperactive parathyroid 
glands in 5 patients in whom hyperparathyroidism subsequently persisted, although 
this observation could not be confirmed in the remaining 15 patients with persistent 
PHPT, who did not have this localisation study before initial surgery. Although
SVS is positive in all patients with persistent PHPT, this localisation study cannot 
accurately localise hyperactive parathyroid glands, as it reflects drainage of the 
hyperactive parathyroid gland rather than its actual anatomical localisation, and 
drainage pattern is further confounded by disturbance in local vascular supply as a 
result of previous surgery.
Although pre-operative localisation studies are important to guide the surgeon
and decrease operating time, knowledge of anatomy and embryology of the 
parathyroid glands is also important to successfully locate previously missed 
hyperactive parathyroid glands. This is particularly so as ectopic parathyroid glands 
are found in 23-77% of cases of persistent hyperparathyroidism (14,22-27). In 
keeping with previous observations (22-27), our case series confirms that the
thymus is one of the most frequent sites of ectopic parathyroid glands (43%),
followed by the mediastinum (14%), ventral to the trachea (14%) and on the 
prevertebral fascia (14%). Other locations of hyperactive parathyroid glands are the
tracheoesophageal groove (2.6-33%), para- or retroesophageal area (1.8-21.4%),
carotid sheath (0.6-14.3%), carotid bifurcation (8.3%), aortopulmonary window 
(1.3-6.3%), and parapharyngeal area (0.6-8.4%) (22-27).
Data on the use of IOPTH measurement during revision surgery for persistent 
PHPT are somewhat conflicting. Some studies thus report a sensitivity of 94-100% 
(24,26,28), whereas data have also been reported on misleading decreases in PTH 
levels of 50-60% during IOPTH measurements (25). Although we show that 78% of 
patients with persistent PHPT have a positive IOPTH measurement at revision 
surgery according to the “Miami criteria” (a drop in PTH levels of more than 50%) 
(29,30), we and others (25,28) demonstrate that patients who achieve cure after 
revision surgery have a greater and more rapid decrease in PTH levels during 
IOPTH measurement compared to patients with persistent PHPT after revision 
surgery. These findings suggest that in patients with persistent PHPT, IOPTH 
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measurements may be more valuable in predicting cure when stricter cut-off values 
than the ones suggested by the “Miami criteria” are used. 
In keeping with previous reports (22-24,26-28), the overall complication rate at 
first revision surgery was 20% in our case series. As expected, the overall 
complication rate significantly increased at second and third revision surgery (50 
and 67%, respectively). The most common complications reported by us and others 
are hypoparathyroidism (2.6-12.9%) and recurrent laryngeal nerve injury leading to 
transient (2.3-13.5%) or permanent paralysis (0.08-25%) (22-28).
A rare but challenging complication of parathyroid surgery is the development 
of parathyromatosis, which is characterized by intraoperative rupture of a
hyperactive parathyroid gland which leads to seeding of parathyroid tissue in and 
around the site from which the ruptured gland is removed. In contrast to previously 
published data (11), we observe in our case series that parathyromatosis leading to 
persistent hyperparathyroidism occurred in only 1 case during initial surgery and in 
2 cases during revision surgery. In these cases, cure could not be achieved by 
surgery, despite repeated removal of small aggregates of hyperactive parathyroid 
tissue. In these cases patients have been shown to benefit from treatment with the 
calcimimetic cinacalcet, with reasonable control of the biochemical features and 
complications of hyperparathyroidism. Long-term studies are required to establish 
the efficacy and safety of these agents in recalcitrant persistent 
hyperparathyroidism.
Our findings from this case series indicate that the management of patients with 
persistent PHPT is complex and challenging. When initial surgery fails to achieve 
cure, each reoperation jeopardizes the ability of localisation studies to accurately
localise residual hyperactive parathyroid glands and increases the risk of 
complications in its own right because of distortion and scarring of surgical planes 
as a result of previous interventions. In these patients, re-operation should be 
carefully planned and attempts at surgery strongly discouraged if a clear localisation
of hyperactive tissue is not secured pre-operatively. The availability of 
calcimimetics allows a more conservative approach in the management of these 
patients. This is particularly if parathyromatosis is strongly suspected, and at least
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until such time as the hyperactive tissue may have grown sufficiently to be 
adequately localised, which may take several years, as parathyroid cell growth and 
proliferation is slow. Whether calcimimetic agents, which have been shown to 
suppress proliferation of parathyroid cells in vitro and in animal studies (31-34),
may have a similar effect in patients with persistent PHPT remains to be 
established. Further studies using cinacalcet in the long-term are required in patients 
with persistent hyperparathyroidism to explore this issue. 
228  /  Chapter 10
REFERENCES
1. Calva-Cerqueira D, Smith BJ, Hostetler ML, Lal G, Menda Y, O'Dorisio TM, Howe JR. 
Minimally invasive parathyroidectomy and preoperative MIBI scans: correlation of gland 
weight and preoperative PTH. J Am Coll Surg 2007;205(4 Suppl):S38-S44.
2. Palmer RM, Lokey JS. Is minimally invasive parathyroidectomy reasonable in the nonuniversity 
setting? Am J Surg 2006;192(6):865-868.
3. Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration 
for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg 
2002;236(5):543-551.
4. Witteveen JE, Kievit J, Morreau H, Romijn JA, Hamdy NA. No recurrence of sporadic primary 
hyperparathyroidism when cure is established 6 months after parathyroidectomy. Eur J 
Endocrinol 2010;162(2):399-406.
5. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J et al. The natural 
history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J 
Clin Endocrinol Metab 2008;93(9):3462-3470.
6. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of 
primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 
1999;341(17):1249-1255.
7. Mihai R, Sadler GP. Pasieka's parathyroid symptoms scores correlate with SF-36 scores in 
patients undergoing surgery for primary hyperparathyroidism. World J Surg 2008;32(5):807-
814.
8. Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following 
surgery in patients with primary hyperparathyroidism. World J Surg 1998;22(6):513-518.
9. Carty SE, Norton JA. Management of patients with persistent or recurrent primary 
hyperparathyroidism. World J Surg 1991;15(6):716-723.
10. Alexander HR, Jr., Chen CC, Shawker T, Choyke P, Chan TJ, Chang R, Marx SJ. Role of 
preoperative localization and intraoperative localization maneuvers including intraoperative 
PTH assay determination for patients with persistent or recurrent hyperparathyroidism. J Bone 
Miner Res 2002;17 Suppl 2:N133-N140.
11. Sokol MS, Kavolius J, Schaaf M, D'Avis J. Recurrent hyperparathyroidism from benign 
neoplastic seeding: a review with recommendations for management. Surgery 1993;113(4):456-
461.
12. Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration 
for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg 
2002;236(5):543-551.
13. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. 
Ann Surg 2002;235(5):665-670.
14. Gough I. Reoperative parathyroid surgery: the importance of ectopic location and multigland 
disease. ANZ J Surg 2006;76(12):1048-1050.
15. Shen W, Duren M, Morita E, Higgins C, Duh QY, Siperstein AE, Clark OH. Reoperation for 
persistent or recurrent primary hyperparathyroidism. Arch Surg 1996;131(8):861-867.
16. Jones JM, Russell CF, Ferguson WR, Laird JD. Pre-operative sestamibi-technetium subtraction 
scintigraphy in primary hyperparathyroidism: experience with 156 consecutive patients. Clin 
Radiol 2001;56(7):556-559.
17. Mihai R, Gleeson F, Buley ID, Roskell DE, Sadler GP. Negative imaging studies for primary 
hyperparathyroidism are unavoidable: correlation of sestamibi and high-resolution ultrasound 
scanning with histological analysis in 150 patients. World J Surg 2006;30(5):697-704.
18. Lumachi F, Zucchetta P, Marzola MC, Boccagni P, Angelini F, Bui F, D'Amico DF et al. 
Advantages of combined technetium-99m-sestamibi scintigraphy and high-resolution 
ultrasonography in parathyroid localization: comparative study in 91 patients with primary 
hyperparathyroidism. Eur J Endocrinol 2000;143(6):755-760.
19. Witteveen JE, Kievit J, Stokkel MP, Morreau H, Romijn JA, Hamdy NA. Limitations of Tc99m-
MIBI-SPECT Imaging Scans in Persistent Primary Hyperparathyroidism. World J Surg 
2010;35(1):128-139.
Management of persistent PHPT  /  229
20. Witteveen J, Kievit J, van Erkel AR, Morreau H, Romijn JA, Hamdy N. The role of selective 
venous sampling in the management of persistent hyperparathyroidism revisited. Eur J 
Endocrinol 2010;163(6):945-952.
21. DeLellis RA. World health organisation classification of tumours. Pathology and genetics of 
tumours of endocrine organs, AIRC press, Lyon. 2006.
22. Feingold DL, Alexander HR, Chen CC, Libutti SK, Shawker TH, Simonds WF, Marx SJ et al. 
Ultrasound and sestamibi scan as the only preoperative imaging tests in reoperation for 
parathyroid adenomas. Surgery 2000;128(6):1103-1109.
23. Hessman O, Stalberg P, Sundin A, Garske U, Rudberg C, Eriksson LG, Hellman P et al. High 
success rate of parathyroid reoperation may be achieved with improved localization diagnosis. 
World J Surg 2008;32(5):774-781.
24. Irvin GL, III, Molinari AS, Figueroa C, Carneiro DM. Improved success rate in reoperative 
parathyroidectomy with intraoperative PTH assay. Ann Surg 1999;229(6):874-878.
25. Thompson GB, Grant CS, Perrier ND, Harman R, Hodgson SF, Ilstrup D, van Heerden JA. 
Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid 
hormone monitoring. Arch Surg 1999;134(7):699-704.
26. Yen TW, Wang TS, Doffek KM, Krzywda EA, Wilson SD. Reoperative parathyroidectomy: an 
algorithm for imaging and monitoring of intraoperative parathyroid hormone levels that results 
in a successful focused approach. Surgery 2008;144(4):611-619.
27. Jaskowiak N, Norton JA, Alexander HR, Doppman JL, Shawker T, Skarulis M, Marx S et al. A 
prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. 
Ann Surg 1996;224(3):308-320.
28. Richards ML, Thompson GB, Farley DR, Grant CS. Reoperative parathyroidectomy in 228 
patients during the era of minimal-access surgery and intraoperative parathyroid hormone 
monitoring. Am J Surg 2008;196(6):937-942.
29. Barczynski M, Konturek A, Hubalewska-Dydejczyk A, Cichon S, Nowak W. Evaluation of 
Halle, Miami, Rome, and Vienna intraoperative iPTH assay criteria in guiding minimally 
invasive parathyroidectomy. Langenbecks Arch Surg 2009;394(5):843-849.
30. Carneiro DM, Solorzano CC, Nader MC, Ramirez M, Irvin GL, III. Comparison of 
intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the 
most accurate? Surgery 2003;134(6):973-979.
31. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N. The calcimimetic 
compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. 
Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997;100(12):2977-
2983.
32. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J. Calcimimetic NPS R-568 prevents 
parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 
2000;57(1):50-58.
33. Chin J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J. Activation of the calcium receptor 
by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic 
rats. J Am Soc Nephrol 2000;11(5):903-911.
34. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D. Cinacalcet 





General discussion  /  233
CONTENTS
I. Introduction
II. Cure after parathyroidectomy for primary hyperparathyroidism 
III. Localisation studies in persistent primary hyperparathyroidism
IV. Complications of the surgical management of primary hyperparathyroidism 
V. Aspects of osteocyte function in primary hyperparathyroidism
VI. Clinical and molecular aspects of parathyroid carcinoma
VII. Management of patients with persistent primary hyperparathyroidism
VIII. Summary
I. Introduction
Primary hyperparathyroidism (PHTP) is the most common cause of hypercalcaemia 
in the outpatient setting. Over the past few decades, the clinical profile of PHPT has 
drastically changed from “bones, stones, groans and psychic moans" to an almost 
asymptomatic disease. Progress in pre-operative localisation studies, surgical 
techniques and intra-operative PTH (IOPTH) monitoring has increased cure rates 
following initial surgery for PHPT to 93-100% (1-3). Despite the progress in initial 
surgery for PHPT, management of persistent and recurrent primary 
hyperparathyroidism remains a challenge.
In this thesis we report the incidence of persistent PHPT after initial surgery for 
primary hyperparathyroidism in our hospital over a period of 24 year. We describe 
the demographic, clinical, biochemical, surgical and pathological characteristics of 
patients with persistent PHPT after initial parathyroidectomy for sporadic PHPT.  In 
addition, we evaluate the value of pre-operative localisation studies prior to revision 
surgery and the skeletal and post-operative complications of chronic high 
circulating levels of PTH. Furthermore we discuss the management of recurrent 
hyperparathyroidism in parathyroid carcinoma, and the effect of molecular 
alterations in the HRPT2 and CASR gene on prognosis in these patients. 
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II. Cure after parathyroidectomy for primary hyperparathyroidism
In primary hyperparathyroidism, surgical removal of all pathological parathyroid 
tissue is the only approach that provides a definitive and durable cure. Patients who 
are cured after surgery show a significant postoperative increase in bone mass (4-6),
no recurrence of renal stones (4,7) and improvement in various parameters of 
quality of life compared to patients who had no surgery or unsuccessful surgery (8-
12). Cure rate has been reported to be in the range of 94-100% for bilateral neck, as 
well as less invasive surgery, more than 6 months after parathyroidectomy (PTx) 
(13-22). Based on these findings, it has become common practice to limit the post-
operative follow-up to 6 months. However, in a 5 year follow-up of 91 patients who 
were successfully operated for PHPT, Westerdahl et al. reported a rather high 
recurrence rate of 4%, which was largely due to previously undiagnosed germline 
mutations in the MEN-1 gene and consequent multiple gland pathology (23). In
Chapter 2 we set out to evaluate cure rate and its maintenance in the long-term after 
initial parathyroidectomy in patients with sporadic PHPT who underwent surgery in 
our hospital in the period between 1984 and 2008. We evaluated the cure at short-
term (3 and 6 months) and long-term follow-up (range 1-24 years) in 73 patients 
with sporadic PHPT. In the process, we also assessed the value of various factors in 
the prediction of cure in patients with sporadic PHPT.
At the time of first follow-up (within 3 months of surgery), 70 of the 73 patients 
(96%) had evidence for biochemical cure of hyperparathyroidism (HPTH). At the 
time of the second post-operative follow-up (6 months after PTx) and the long-term 
follow-up (range 1-24 years), 68 of the 73 patients (93%) had evidence for 
biochemical cure. There were no significant differences in gender, age at 
presentation, clinical presentation, biochemical and pathological findings between 
patients who achieved and maintained cure and patients with persistence of HPTH 
after initial PTx. It was of note, that all 5 patients with persistent HPTH had 
undergone surgery before 2001 and that with the implementation of pre-operative 
localisation studies and intra-operative PTH (IOPTH) monitoring in the standard 
care of patients with PHPT, cure rate has increased to 100% since 2001.
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Our study provides evidence that ‘recurrent’ hyperparathyroidism does not 
occur in sporadic PHPT when cure is established 6 months after parathyroidectomy.
This strongly suggests that long-term follow-up of these patients is not necessary. In 
contrast, close follow-up is advocated within the first 6 months after PTx to 
definitively establish cure and to enable the identification of those with residual 
gland pathology and thus persistent hyperparathyroidism.
III. Localisation studies in persistent primary hyperparathyroidism
In Chapter 2 we demonstrated that the use of pre-operative localisation studies
increased the cure rate in patients with sporadic PHPT who underwent initial PTx.
Before initial bilateral neck surgery preoperative localisation studies are not deemed 
necessary, because experienced surgeons have, on average, a 98% chance of 
excising all pathological tissue (22,24). However, localisation studies become 
mandatory when the surgeon opts for a more focused unilateral or minimally 
invasive approach and before reoperative parathyroidectomy for persistent 
hyperparathyroidism, as a second (or more) neck exploration is technically more 
challenging than initial surgery and may be associated with as much as a threefold 
increase in morbidity (22,25-27). Limited data suggest that the localizing value of 
Tc99m-MIBI-SPECT is much lower for the preoperative localisation of residual 
active parathyroid glands before reoperative parathyroidectomy (28-30).
In Chapter 3 we evaluated the predictive value of Tc99m-MIBI-SPECT in patients 
with persistent PHPT prior to revision surgery and compared this to the predictive 
value of this localisation study in patients with sporadic PHPT prior to initial 
surgery.
Tc99m-MIBI-SPECT was able to detect and accurately localize 61% of the 
pathological glands removed at initial surgery in patients with sporadic PHPT and 
33% of the pathological glands removed at reoperative parathyroidectomy in 
patients with persistent PHPT. Compared to patients with sporadic PHPT cured 
after initial surgery, patients with persistent PHPT had a higher proportion of 
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hyperplastic glands (55% vs. 26%), more ectopically located glands (44% vs. 22%), 
and smaller pathological gland size (1.21 cm vs. 2.03 cm). We demonstrate that the 
ability of Tc99m-MIBI-SPECT to detect and accurately localize pathological 
parathyroid glands was decreased in the case of hyperplasia and a gland diameter 
<1.5 cm, explaining the decreased diagnostic value of Tc99m-MIBI-SPECT 
observed in patients with persistent PHPT. 
The combined effect of disturbance in the local vascular supply by previous 
surgery, as well as differences in gland pathology and size ultimately affecting 
radiopharmaceutical uptake, are likely to lead to the limited ability of the widely 
used Tc99m-MIBI-SPECT to detect and accurately localize pathological 
parathyroid glands in patients with persistent hyperparathyroidism before 
reoperative parathyroidectomy.
Because of the limited diagnostic value of Tc99m-MIBI-SPECT prior to revision 
surgery for persistent PHPT, we assessed in Chapter 4 whether selective venous 
sampling (SVS) of parathyroid hormone (PTH) could contribute to a more accurate 
preoperative localisation of residual hyperactive parathyroid tissue in patients with 
persistent hyperparathyroidism. The diagnostic value of SVS is based on the 
assumption that regional drainage of each one of the four parathyroid glands is into 
the adjacent superior, middle and inferior thyroid veins, respectively (31). Despite 
potential anatomical variations, SVS is successful in predicting the side of a 
pathological parathyroid gland in 39-93% of patients with PHPT (31-41) and, more 
importantly, in 66-75% of patients with negative noninvasive studies (36,37,42).
However, the major limitation of SVS is that it pinpoints the area of venous 
drainage of a hyperactive gland rather than its exact anatomical location. 
We evaluated the results of Tc99m-MIBI-SPECT and SVS performed prior to 20 
revision surgeries in 18 patients with persistent or recurrent PHPT or with 
autonomous tertiary hyperparathyroidism (THPT) due to end-stage renal failure. 
Tc99m-MIBI-SPECT was found to have a sensitivity of 30% compared to a 
sensitivity of 75% with SVS. SVS was found to accurately localize 10 of the 14 
pathological glands (71%) which had been inaccurately localized or completely 
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missed by Tc99m-MIBI-SPECT, while Tc99m-MIBI-SPECT was only able to 
localise 1 of the 6 pathological glands (17%) inaccurately localised by SVS. 
Localising sensitivity was 100% when concordance was achieved between SVS and 
Tc99m-MIBI-SPECT. In keeping with Tc99m-MIBI-SPECT, the diagnostic value 
of SVS was also decreased, although to a lesser extent, in the case of hyperplastic 
parathyroid glands and glands with a diameter of less than 1.5 cm. In contrast to 
Tc99m-MIBI-SPECT, SVS had a sensitivity of 83% for ectopic parathyroid glands, 
which are a frequent cause of persistent PHPT. This study also demonstrates that the 
ability of selective venous sampling for PTH to accurately localize residual 
hyperactive parathyroid glands in patients with persistent PHPT is significantly 
higher than that of the non-invasive Tc99m-MIBI-SPECT imaging technique. 
These data hold implications for the management of patients with persistent 
PHPT. From a practical point of view, and in keeping with recent guidelines of the 
European Association of Nuclear Medicine (43), our data suggest that it is always 
worth to perform a Tc99m-MIBI-SPECT scan as a first preoperative localisation 
study in patients with persistent hyperparathyroidism, followed by the invasive, but 
more reliable, selective venous sampling for PTH technique. Concordance of both 
techniques leads to a reassuring sensitivity of 100%. Our data clearly suggest that 
SVS for PTH should be reinstated as a valuable tool in the armamentarium of 
localisation studies in the pre-operative work-up of patients with persistent 
hyperparathyroidism. 
 
IV. Complications of the surgical management of primary 
hyperparathyroidism  
 
High circulating levels of PTH are associated with increased bone turnover in 
favour of bone resorption leading to mineral depletion and decreased bone mass 
(44). This effect is achieved by the binding of PTH to its specific receptor (PTHR1) 
on stromal/osteoblastic cells of the bone marrow, which stimulates the production 
of RANK ligand and decreases that of its decoy receptor osteoprotegerin (OPG) 
(45-59). Following successful surgery, the rapid decrease in serum PTH levels and 
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the pre-operative high bone turnover state, lead to a transient hypocalcaemia, due to 
increased influx of calcium, phosphate and magnesium into bone. Post-operative,
severe and persistent hypocalcaemia is usually due to a "hungry bone syndrome", a 
syndrome seldom seen in patients with sporadic PHPT. The syndrome is 
predominantly observed in patients with severe hyperparathyroidism-associated 
increase in bone turnover, particularly in patients with parathyroid carcinoma. In 
Chapter 5, we performed a systemic review of the literature on hungry bone 
syndrome, summarizing its main features and suggestions for its prevention and 
management. 
Although exact numbers are missing, the number of patients who develop 
hungry bone syndrome is presumed to have largely decreased due to a considerable
decrease in the number of patients with clinically evident bone disease, such as 
osteitis fibrosa cystica, due to the earlier detection of mostly asymptomatic PHPT 
by routine calcium screening (60,61). An older age at diagnosis, radiological 
evidence of PHPT-related bone disease, and greater weight/volume of the resected 
parathyroid glands have been reported to be risk factors associated with the 
development of a post-operative hungry bone syndrome. There are scarce data on 
the best means to treat, minimize or prevent this severe complication of 
parathyroidectomy. Treatment of the hungry bone syndrome is aimed in the short 
term primarily at replenishing the circulating calcium deficit caused by the 
increased calcium utilisation to refill the multiple resorption cavities. In the longer 
term, treatment is aimed at restoring calcium homeostasis by substituting the 
temporarily missing stimulatory effect of PTH on the 1α-hydroxylase enzyme by 
providing the active form of vitamin D to ensure adequate intestinal absorption of 
calcium (61-66). Pre-operative normalisation of bone turnover with the use of
bisphosphonates and pre-operative 1,25(OH)2D supplementation are useful options
to prevent the hungry bone syndrome, but there are no available prospective data to 
confirm this premise (60,67-72).
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V. Aspects of osteocyte function in primary hyperparathyroidism
The PTH/PTHrP receptor (PTHR1) is also present on osteocytes (73). Recent in 
vitro and animal studies suggest that binding of PTH to the PTHR1 on osteocytes 
leads to inhibition of the expression of the SOST gene (74-77). This gene encodes 
sclerostin, a protein exclusively expressed in osteocytes in the skeleton (78), which 
decreases bone formation by binding to LRP5/6, resulting in inhibition of the Wnt 
signaling pathway in osteoblasts (79,80). To evaluate whether chronic PTH excess 
has similar effects on sclerostin secretion in humans as in animal models, we tested 
the hypothesis that chronic hypersecretion of PTH, as seen in PHPT, may decrease 
sclerostin secretion, and that PTH may thus represent a potential regulator of 
sclerostin production in humans in Chapter 6.
To this effect, we measured sclerostin in serum of 34 patients with untreated,
persistent, or recurrent PHPT and in 54 patients cured after successful 
parathyroidectomy for PHPT (EuPTH). Mean serum sclerostin level of patients 
with PHPT (30.5 pg/ml, 95% CI: 26.0-35.1) was significantly lower than that of 
patients with EuPTH (45.4 pg/ml, 95% CI: 40.5-50.2; P<0.001). There was a 
negative correlation between serum sclerostin and PTH concentrations when all 
patients were pooled together (r= −0.44, P<0.001).
Data from our study demonstrate that in humans, chronic PTH excess, as 
observed in patients with PHPT, is associated with a significant decrease in 
circulating sclerostin levels and that there is a significant negative correlation 
between PTH and serum sclerostin levels. Taken together, these results suggest that, 
similar to the case in animal models (74-77), PTH has a regulatory role on 
sclerostin production also in humans. The functional significance of circulating 
sclerostin is as yet to be established.
Recent in vitro studies have also shown that binding of PTH to the PTHR1 on 
osteocytes upregulates Fibroblast Growth Factor 23 (FGF23) mRNA expression 
(81,82). FGF23 is believed to be the major player in the bone-kidney axis 
controlling phosphate homeostasis. FGF23 acts as a phosphaturic factor by the 
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same mechanism of action as PTH, by down regulating the cotransporters NaPi2a 
and NaPi2c in the proximal tubules of the kidney after binding to its receptor, 
FGFR-1, in the presence of Klotho (83,84). FGF23 also decreases 1,25(OH)2D
synthesis in the proximal tubules by direct inhibition of the 1α-hydroxylase enzyme 
(83-85). In patients with PHPT, data on the relationship between PTH and FGF23 
are scarce and not always concordant. Compared to healthy controls, circulating 
FGF23 levels have been found to be elevated in patients with PHPT before 
parathyroidectomy (86,87) and to decrease immediately post-operatively (87),
supporting the notion that PTH stimulates FGF23 secretion. The aim of the study 
described in Chapter 7 was to address the relationship between PTH and FGF23 in 
patients with PHPT and in patients cured after successful parathyroidectomy for 
PHPT. 
We measured serum intact FGF23 in 22 patients with untreated, persistent, or 
recurrent PHPT and in 24 patients cured after successful parathyroidectomy for 
PHPT (EuPTH). Mean serum FGF23 concentration was significantly higher in
patients with PHPT than in EuPTH patients (50.4 ± 27.2 pg/ml vs. 33.1 ± 12.5 
pg/ml, P=0.01). There was a positive correlation between PTH and FGF23 levels 
(r=0.362, P=0.01), and this relationship was sustained and more pronounced after 
correction for 1,25(OH)2D levels (r=0.422, P=0.01). In patients with PHPT, there 
was a significant negative correlation between FGF23 and 1,25(OH)2D (r= −0.780, 
P<0.01). This relationship remained significant albeit less marked in EuPTH 
patients (r= −0.519, P=0.02).
In conclusion, we demonstrate that FGF23 production is increased in the 
presence of high circulating PTH levels and that this increase is reversible after the 
euparathyroid state is achieved following successful PTx. We further demonstrate a 
significant negative relationship between FGF23 and 1,25(OH)2D levels, which is 
more pronounced in patients with PHPT. Based on the more pronounced negative 
relationship between FGF23 and 1,25(OH)2D in PHPT patients, we propose that the 
PTH-induced increase in FGF23 levels may be an adaptive mechanism to maintain 
serum phosphate levels within normal limits by counteracting the potentially 
deleterious 1,25(OH)2D-induced phosphate retention. 
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The findings that PTH inhibits sclerostin production and stimulates FGF23 
production demonstrate that the actions of PTH on bone are more complex than 
previously suggested, involving a variety of signaling pathways within bone itself,
but also in the parathyroid-bone-kidney axis. Despite the significant progress in our 
understanding of the actions of PTH on bone, it should be appreciated that the 
cellular and molecular actions of PTH have only been partially unraveled and 
studies are needed to further elucidate these actions.
VI. Clinical and molecular aspects of parathyroid carcinoma
Surgical and medical advances have secured longer survival in patients with 
parathyroid carcinoma. To illustrate this point, we report in Chapter 8 the case of a 
patient with metastatic parathyroid carcinoma with a follow up spanning 17 years. 
We also review all original case reports and case series on patients with parathyroid 
carcinoma, who fulfill the WHO criteria for this malignancy who had been 
followed-up for at least 6 months after initial parathyroidectomy, which were 
published in the English literature since the last large review on this topic in 2001 
(88).
Data from our case are in keeping with those obtained from our review of the 
literature on this topic, showing that radical initial surgery is of paramount 
importance to prevent local seeding of tumor tissue, thereby not only increasing 
disease-free survival and survival, but also decreasing the chance of having to 
undergo re-operative surgery. Invasive growth of tumor tissue in adjacent 
structures, such as the recurrent laryngeal nerve or esophagus, increases the 
morbidity associated with re-operative surgery in patients with parathyroid 
carcinoma. The increasing morbidity associated with repeated surgical interventions 
has led to the search for other treatment options for this malignancy, such as 
radiotherapy, chemotherapy, radiofrequency (RF) ablation, embolization, use of the 
calcimimetic Cinacalcet and that of PTH immunisation. Parathyroid tumors are 
relatively resistant to chemotherapy and radiotherapy (88-93) and the use of both 
therapies has significantly decreased over the last 10 years. Successful embolization 
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has only been described in combination with RF ablation (94) and was unsuccessful 
in our patient, while RF ablation has been shown to be successful in 3 cases (95-97)
as well as in our patient. The eventual inability to control hypercalcaemia is 
associated with increased bone turnover with an increased risk of fractures and with 
fatal renal and cardiovascular complications (89,90,98,99). When attempts at 
reducing tumor load are not successful, intensive rehydration, use of medications 
such as bisphosphonates and calcimimetics and use of dialysis are used with 
variable results. A potential non-invasive option is PTH immunisation, although 
experience with this approach is still limited (100-102).
In conclusion, the long-term management of patients with metastatic parathyroid 
carcinoma remains indeed a daunting task, despite all recent imaging, surgical and 
medical advances.
Several genes have been discovered to play a role in the etiology of PHPT among 
which are the MEN-1, HRPT2/CDC73 and CASR genes. Mutations in the 
HRPT2/CDC73 gene, which encodes for the protein parafibromin (103), are 
associated with the hyperparathyroidism-jaw tumor syndrome (HPT-JT; OMIM 
607393). Patients with a HPT-JT syndrome have a 15-24% chance of developing 
parathyroid carcinoma (88,104-106). In patients with the HPT-JT syndrome, as well 
as patients with sporadic carcinoma, downregulation of the calcium sensing 
receptor (CASR) was also discovered (107). Moreover, downregulation of CASR 
expression, mutations in the HRPT2/CDC73 gene and loss of its protein, 
parafibromin, have been shown to be valuable markers to assist in establishing a 
diagnosis of parathyroid carcinoma. There are, however, no available data on the 
prognostic value of these markers in parathyroid carcinoma. In Chapter 9 we 
evaluated the prognostic value of downregulation of CASR expression, loss of 
parafibromin staining and the presence of mutations in the HRPT2/CDC73 gene in 
patients with a WHO criteria based diagnosis of parathyroid carcinoma.
We determined the disease-free survival and overall survival in 23 patients who 
had initial surgery for parathyroid carcinoma in various hospitals in the Netherlands 
in the period 1985-2000. Resected primary parathyroid carcinomas of all 23 patients 
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had previously undergone HRPT2/CDC73 and MEN-1 gene mutations analysis 
(108) and parafibromin and CASR staining analysis (104,109).
The 5-year disease-free survival and the 5-year overall survival were lower in 
patients with downregulation of CASR expression compared to patients with 
normal CASR expression (81% vs. 0% and 94% vs. 29%, respectively). Both the 5-
year disease-free survival (73% vs. zero) and the 5-year overall survival (79% vs. 
50%) were lower in patients with a HRPT2/CDC73 mutation compared to patients 
without this mutation. Both the 5-year disease-free survival (89% vs. 41%) and the 
5-year overall survival (100% vs. 57%) were lower in patients with global 
parafibromin loss compared to patients with focal parafibromin loss. The risk of 
developing a local or distant metastasis was 16-fold increased in the case of 
downregulation of CASR expression, 7-fold increased in the case of 
HRPT2/CDC73 mutations and also 7-fold increased in the case of global 
parafibromin loss. The 5-year disease-free survival and the 5-year overall survival 
were lower in patients with somatic MEN-1 mutations compared to patients without 
this mutation (respectively 64% vs. 33% and 80% vs. 33%), but somatic MEN-1
mutations were not associated with a significant increased risk of developing a local 
recurrence and/or distant metastasis.
Findings from this study hold several clinical implications. Firstly,
downregulation of CASR, HRPT2/CDC73 mutations and global loss of 
parafibromin are strong negative determinants of the malignant potential of 
parathyroid carcinomas. Secondly, the finding of somatic MEN-1 mutations in 
patients with parathyroid carcinoma, suggests that these mutations could play a role 
in parathyroid carcinogenesis, although they do not influence the prognosis of 
parathyroid carcinoma. Thirdly, evaluation of CASR expression may also serve to 
determine whether calcimimetics may play a role in the therapeutic management of 
patients with parathyroid carcinoma.
On the basis of the findings described in Chapter 9, we advocate the use of the 
assessment of downregulation of CASR, HRPT2/CDC73 mutations and global loss 
of parafibromin not only as diagnostic tools but also as prognostic tools in the 
management of patients with parathyroid carcinoma.
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VII. Management of patients with persistent primary hyperparathyroidism
The management of patients with persistent sporadic PHPT represents a significant 
clinical challenge, which requires a multidisciplinary approach. In Chapter 10 we 
report in a case serie, the demographic, clinical, biochemical, surgical and 
pathological characteristics of patients with persistent PHPT after initial 
parathyroidectomy for sporadic PHPT.
Our data suggest that the most common causes of persistent 
hyperparathyroidism are a missed ectopic gland at initial surgery (33%) and missed 
multiglandular disease (15%). We documented parathyromatosis in 9% of patients. 
Pre-operative localisation studies had poor sensitivity: ultrasound 18%, Tc99m-
MIBI-SPECT 25%, CT 30%, MRI 20%. In contrast, selective venous sampling for 
PTH had a sensitivity of 50% and a specificity of 89%. The decrease in 
intraoperative PTH was significantly less marked in patients in whom 
hyperparathyroidism persisted compared to those who achieved cure (63 ± 26 vs. 89 
± 11%, P=0.003). The risk of complications increased with each subsequent 
surgery: 20% after first, 50% after 2nd and 67% after 3rd surgery.
Our findings from this case series indicate that the management of patients with 
persistent PHPT is complex and challenging. When initial surgery fails to achieve 
cure, each reoperation jeopardizes the ability of localisation studies to accurately 
localise residual hyperactive parathyroid glands and increases the risk of 
complications in its own right because of distortion and scarring of surgical planes 
as a result of previous interventions. In these patients, re-operation should be 
carefully planned and attempts at surgery strongly discouraged if a clear localisation
of hyperactive tissue is not secured pre-operatively. 
VIII. Summary
- In patients with sporadic PHPT, the rate of persistence after initial PTx is 
7% and that of recurrence none. 
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- In the case of persistent PHPT, the sensitivity of the widely used, non-
invasive Tc99m-MIBI-SPECT imaging technique is decreased and is 
significantly lower than that of the invasive technique of selective venous 
sampling for PTH.  
- Chronic excess of PTH has a catabolic effect on bone, leading to mineral 
depletion of bone. Patients with pre-operative radiological signs of severe 
PTH-associated bone disease are at risk of developing hungry bone 
syndrome after surgery, which may be prevented by pre-operative treatment 
with bisphosphonates and 1,25(OH)2D.  
- PTH inhibits sclerostin production and stimulates FGF23 production, 
presumably to counterbalance its own actions on bone and on 1,25(OH)2D, 
resulting in novel feedback loops.  
- In contrast to sporadic PHPT, recurrent PHPT does occur in patients with 
parathyroid carcinoma. In these patients, downregulation of CASR, 
HRPT2/CDC73 mutations and global loss of parafibromin are strong 
negative determinants of the disease-free survival and overall survival.  
- Recent progresses in surgical and medical treatment of patients with 
parathyroid carcinoma have made it possible to secure longer survival, even 
in patients with tumors demonstrating 2 of the 3 identified molecular 
negative prognostic factors. 
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VIII. Conclusie
I. Introductie
Primaire hyperparathyreoïdie (PHPT) is de meest voorkomende oorzaak van 
hypercalciëmie in de algemene bevolking. De klinische presentatie van PHPT is 
over de laatste decennia drastisch veranderd, van een symptomatische ziekte met 
verminderde botdichtheid, verhoogde kans op fracturen, nierstenen, en psychische 
symptomen, naar een bijna asymptomatische ziekte. Vooruitgang in pre-operatieve 
lokalisatie studies, chirurgische technieken, en intra-operatieve PTH (IOPTH) 
metingen hebben er voor gezorgd dat de genezingspercentages voor initiële operatie 
voor PHPT gestegen zijn naar 93-100% (1-3). Ondanks deze vorderingen in initiële 
behandeling van PHPT, blijft de behandeling van persisterende en recidiverende 
primaire hyperparathyreoïdie een uitdagende taak.
In dit proefschrift rapporteren we de incidentie van persisterende PHPT na 
initiële operatie voor PHPT in ons ziekenhuis over een periode van 24 jaar. We 
beschrijven de demografische, klinische, biochemische, chirurgische en 
pathologische karakteristieken van patiënten met persisterende PHPT na initiële
operatie voor sporadische PHPT. Tevens evalueren we de waarde van pre-
operatieve lokalisatie studies voor revisie chirurgie en de skelet en post-operatieve 
complicaties van chronisch verhoogde concentraties van serum PTH. Verder 
bespreken we de behandeling van recidiverende hyperparathyreoïdie in patiënten 
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met bijschildklier carcinoom, en het effect van moleculaire veranderingen in het
HRPT2 en CASR gen op de prognose van deze patiënten. 
II. Genezing na parathyreoïdectomie voor primaire hyperparathyreoïdie  
Chirurgische verwijdering van alle pathologische bijschildklieren is de enige 
behandeling om patiënten met primaire hyperparathyreoïdie definitief te genezen. 
Na een succesvolle operatie is er een significante post-operatieve stijging in 
botmassa (4-6), ontstaan er geen nieuwe nierstenen (4,7) en verbeteren
verschillende parameters van kwaliteit van leven (8-12). Genezingspercentages van 
93-100% zijn gerapporteerd voor bilaterale halsoperaties en minder invasieve 
operaties, meer dan 6 maanden na parathyreoïdectomie (PTx) (13-22). Op basis van 
deze bevindingen is het gangbaar geworden om patiënten te controleren tot 6 
maanden na de operatie. Echter, tijdens een 5 jarige controle periode van 91 
patiënten die succesvol geopereerd waren voor PHPT, rapporteerde Westerdahl et 
al. een recidief percentage van 4%, wat voornamelijk bleek te berusten op niet 
eerder gediagnosticeerde kiembaan mutaties in het MEN-1 gen (23). In Hoofdstuk 2
hebben we daarom gekeken naar het genezingspercentage na PTx op de korte (3 en 
6 maanden) en lange termijn (1-24 jaar) in 73 patiënten met sporadische PHPT die 
een initiële operatie ondergingen tussen 1984 en 2008. Tevens hebben we gekeken 
naar voorspellende factoren voor genezing in patiënten met sporadische PHPT.
Bij de eerste controle (binnen 3 maanden na operatie) waren 70 van de 73 
patiënten (96%) genezen. Bij de 2e controle (6 maanden na operatie) en bij de lange 
termijncontrole (1-24 jaar) waren 68 van de 73 patiënten (93%) genezen. Er waren 
geen significante verschillen in geslacht, leeftijd bij presentatie, klinische 
presentatie, biochemische en pathologische bevindingen tussen patiënten die 
genezen zijn en diegene met persisterende hyperparathyreoïdie (HPTH) na een 
initiële operatie. Het was opmerkelijk dat alle 5 patiënten met persisterende HPTH 
een operatie hadden ondergaan voor 2001 en dat na de implementatie van pre-
operatieve lokalisatie studies en intra-operatieve PTH (IOPTH) bepaling als 
standaard zorg in 2001 het genezingspercentage gestegen is naar 100%.
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Onze studie laat zien dat ‘recidiverende’ hyperparathyreoïdie niet voorkomt in 
sporadische PHPT indien genezing vastgesteld is 6 maanden na PTx. Dit suggereert 
dat lange termijncontrole niet nodig is in deze patiënten groep. De eerste 6 maanden 
na PTx is nauwlettende controle wel sterk aanbevolen om definitieve genezing vast 
te stellen en diegene met achtergebleven klier pathologie in een vroeg stadium te 
kunnen identificeren.
III. Lokalisatie studies in persisterende primaire hyperparathyreoïdie
In Hoofdstuk 2 hebben we laten zien dat het genezingspercentage in patiënten met 
sporadische PHPT die PTx ondergingen, steeg door het gebruik van pre-operatieve 
lokalisatie studies. Pre-operatieve lokalisatie studies worden niet nodig geacht voor 
initiële bilaterale nek operaties, omdat een ervaren chirurg in gemiddeld 98% van 
de gevallen al het pathologische weefsel verwijdert (22,24). Lokalisatie studies zijn
wel nodig wanneer de chirurg een unilaterale of minimaal invasieve aanpak kiest en 
voorafgaand aan re-operatieve PTx voor persisterende HPTH, aangezien een tweede 
(of volgende) nek exploratie technisch ingewikkelder is dan een initiële en 
geassocieerd is met een soms drievoudige stijging in morbiditeit (22,25-27).
Beperkte data suggereren dat de lokalisatie waarde van Tc99m-MIBI-SPECT lager 
is voorafgaand aan re-operatieve PTx dan voorafgaand aan initiële PTx (28-30).
In Hoofdstuk 3 hebben we de voorspellende waarde van Tc99m-MIBI-SPECT in 
patiënten met persisterende PHPT voorafgaand aan revisie operatie beoordeeld en 
vergeleken met de voorspellende waarde in patiënten met sporadische PHPT 
voorafgaand aan initiële operatie.
Tc99m-MIBI-SPECT was in staat 61% van de pathologische bijschildklieren 
die verwijderd werden tijdens initiële operatie in patiënten met sporadische PHPT
accuraat te lokaliseren en 33% van de pathologische bijschildklieren die verwijderd 
werden tijdens re-operatieve PTx in patiënten met persisterende PHPT. Patiënten
met persisterende PHPT hadden vaker hyperplastische klieren (55% vs. 26%), meer 
ectopisch gelokaliseerde klieren (44% vs. 22%), en kleinere pathologische klieren 
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(1.21 cm vs. 2.03 cm) dan patiënten met sporadische PHPT die genezen waren na 
initiële operatie. Tc99m-MIBI-SPECT heeft een lagere sensitiviteit voor het 
lokaliseren van hyperplastische klieren en klieren met diameter <1.5 cm, wat de 
lagere diagnostische waarde in patiënten met persisterende PHPT kan verklaren.
De beperkte sensitiviteit van Tc99m-MIBI-SPECT in patiënten met 
persisterende PHPT voorafgaand aan re-operatieve PTx, is waarschijnlijk het 
resultaat van verminderde opname van het radiofarmacon door een combinatie van
een verstoring in de lokale bloed toevoer door voorafgaande operaties en 
verschillen in klier pathologie en grootte.
Vanwege de beperkte diagnostische waarde van Tc99m-MIBI-SPECT voorafgaand 
aan revisie chirurgie voor persisterende PHPT, hebben we in Hoofdstuk 4
onderzocht of selectieve veneuze sampling (SVS) van bijschildklierhormoon (PTH) 
kan bijdragen aan een betere pre-operatieve lokalisatie van achtergebleven 
hyperactief bijschildklierweefsel in patiënten met persisterende HPTH. De 
diagnostische waarde van SVS is gebaseerd op de aanname dat regionale drainage 
van elk van de 4 bijschildklieren geschiedt via, respectievelijk, de naastgelegen 
bovenste, middelste of onderste schildkliervenen (31). Ondanks potentiële 
anatomische variaties, kan een SVS in 39-93% van de patiënten met PHPT de kant 
van een pathologische bijschildklier aanwijzen (31-41) en, nog belangrijker, in 66-
75% van de patiënten met negatieve non-invasieve lokalisatie studies (36,37,42).
De grootste beperking van SVS is dat het gebied van veneuze drainage van een 
hyperactieve klier wordt aangewezen en niet de exacte anatomische lokalisatie.
We hebben de resultaten geëvalueerd van Tc99m-MIBI-SPECT en SVS, welke
verricht waren voorafgaande aan 20 revisie operatie in 18 patiënten met 
persisterende of recidiverende PHPT of autonome tertiaire hyperparathyreoïdie 
(THPT) ten gevolge van eind stadium nierfalen. Tc99m-MIBI-SPECT had een 
sensitiviteit van 30% en SVS had een sensitiviteit van 75% in deze patiënten groep.
SVS kon accuraat 10 van de 14 pathologische klieren (71%) lokaliseren die door 
Tc99m-MIBI-SPECT niet goed gelokaliseerd of compleet gemist waren, terwijl 
Tc99m-MIBI-SPECT alleen 1 van de 6 pathologische klieren (17%) accuraat kon 
258  /  Chapter 12
lokaliseren die niet goed gelokaliseerd waren door SVS. De lokalisatie sensitiviteit 
was 100% indien er overeenstemming was tussen SVS en Tc99m-MIBI-SPECT. In 
overeenstemming met Tc99m-MIBI-SPECT, was de diagnostische waarde van SVS 
ook verlaagd, hoewel in mindere mate, in het geval van hyperplastische 
bijschildklieren en klieren met een diameter <1.5 cm. In tegenstelling tot Tc99m-
MIBI-SPECT, had SVS een sensitiviteit van 83% voor ectopische bijschildklieren,
een frequente oorzaak van persisterende PHPT. 
Deze bevindingen hebben aanzienlijke betekenis voor de zorg van patiënten met 
persisterende PHPT. Vanuit praktisch oogpunt en in overeenstemming met de 
recente richtlijnen van de Europese Associatie van Nucleaire Geneeskunde (43),
laten onze data zien dat het altijd de moeite waard is om een Tc99m-MIBI-SPECT 
scan te maken als een eerste pre-operatieve lokalisatie studie in patiënten met 
persisterende PHPT, gevolgd door de invasieve maar betrouwbaardere SVS. 
Overeenstemming tussen deze beiden technieken leidt tot een geruststellende 
sensitiviteit van 100%. Onze data laten duidelijk zien dat SVS voor PTH 
geherintroduceerd zou moeten worden als diagnosticum in de pre-operatieve zorg 
van patiënten met persisterende PHPT.
IV. Complicaties van chirurgische behandeling van primaire 
hyperparathyreoïdie 
Een chronisch verhoogde waarde van het serum PTH is geassocieerd met 
verhoogde bot omzetting ten gunste van bot resorptie, wat leidt tot mineraal 
onttrekking en verminderde botdichtheid (44). Binding van PTH aan zijn specifieke 
receptor (PTHR1), op stromale/osteoblastische cellen van het beenmerg, stimuleert 
de productie van RANK ligand en vermindert dat van zijn oplosbare 
‘lokaasreceptor’ osteoprotegerine (OPG) (45-59). Na succesvolle chirurgie zorgt de 
snelle daling in serum PTH en de pre-operatieve hoge bot omzetting, voor een 
tijdelijke hypocalciëmie, door instroom van calcium, fosfaat en magnesium in het 
bot. Ernstige post-operatieve hypocalciëmie, wordt meestal veroorzaakt door het 
"hungry bone" syndroom, een syndroom dat zelden gezien wordt in patiënten met 
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sporadische PHPT. Het syndroom wordt met name gezien bij patiënten met ernstige 
hyperparathyreoïdie geassocieerde bot omzetting, met name in patiënten met 
bijschildkliercarcinoom. In Hoofdstuk 5 vatten we de belangrijkste kenmerken en 
suggesties voor preventie en behandeling samen die voortgekomen zijn uit een 
systemische review van de literatuur over "hungry bone" syndroom. 
De exacte incidentie van patiënten die post-operatief een "hungry bone"
syndroom ontwikkelen is onbekend, maar er wordt verondersteld dat het aantal 
patiënten met deze post-operatieve complicatie gedaald is door een daling in het 
aantal patiënten met klinische evidente botaandoeningen, zoals osteitis fibrosa 
cystica, vanwege de eerdere opsporing van veelal asymptomatische PHPT door
routinematig screenen van serum calcium (60,61). Risico factoren voor het krijgen 
van een "hungry bone" syndroom zijn oudere leeftijd bij diagnose, radiologische 
tekenen van hyperparathyreoïdie geassocieerde bot ziekten, en groter 
gewicht/volume van de verwijderde bijschildklier(en). Er zijn weinig data over de 
beste manier om deze ernstige complicatie van PTx te behandelen, minimaliseren of 
te voorkomen. De behandeling van het "hungry bone" syndroom is in eerste 
instantie gericht op het aanvullen van het calcium tekort, wat veroorzaakt wordt 
door het toegenomen calcium verbruik bij het vullen van de velen resorptie holtes in 
het bot. Op de langere termijn is behandeling gericht op herstel van de calcium 
homeostase, door tijdelijk het ontbrekende stimulerende effect van PTH op het 1α-
hydroxylase enzym te vervangen, door het geven van de actieve vorm van vitamine 
D, en zodoende de intestinale calcium absorptie te garanderen (61-66). Pre-
operatieve normalisatie van bot omzetting door middel van bisfosfonaten en pre-
operatieve suppletie van actief vitamine D worden gezien als waardevolle opties om 
"hungry bone" syndroom te voorkomen, maar er zijn geen prospectieve data om 
deze aanname te bevestigen (60,67-72).
V. Aspecten van osteocyt functie in primaire hyperparathyreoïdie
De PTH/PTHrP receptor (PTHR1) is ook aangetoond op osteocyten (73). Recente
in vitro en dierstudies suggereren dat binding van PTH aan de PTHR1 op
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osteocyten leidt tot remming van de expressie van het SOST gen (74-77). Dit gen 
codeert voor sclerostine, een eiwit dat alleen in de osteocyten van het skelet
gevonden wordt (78), en de botformatie remt door binding aan LRP5/6, met als 
resultaat remming van Wnt signaal routes in osteoblasten (79,80). Om te bepalen of 
chronisch verhoogde serum PTH concentraties hetzelfde effect heeft op sclerostine
secretie in mensen als in diermodellen, hebben we in Hoofdstuk 6 de hypothese 
getest dat chronisch verhoogde serum PTH concentraties, zoals in PHPT, 
sclerostine secretie verlagen, en dat PTH dus een potentiële regulator van 
sclerostine productie in mensen is. 
Hiervoor hebben we sclerostine gemeten in het serum van 34 patiënten met 
onbehandelde, persisterende of recidiverende PHPT en in 54 patiënten die genezen 
waren na PTx voor PHPT (EuPTH). De gemiddelde serum sclerostine concentratie 
was lager in patiënten met PHPT dan in patiënten met EuPTH (30.5 pg/ml, 95% CI: 
26.0-35.1 vs. 45.4 pg/ml, 95% CI: 40.5-50.2; P<0.001). Er was ook een negatieve 
correlatie tussen sclerostine en PTH wanneer alle patiënten samen genomen werden 
(r= −0.44, P<0.001).
Deze resultaten laten zien dat in mensen, chronisch verhoogde serum PTH
concentraties, zoals in patiënten met PHPT, is geassocieerd met een daling in 
circulerende sclerostine waarden en dat er een negatieve correlatie is tussen PTH en 
sclerostine spiegels. Samenvattend, suggereren deze bevindingen dat PTH ook een 
remmend effect heeft op sclerostine productie in mensen, net als in diermodellen.
De functionele betekenis van serum sclerostine dient nog verder uitgezocht te 
worden.
Recente in vitro studies hebben ook laten zien dat binding van PTH aan de PTHR1 
op osteocyten fibroblast growth factor 23 (FGF23) mRNA expressie stimuleert 
(81,82). Het wordt verondersteld dat FGF23 de grootste speler is in de bot-nier as
en de fosfaat homeostase reguleert. FGF23 werkt als een fosfaat excretie 
bevorderende factor via hetzelfde mechanisme als PTH, door het verminderen van 
NaPi2a en NaPi2c co-transporters in de proximale tubuli van de nieren na het 
binden aan zijn receptor, FGFR-1, in de aanwezigheid van Klotho (83,84). FGF23 
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vermindert ook 1,25 (OH)2D synthese in de proximale tubuli door directe remming 
van het 1α-hydroxylase enzym (83-85). Gegevens over de relatie tussen PTH en 
FGF23 in patiënten met PHPT zijn schaars en vaak tegenstrijdig. De circulerende 
FGF23 waarden zijn hoger in patiënten met PHPT dan in gezonde vrijwilligers
(86,87) en dalen direct na PTx (87), hetgeen het idee ondersteunt dat PTH de 
FGF23 secretie stimuleert. Het doel van de studie die beschreven wordt in 
Hoofdstuk 7 was het bepalen van de relatie tussen PTH en FGF23 in patiënten met 
PHPT en in patiënten genezen na succesvolle PTx voor PHPT.
We hebben intact FGF23 spiegels gemeten in 22 patiënten met onbehandelde, 
persisterende, of recidiverende PHPT en in 24 patiënten genezen na succesvolle 
PTx voor PHPT (EuPTH). De gemiddelde serum FGF23 concentratie was 
significant hoger in patiënten met PHPT dan in EuPTH patiënten (50.4 ± 27.2 
pg/mL vs. 33.1 ± 12.5 pg/mL, P=0.01). Er was een positieve correlatie tussen PTH
en FGF23 concentraties (r=0.362, P=0.01), en deze correlatie was behouden en 
zelfs uitgesprokener na correctie voor 1,25(OH)2D concentraties (r=0.422, P=0.01). 
Er was een negatieve correlatie tussen FGF23 and 1,25(OH)2D gevonden (r=-0.780, 
P<0.01) in patiënten met PHPT. Deze correlatie was ook significant, maar minder 
uitgesproken in EuPTH patiënten (r= −0.519, P=0.02).
De data van onze studie laten zien dat FGF23 productie verhoogd is bij
patiënten met verhoogde serum PTH waarden en dat deze stijging in FGF23 
reversibel is nadat verhoogde serum PTH waarden genormaliseerd zijn na 
succesvolle PTx. We laten verder zien dat er een negatieve correlatie is tussen 
FGF23 en 1,25(OH)2D concentraties, die sterker is in patiënten met PHPT. Door
deze sterkere negatieve correlatie tussen FGF23 en 1,25(OH)2D bij patiënten met 
PHPT, veronderstellen wij dat de PTH-geïnduceerde stijging in FGF23 
concentraties een aanpassingsmechanisme is om serum fosfaat concentraties binnen 
de normale grenzen te houden, door de potentieel schadelijke 1,25(OH)2D-
geinduceerde fosfaat retentie te compenseren.
De bevinding dat PTH sclerostin productie remt en FGF23 productie stimuleert laat 
zien dat de effecten van PTH op bot complexer zijn dan voorheen gesuggereerd 
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werd en betrekking hebben op verschillende signaal routes in het bot zelf, maar ook 
in de bijschildklier-bot-nier as. Ondanks de significante voortgang van onze kennis 
van de effecten van PTH op bot, moeten we toch erkennen dat de cellulaire en 
moleculaire effecten van PTH nog maar deels ontrafeld zijn en verdere studies zijn 
nodig om de effecten verder verklaren.
VI. Klinische en moleculaire aspecten in primaire hyperparathyreoïdie
Chirurgische en medicinale ontwikkelingen hebben gezorgd voor een langere 
overleving in patiënten met een bijschildkliercarcinoom. Om dit te illustreren 
beschrijven we in Hoofdstuk 8 de casus van een patiënt met gemetastaseerd 
bijschildkliercarcinoom met een follow-up van 17 jaar. Tevens hebben we alle 
originele casus beschrijvingen en case series over patiënten met 
bijschildkliercarcinoom bekeken, die voldeden aan de WHO criteria, een follow-up 
van minimaal 6 maanden na PTx hadden en die werden gepubliceerd in de Engelse 
literatuur, sinds het verschijnen van het laatste grootte overzicht over dit onderwerp 
in 2001 (88).
De gepresenteerde casus en de in de literatuur beschreven casussen laten zien 
dat radicale initiële operatie extreem belangrijk is om locale verspreiding van tumor 
weefsel te voorkomen en daardoor niet alleen de ziektevrije overleving en 
overleving te verhogen, maar ook de kans op re-operatie te verkleinen. Invasieve 
groei van tumor weefsel in naastliggende structuren, zoals de nervus recurrens of de 
oesofagus, verhoogt het risico op morbiditeit tijdens re-operatie. De gestegen 
morbiditeit die verbonden is aan re-operaties heeft ervoor gezorgd dat er andere 
behandelingsopties zijn ontwikkeld, zoals radiotherapie, chemotherapie, 
radiofrequentie ablatie, embolisatie, het calciumimeticum cinacalcet en PTH 
immunisatie. Bijschildkliercarcinomen zijn relatief resistent voor chemotherapie en 
radiotherapie (88-93), waardoor het gebruik van deze technieken gedaald is 
gedurende de afgelopen 10 jaar. Succesvolle embolisatie is alleen beschreven in 
combinatie met RF ablatie (94) en was niet succesvol in onze patiënt, terwijl RF 
ablatie wel succesvol was in 3 casussen (95-97) net als in onze patiënt. Het ontstaan 
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van oncontroleerbare hypercalciëmie is geassocieerd met dodelijke nier en 
cardiovasculaire complicaties (89,90,98,99) en verhoogde botomzetting met een 
verhoogd risico op fracturen. Wanneer pogingen om het tumor volume te 
verminderen niet slagen, worden intensieve rehydratie, medicatie zoals 
bisfosfonaten en calciumimetica en dialyse vaak gebruikt met wisselend resultaat. 
Een nieuwe potentiële niet-invasieve optie is PTH immunisatie, ondanks dat 
ervaringen met deze aanpak nog beperkt zijn (100-102).
Concluderend blijft de lange termijn zorg van patiënten met een gemetastaseerd 
bijschildkliercarcinoom een uitdagende taak, ondanks recente diagnostische, 
chirurgische en medicinale vooruitgang.
Er zijn verschillende genen ontdekt die een rol spelen bij de ontwikkeling van 
PHPT, onder andere het MEN-1, HRPT2 en CASR gen. Mutaties in het
HRPT2/CDC73 gen, dat codeert voor het eiwit parafibromine (103), zijn 
geassocieerd met het hyperparathyroidism-jaw tumor syndroom (HPT-JT; OMIM 
607393). Patiënten met een HPT-JT syndroom hebben 15-24% kans op het 
ontwikkelen van een bijschildkliercarcinoom (88,104-106). In patiënten met het 
HPT-JT syndroom en patiënten met sporadische bijschildkliercarcinomen is een
verminderde expressie van het calcium sensing receptor (CASR) aangetoond (107).
Bovendien, is het bekend dat verminderde CASR expressie, mutaties in het 
HRPT2/CDC73 gen en verlies van zijn eiwit, parafibromine, waardevolle 
hulpmiddelen zijn bij het vast stellen van de diagnose bijschildkliercarcinoom. Er 
zijn echter geen gegevens bekend over de prognostische waarde van deze markers 
in bijschildkliercarcinomen. In Hoofdstuk 9 hebben we de prognostische waarde 
van verminderde CASR expressie, verlies van parafibromine kleuring en de 
aanwezigheid van mutaties in het HRPT2/CDC73 gen in patiënten met een op 
WHO criteria gebaseerde diagnose van bijschildkliercarcinoom vastgesteld.
We hebben de ziektevrije overleving en overleving bepaald van 23 patiënten die 
een initiële operatie voor bijschildkliercarcinoom ondergingen in verschillende 
ziekenhuizen in Nederland gedurende de periode 1985 en 2000. De verwijderde 
bijschildkliercarcinomen van alle 23 patiënten hadden tijdens een eerdere studie 
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HRPT2/CDC73 en MEN-1 gen mutatie analyse (108) en parafibromine en CASR 
kleuring analyse (104,109) ondergaan.  
De 5-jaars ziektevrije overleving en de 5-jaars overleving waren lager in 
patiënten met verminderde CASR expressie dan in patiënten met normale CASR 
expressie (81% vs. 0% en 94% vs. 29%, respectievelijk). Zowel de 5-jaars 
ziektevrije overleving (73% vs nul) als de 5-jaars overleving (79% vs. 50%) waren 
lager in patiënten met een HRPT2/CDC73 mutatie dan in patiënten zonder deze 
mutatie. Zowel de 5-jaars ziektevrije overleving (89% vs. 41%) als de 5-jaars 
overleving (100% vs. 57%) waren lager bij patiënten met globaal verlies van 
parafibromine vergeleken met patiënten met focaal parafibromine verlies. Het risico 
op het ontwikkelen van metastasen lokaal en/of op afstand was 16 keer verhoogd in 
het geval van verminderde CASR expressie, 7 keer verhoogd in het geval van 
HRPT2/CDC73 mutaties en ook 7 keer verhoogd in het geval van globaal 
parafibromine verlies. De 5-jaars ziektevrije overleving en 5-jaars overleving waren 
lager in patiënten met somatische MEN-1 mutaties vergeleken met patiënten zonder 
deze mutaties (respectievelijk 64% vs. 33% en 80% vs. 33%), maar somatische 
MEN-1 mutaties waren niet geassocieerd met een significante stijging in het risico 
op het ontwikkelen van metastasen lokaal en/of op afstand. 
De bevindingen van deze studie hebben verschillende klinische implicaties. Ten 
eerste, zijn verminderde CASR expressie, HRPT2/CDC73 mutaties en globaal 
verlies van parafibromine sterke negatieve determinanten van de maligne potentie 
van bijschildkliercarcinomen. Ten tweede, de observatie dat somatische MEN-1 
mutaties gevonden worden bij patiënten met bijschildkliercarcinomen, suggereert 
dat deze mutaties een rol kunnen spelen in het ontstaan van 
bijschildkliercarcinomen, hoewel ze de prognose niet beïnvloeden. Ten derde, kan 
de bepaling van CASR expressie ook gebruikt worden om te bepalen of patiënten 
met bijschildkliercarcinoom behandeld kunnen worden met een calciumimetica.  
Op basis van de resultaten beschreven in Hoofdstuk 9, bevelen we de bepaling 
van verminderde CASR expressie, HRPT2/CDC73 mutaties en globaal verlies van 
parafibromine aan, niet alleen als diagnostisch hulpmiddel, maar vooral als 
prognostisch hulpmiddel in de zorg voor patiënten met bijschildkliercarcinomen.  
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VII. Zorg voor patiënten met persisterende primaire hyperparathyreoïdie
De zorg voor patiënten met persisterende sporadische PHPT vormt een grote 
klinische uitdaging, die vraagt om een multidisciplinaire aanpak. In Hoofdstuk 10
beschrijven we de demografische, klinische, biochemische, chirurgische en 
pathologische karakteristieken van patiënten met persisterende PHPT na initiële 
parathyreoïdectomie voor sporadische PHPT.
Data van onze studie suggereren dat een gemiste ectopische bijschildklier bij 
initiële operatie (33%) en gemiste hyperplasie in meerdere bijschildklieren (15%)
de meest voorkomende oorzaken van persisterende hyperparathyreoïdie zijn. We 
hebben parathyromatose gedocumenteerd in 9% van de patiënten. Pre-operatieve 
studies hebben een slechte sensitiviteit: echografie 18%, Tc99m-MIBI-SPECT 
25%, CT 30%, MRI 20%. Selectieve veneuze sampling van PTH heeft echter een 
sensitiviteit van 50% en een specificiteit van 89%. De daling in intra-operatief PTH 
was significant minder uitgesproken in patiënten bij wie hyperparathyreoïdie 
persisteerde in vergelijking tot patiënten die genezen waren na operatie (63 ± 26 vs 
89 ± 11%, P=0.003). Het risico op complicaties nam toe met elke volgende 
operatie: 20% na de eerste, 50% na de 2e en 67% na de 3e operatie. 
Onze bevindingen van deze serie patiënten laten zien dat de behandeling van
patiënten met persisterende hyperparathyreoïdie complex en uitdagend is. Elke 
heroperatie verlaagt de sensitiviteit van de lokalisatie studies om resterende 
hyperactieve bijschildklieren accuraat te lokaliseren en verhoogt het risico op 
complicaties, door verstoring en verlittekening van het chirurgische veld bij eerdere 
chirurgische interventies. In deze patiënten dient heroperatie zorgvuldig gepland te 
worden en chirurgische pogingen uitgesteld te worden totdat hyperactief weefsel 
duidelijk gelokaliseerd kan worden pre-operatief. 
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VIII. Conclusie
- De kans op persisteren van hyperparathyreoïdie is 7% en dat van 
recidiveren van hyperparathyreoïdie nul, na initiële operatie voor 
sporadische PHPT.
- De veel gebruikte, niet-invasieve Tc99m-MIBI-SPECT scan techniek heeft 
een lagere sensitiviteit in het geval van persisterende PHPT, en deze 
sensitiviteit is significant lager dan de sensitiviteit van de invasieve SVS 
techniek. 
- Chronische hyperparathyreoïdie heeft een catabool effect op bot, wat zorgt
voor mineraal onttrekking van bot. Patiënten met pre-operatieve 
radiologische tekenen van ernstig hyperparathyreoïdie geassocieerde 
botziekten lopen post-operatief het risico op het ontwikkelen van "hungry 
bone" syndroom, wat voorkomen zou kunnen worden door pre-operatieve 
behandeling met bisfosfonaten en actief vitamine D.
- PTH remt de productie van sclerostine en stimuleert de productie van 
FGF23, waarschijnlijk om het eigen effect van PTH en dat van 1,25(OH)2D
op bot tegen te gaan, waardoor nieuwe feedback mechanismen ontstaan.
- Patiënten met bijschildkliercarcinoom hebben in tegenstelling tot patiënten 
met sporadische PHPT wel een kans op recidiverende PHPT. In deze
patiënten, zijn verminderde CASR expressie, HRPT2/CDC73 mutaties en
globaal verlies van parafibromine expressie sterke negatieve determinanten 
van de ziektevrije overleving en overleving. 
- Recente ontwikkelingen in de chirurgische en medicinale behandeling van 
patiënten met bijschildkliercarcinoom hebben het mogelijk gemaakt een 
langere overleving te verzekeren voor deze patiënten, zelfs in patiënten met 
tumoren waarin 2 van de 3 negatieve prognostische factoren gevonden 
worden.
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